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Abstract of thesis 
 
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is characterised by 
repeated cycles of upper airway obstruction during sleep, leading to diurnal 
symptoms. Individuals with Down syndrome (DS) are predisposed to this as the DS 
phenotype overlaps with OSAHS risk factors. Around 2-4% of the general adult 
population and 55% of children with DS have OSAHS but, to date, no large-scale 
study has assessed OSAHS prevalence or efficacy of treatment in DS adults. 
This study aimed to: 1) Systematically assess subjective and objective OSAHS 
prevalence; 2) Assess the effectiveness of continuous positive airway pressure 
(CPAP) in an adult DS population. 
Standard questionnaires including pictorial Epworth Sleepiness Scale (pESS) and 
Developmental Behaviour Checklist for Adults (DBC-A) were sent to UK adults 
aged ≥16yr with DS and their caregivers. All questionnaire responders were invited 
to undergo home polygraphy. Symptomatic adults with DS with ≥10 
apnoeas/hypopnoeas per hour in bed (AH) on home polygraphy were invited to 
participate in a prospective randomised controlled trial (RCT) of CPAP v. lifestyle 
advice, with review at 1, 3, 6 and 12m. Participants in the lifestyle arm were offered 
CPAP at 1m. Standard measurements of sleepiness, behaviour, cognitive function 
and general health were undertaken. Standard statistical analyses were conducted, 
with significance set at p<0.001 to control for multiple testing. 
Of 5270 questionnaires sent, 1105 responses were valid (21%). Responders (55% 
males) were overweight/obese young adults: mean BMI 29.0±6.8kg/m2; mean age 
28±9 years. Women had a higher BMI (p<0.0001), but collar size was greater in men 
(p<0.0001). Mean pESS scores were broadly within the normal range (7±5/24). No 
significant gender differences in OSAHS symptoms were noted. Individuals with 
probable OSAHS had higher pESS and DBC-A scores, and significantly more 
symptoms of OSAHS. Subjective OSAHS prevalence was estimated at 35%. Of the 
790 individuals invited, 149 underwent polygraphy, with 134 valid studies obtained: 
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mean AH 21.8(10.9-42.7); mean oximetry desaturation index (ODI) 6.6(2.3-20.0). 
No significant gender differences were observed. Forty-two percent of participants 
met standard clinical diagnostic criteria for OSAHS. Twenty-eight eligible adults 
with DS (19 male) were randomised: age 28±9yr; BMI 31.5±7.9kg/m2; AH 
28.6(14.8-47.9); ODI 7.3(1.8-21.9); pESS 11±6/24. Groups did not differ 
significantly at baseline. By 12m, 4 participants had withdrawn (all remaining 
participants on CPAP). The pESS (p=0.001), DBC-A Disruptive (p<0.0001) and 
Kaufmann Brief Intelligence Test verbal subscale (p=0.001) scores improved 
significantly.  
This first large study of OSAHS prevalence in the adult DS population estimates a 
prevalence of 35-42% - around 10 times higher than in the general adult population. 
Sustained, significant improvements in sleepiness, cognitive function and 
behavioural/emotional outcomes with CPAP use over a 12m period were 
demonstrated during this first RCT of CPAP in adults with DS. A larger trial of 





Lay summary of thesis  
 
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a condition in which 
repeated breathing pauses during sleep cause daytime symptoms such as sleepiness. 
People with Down syndrome (DS) are prone to this as some of the features of DS are 
also risk factors for OSAHS. We think that 2-4% of the general adult population and 
55% of children with DS have OSAHS but, to date, no large studies have looked at 
how many adults with DS have OSAHS or how well treatment works for them. This 
study aimed to address this.  
Questionnaires asking about sleepiness, behaviour and symptoms of OSAHS were 
sent to UK adults aged 16 years and over with DS and their relative or carer. 
Everyone returning a questionnaire was invited to have a sleep study at home to test 
for OSAHS. Everyone with symptoms and features of OSAHS on the home sleep 
study was invited to take part in a trial of CPAP, and they were then chosen at 
random to receive either continuous positive airway pressure (CPAP) or lifestyle 
advice, with review at 1, 3, 6 and 12 months. Individuals in the lifestyle group were 
offered CPAP after 1m. We measured sleepiness, behaviour, daytime function and 
general health at each visit.  
We sent out 5270 questionnaires, of which 21% were completed and returned. 
People who replied were, on average, overweight/obese young adults. Just over half 
(55%) were men. Symptoms of OSAHS were similar in men and women, and 
sleepiness scores were broadly within the normal range. The questionnaire suggested 
that around 35% of adults with DS may have OSAHS. Those who might have 
OSAHS were sleepier, had more problem behaviour and had more symptoms than 
those unlikely to have OSAHS. Of the 790 individuals invited to participate in the 
treatment study, 149 had sleep studies, of which 134 were successful. There were no 
significant differences in sleep study results between men and women. Forty-two 
percent were diagnosed with OSAHS using the sleep study results. Twenty-eight 
adults with DS (19 men, 9 women) took part in the treatment study, 14 per group – 
again, these were overweight/obese young adults, this time with mild/moderate 
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sleepiness. By 12m, 4 participants had withdrawn, and all the remaining participants 
were on CPAP. Sleepiness and behaviour improved significantly with CPAP use, as 
did scores on a test of verbal intelligence.  
This study estimates that 35-42% of adults with DS may have OSAHS - around 10 
times more than in the general adult population. CPAP therapy is effective in adults 
with DS, with improvements in sleepiness, daytime function and behaviour 
maintained over a 12m period. Results suggest that a larger trial of CPAP in adults 
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Chapter 1: Down syndrome: an overview 
First described by J. Langdon Down in 1866 (Down 1866), Down syndrome (DS) is 
one of the commonest congenital conditions world-wide. This chapter provides an 
overview of the genetic basis, prevalence and impact of DS. 
1.1 Genetic basis of DS 
DS is an aneuploid disorder of human chromosome 21 (HSA21). An additional copy 
of HSA21 (trisomy 21) in the cells of individuals with DS was first identified by 
Jérôme Lejeune and colleagues in 1959 (Lejeune et al. 1959), and the majority of 
people with DS have this trisomy 21 karyotype. HSA21 is the smallest human 
chromosome, constituting only 1-1.5% of the human genome (Hattori et al. 2000); 
however, an additional copy of this small portion of the genetic blueprint has 
significant impact on the human phenotype. 
Trisomy 21 most commonly arises due to nondisjunction during gametogenesis in 
one of the parents (more often the mother). DS can also arise from translocation of 
HSA21, where part of an additional HSA21 is fused to or transposed with another 
chromosome and present in all cells (Polani et al. 1960), or by mosaicism, where 
some, but not all, cells in the individual have an additional copy of HSA21 (Clarke et 
al. 1961). True Trisomy 21 is found in approximately 95% of individuals with DS, 
translocation in 4% and mosaicism in 1% (Sherman et al. 2007). Despite these 
differences in the genetic basis of DS, “Trisomy 21” is commonly used 
interchangeably with DS to describe the condition. For consistency and accuracy, the 
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Figure 1: Female human trisomy 21 karyotype, with triple copy of HSA21 highlighted. Adapted 
by permission from Macmillan Publishers Ltd: NATURE REVIEWS GENETICS (Stylianos E. 
Antonarakis, Robert Lyle, Emmanouil T. Dermitzakis, Alexandre Reymond & Samuel Deutsch, 
Chromosome 21 and Down syndrome: from genomics to pathophysiology, Nature Reviews 
Genetics, 5, 725-738), copyright (2004). 
 
 
Figure 2: Possible phenotypic consequences of gene action in Down syndrome. From Roper RJ, 
Reeves RH (2006) Understanding the Basis for Down Syndrome Phenotypes. PLoS Genet 2(3): 
e50. Reproduced under the terms of the Creative Commons Attribution License. 
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Although DS arises from broadly the same genetic mutation – that is, a 50% increase 
in expression of the genes of HSA21 - wide phenotypic variation is observed in 
individuals with DS. This is likely due to the interaction of the triplicated genes of 
HSA21 with the non-trisomic genes of the remaining chromosomes, along with 
environmental factors – see  
Figure 2 (Roper & Reeves 2006). It is important to remember that familial and ethnic 
characteristics will be expressed alongside those related to DS; for example, although 
there are recognisable facial characteristics associated with DS, individuals also 





DS is a common disorder, affecting around 1 in 1000 live births world-wide (World 
Health Organization 2015). However, prevalence varies with a number of factors 
including maternal age, country and ethnicity, and can be ascertained in a number of 
ways. 
1.2.1.1 Live birth prevalence 
Despite the introduction of routine screening for DS during pregnancy in recent 
decades and a rise in termination rates, the birth rate has remained steady across 
Europe at around 1 in 1000 live births (Dolk et al. 2005; Loane et al. 2013).  
In Scotland, a cytogenetic register has recorded data on all trisomies, including DS, 
since 1989. From 1989-1991, live birth prevalence was estimated at 1.2 per 1000, 
with no significant regional variations (Carothers 1994). A similar register collecting 
data on DS in England and Wales was also founded in 1989. At this time, DS 
prevalence was 1.10 per 1000 live births, falling by 1% to 1.08 in 1000 in 2008, due 
to antenatal screening and subsequent termination (Morris & Alberman 2009). It is 
estimated that around 700 babies are born with DS in England and Wales every year 
(Charleton et al. 2010). 
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Live birth rate in the US is similar to that of the UK and Europe. Estimated live birth 
prevalence has increased over time, from 0.9 per 1000 live births in 1979 to 1.2 per 
1000 in 2003 (Shin et al. 2009), with an estimated 1.4 in 1000 live births in the 
period 2004-2006 (Parker et al. 2010). 
The two main factors which determine the live DS birth rate are the true incidence of 
DS, which is influenced by the distribution of maternal age, and the rate of 
termination of pregnancy secondary to antenatal screening (Morris & Alberman 
2009). Data from a European network of DS data registries shows that the percentage 
of DS live births to women aged ≥35 years has risen steadily, from 8% in 1980 to 
13% in 1990 and 19% in 2009 (Dolk et al. 2005; Loane et al. 2013). Similar trends 
were noted in the North of England, rising from 6% in 1985 to 15% in 2004 (Irving 
et al. 2008), and in Victoria, Australia, rising from 8% in 1986 to 23% in 2004 
(Collins et al. 2008). However, although the prevalence of DS rises with maternal 
age, this reaches a plateau at around 45 years of age (Morris et al. 2002). 
Countries in which termination of pregnancy is illegal consequently have a higher 
live birth rate, averaging 1.6 per 1000 in Malta and 2.0 per 1000 in Ireland (Dolk et 
al. 2005). Where termination is available, the rate of uptake varies with maternal age, 
gestational age at diagnosis and ethnicity (Natoli et al. 2012). 
Studies of ethnically-diverse states in the US have compared the prevalence of DS 
among ethnicities. Two studies in California noted a higher DS birthrate in Hispanic 
women compared with white women of European origin, particularly in younger 
mothers (Bishop et al. 1997; Hook et al. 1999). A further study in Hawaii found 
ethnic variation in live birth rate, ranging from 0.8 per 1000 in African-Americans, 
Hawaiians and Samoans, to 2.4 per 1000 in Koreans, against an overall prevalence of 
0.8 per 1000 (McDermott & Johnson 2011). Although there are few studies of DS in 
Africa, live birth prevalence of DS has been estimated in the region of 1.2-1.8 per 
1000 (Christianson 1996).  Prevalence in Japan appears to be lower than the 
worldwide average, at 0.6 per 1000 live births (Hoshi et al. 1999), though a 
prevalence of 1.7 per 1000 was noted in Japanese mothers living in Hawaii 
(McDermott & Johnson 2011). However, a review of 36 studies covering 49 
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populations worldwide found that, once standardised for maternal age, the variation 
in prevalence between populations was only ±25%, though the increased rates in 
Hispanic mothers may remain (Carothers et al. 1999). 
1.2.1.2 Total prevalence 
Ascertainment of total prevalence takes into account not just the number of live 
births affected by DS, but also the number of stillbirths and late foetal deaths and the  
termination of pregnancy for foetal abnormality following an antenatal diagnosis of 
DS. 
In a study of 12 countries across Europe, the total prevalence during the period 1990-
2009, corrected for these outcomes, averaged 2.2 per 1000 births, versus a live birth 
prevalence of 1.1 per 1000 (Loane et al. 2013). While the total prevalence increased 
across this period, the live birth rate remained essentially stable. The stability of live 
birth rates across Europe suggests that the rise in mean maternal age, giving rise to 
an increase in the number of DS pregnancies, is counterbalanced by an increased 
termination rate.  
Data from the England and Wales National Down Syndrome Cytogenetic Register 
shows that, whilst live birth prevalence remained relatively steady between 1989 and 
2008, the number of DS diagnoses increased by 71%; during this period, the 
percentage of women opting to terminate their pregnancy after an antenatal diagnosis 
of DS remained stable at 92% (Morris & Alberman 2009). Interestingly, the total 
prevalence of DS in the USA including live births, still births and terminations was 
1.6 per 1000, differing only slightly from the live birth prevalence and  prevalence of 
live and stillbirths combined, both of which averaged 1.4 per 1000 (Parker et al. 
2010). This would suggest either a lower rate of antenatal detection or uptake of 
elective termination than elsewhere in the world, though the reasons for this are 
unclear. 
1.2.1.3 Population prevalence 
Fewer studies have attempted to document the population prevalence of individuals 
living with DS. The population prevalence in England and Wales was estimated at 
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0.7 per 1000 people in 2011, equating to over 37,000 people in England and Wales 
and over 47,000 in the whole of the UK (Wu & Morris 2013). Similarly, a study in 
the USA estimated that DS affected 0.8 in 1000 people, with over 250,000 living 
with DS in 2008 (Presson et al. 2013). In 2002, a further US study estimated that the 
prevalence of DS in children and adolescents aged 0-19 years was 1.0 in 1000; that 
is, over 83,000 young people in the USA alone (Shin et al. 2009). 
 Life expectancy of people with DS 1.2.2
As recently as 1983, the median age of death for people with DS was 25 years (Yang 
et al. 2002). However, life expectancy has increased steadily; in 2011, 37% of people 
with DS in England and Wales were aged >40 years, and the median life expectancy 
for a baby born that year was an estimated 58 years (Wu & Morris 2013). Life 
expectancy in a cohort of people with DS in Western Australia was 59 years, with a 
quarter of individuals living to 63 years and the oldest into their 70s (Glasson et al. 
2002). This improved life expectancy is in part related to the early treatment of 
health problems, with an overall one-year survival rate of 90%, rising to 97% in 
those without congenital heart problems (Irving et al. 2008; Coppus 2013). Given the 
comorbidities associated with DS, which are discussed in more detail in Section 
1.3.2, the ageing population of individuals with DS has important implications for 
health and social care services. 
 
1.3 The DS phenotype 
Although all cases of DS result from essentially the same underlying genetic cause, 
there is a broad spectrum of phenotypic expression (see 
Figure 2), and a wide range of features and comorbidities are associated with the 
condition. This section outlines these features, highlighting the similarities and 
differences between individuals with DS. Given the topic of this thesis, special 
consideration will be given to sleep disturbances associated with DS. 
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 Physical features 1.3.1
DS is characterised by a widely-recognised set of physical features, many of which 
were described in Down’s original observations of 1866 and formed the basis of 
identification of DS prior to the advent of genetic testing (Down 1866). A checklist 
of 25 features, subsequently narrowed down to the 10 most useful discriminating 
factors, was used by Jackson et al to identify DS in children suspected of having the 
disorder prior to cytogenetic analysis (Jackson et al. 1976) – see Table 1. Using the 
10-feature checklist, almost three-quarters of the children tested were correctly 
classified, with a false positive rate of 4.6% and a false negative rate of 12.2%. A 
“phenotypic map”, detailing the genes suspected to be responsible for many of these 
physical features has since been constructed (Korenberg et al. 1994). Postmortem 
analysis has allowed further characterisation of internal and external morphological 
features commonly found in individuals with DS (Byard 2007). Although the 
characteristic features of DS are evident in individuals with mosaic DS, these tend to 
be more subtle, reflecting the proportion of cells with an additional HSA21 
chromosome (Papavassiliou et al. 2009; Hultén et al. 2013). 
Of course, it is important to bear in mind that, despite these characteristic features, 
there are many more differences between individuals with DS than there are 
similarities, with individuals resembling their parents more than each other. 
Although there is trisomy of HSA21, other traits related to the rest of the genotype 
will still be expressed (Dierssen et al. 2009). 
1.3.1.1 Short stature 
Short stature is a common feature of nearly all individuals with DS (Roizen & 
Patterson 2003; Byard 2007). The reasons for this are unclear in most, although poor 
growth can be secondary to some of the comorbidities associated with the condition, 
including congenital heart disease, thyroid dysfunction and coeliac disease, as well as 
upper airway resistance, which will be discussed in greater detail in Chapter 2 (Styles 
et al. 2002).  
DS-specific growth charts have been published for the UK and Republic of Ireland, 
US and Sweden, documenting observed (but not necessarily desirable) height and 
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weight in children with DS (Cronk et al. 1988; Styles et al. 2002; Myrelid et al. 
2002). The average height of men with DS is 157cm, and of women, 145cm 
(Charleton et al. 2010), significantly lower than the general UK population averages 




Table 1: Jackson’s 25 signs of Down syndrome, with the ten most distinguishing features 
highlighted *. (Adapted from Jackson et al. 1976) 
Brachycephaly * Folded ear * 
Oblique eye fissure * Short neck * 
Epicanthic eye fold Loose skin of neck 
Blepharitis/conjunctivitis Short and broad hands 
Brushfield spots Short fifth finger 
Nystagmus * Incurved fifth finger * 
Flat nasal bridge * Transverse palmar crease 
Mouth permanently open Gap between first and second toes * 
Abnormal teeth Congenital heart defect 
Protruding tongue Murmur 
Furrowed tongue Joint hyperflexibility 
High arched palate Muscular hypotonia * 





Obesity is common in individuals with DS. Children with DS are commonly 
overweight by the age of 4 years (Roizen & Patterson 2003), with one study of 
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children in the UK and Republic of Ireland finding that, by the age of 10, 30% were 




 centiles for the 
general population respectively (Styles et al. 2002). This trend continues into 
adulthood, with obesity evident in 20-77% of adults with DS (Prasher 1995; Van 
Allen et al. 1999; Melville et al. 2005; Melville et al. 2007; Henderson et al. 2007).  
The tendency towards overweight and obesity may be related, at least in part, to short 
stature, though the cause is multifactorial. Obesity appears to be more prevalent in 
women, but not men, with DS, compared with adults with ID due to other causes 
(Melville et al. 2005). A further study by the same group noted that the risk of being 
overweight or obese decreased with increasing severity of ID (Melville et al. 2005; 
Melville et al. 2007). Of course, common comorbidities of DS which can impact on 
weight gain, such as hypothyroidism, should be screened for across the lifespan (Van 
Allen et al. 1999; Roizen & Patterson 2003; Bull 2011).  
Residential status may be important; in the Scottish study discussed above (Finlayson 
et al. 2009), residential setting was a significant factor impacting on low levels of 
physical activity; living in a congregate care setting was a significant predictor of 
low levels of physical activity. Living in the family home has been associated with 
increased risk of being overweight or obese in comparison to supervised care or 
hospital in a previous study in the US (Prasher 1995). 
Obesity is a major risk factor for sleep-disordered breathing in both adults with DS 
and the general population, and this is discussed further in Chapters 2 and 3. 
1.3.1.3 Premature ageing 
Premature ageing is a characteristic feature of adults with DS. As well as features of 
accelerated ageing per se, there is often an earlier onset of other disorders associated 
with advancing age in the general population, such as hypothyroidism and hearing 
and visual impairment (Esbensen 2010; Coppus 2013), which are discussed 
elsewhere in this chapter. One of the most striking and common features of 
premature ageing in adults with DS is early-onset dementia, similar to Alzheimer’s 
disease, and, again, this is discussed in further detail later in the Chapter. 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Down syndrome: an overview  10 
 Comorbidities 1.3.2
Although general health varies widely between individuals with DS, there are a range 
of comorbidities which occur more frequently in the DS population across the 
lifespan (Charleton et al. 2010).   
1.3.2.1 Cardiovascular comorbidities 
Congenital heart defects, including atrial and/or ventricular septal defects, are 
common in individuals with DS. Reported prevalence rates at birth range from 40% 
to 75% (Irving et al. 2008; Vis et al. 2009; Charleton et al. 2010; McDermott & 
Johnson 2011), with possible gender and ethnic differences evident (Yang et al. 
2002; Vis et al. 2009). Better treatment of congenital heart disease in early life has 
been a significant contributor to the increased life expectancy of individuals with DS 
(Coppus 2013), although, in one study, 13% of deaths in children and young people 
with DS aged <18 years were attributed to congenital heart defects (Bittles et al. 
2002). Two cohort studies estimate that 14-16% of adults with DS have untreated 
congenital heart defects (Van Allen et al. 1999; Henderson et al. 2007). Patients with 
DS are at an increased risk of pulmonary arterial hypertension, which is present in 
around 51% of children and 8% of adults with the condition (Van Allen et al. 1999; 
Vis et al. 2009; Hawkins et al. 2011; Sharma et al. 2013). This can be related to 
uncorrected cardiac defects, with children with DS developing pulmonary 
hypertension sooner than children with similar abnormalities but without DS (D’Alto 
et al. 2013). Of importance to the current study, pulmonary hypertension can also 
result from or be exacerbated by upper airway obstruction, and this is discussed in 
more detail in Chapter 2. 
1.3.2.2 Dermatological issues 
Dermatological problems, such as dry skin, atopic and seborrhoeic dermatitis and 
fungal infections of the nail and skin, are common in people with DS (Schepis et al. 
2002; Madan et al. 2006). One community-based survey in the UK found eczema in 
23% of adults with DS (Henderson et al. 2007), and a retrospective study of adults 
with DS in the US found 26% of individuals had a skin disorder of some type 
(Kerins et al. 2008).  
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1.3.2.3 Endocrine dysfunction 
Thyroid dysfunction, particularly hypothyroidism, is common in individuals with DS 
(Prasher 1999). It can be present from birth; 1% of newborns with DS will have 
congenital hypothyroidism, compared with 1 in 4000 in the general population 
(Roizen & Patterson 2003; Bull 2011). Hyperthyroidism may also occur, though less 
commonly so, in around 2% of adults with DS (Prasher 1999; Charleton et al. 2010). 
1.3.2.4 Gastrointestinal comorbidities 
Congenital abnormalities of the gastrointestinal tract, such as gastrointestinal atresia, 
are evident in 7-12% of children with DS, and are usually picked up and corrected 
shortly after birth Coeliac disease, an autoimmune disorder triggered by gluten 
ingestion, occurs in 5-7% of individuals with DS, with a mean diagnostic delay of 
3.8 years from onset of symptoms (Roizen & Patterson 2003; Bull 2011). 
1.3.2.5 Haematological problems 
Although overall rates of cancer are lower in DS than in the general population, 
incidence of leukaemia is increased, estimated to affect 1-2%; studies have reported a 
14-22 times increase in risk generally (Van Allen et al. 1999; Goldacre et al. 2004; 
Byard 2007; Charleton et al. 2010), rising to 60 times in those aged ≤4 years 
(Sullivan et al. 2007). Leukaemia is a common cause of mortality in children with 
DS, and carries a standardised mortality odds ratio of 1.6 (Yang et al. 2002). 
However, risk decreases with age (Esbensen 2010). 
1.3.2.6 Immunological disorders 
Individuals with DS often have impaired immune function from birth, which can lead 
to recurrent bacterial and viral infections (Charleton et al. 2010). Increased 
prevalence of a number of autoimmune disorders has been noted, including coeliac 
disease, autoimmune thyroiditis, leukaemia, type 1 diabetes, autoimmune hepatitis 
and skin conditions such as vitiligo and alopecia areata. 
.  
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1.3.2.7 Musculoskeletal disorders 
Around a fifth of individuals with DS have associated musculoskeletal disorders 
(Mik et al. 2008). Collagen is an important protein present in muscles, ligaments and 
tendons, constituting up to 6% of muscle tissue. The genes for type VI collagen are 
located on HSA21; type VI collagen is of particular importance in formation of 
skeletal and cardiac muscle, which may be related to the musculoskeletal and cardiac 
defects noted in individuals with DS (Dey et al. 2013). 
Generalised hypotonia (see  
Figure 3), related to abnormal development of the cerebellum, is evident in 
individuals with DS, who present as “floppy babies” at birth  (Lott 2012). Hypotonia 
continues into adulthood, and older adults with DS tend to have greater muscle 
weakness than others with ID and the general population.  
 
Figure 3: Generalised hypotonia in a baby with Down syndrome. Note the head lag upon pull to 
sitting and the inability to support posture in ventral suspension. Reprinted from Progress in 
Brain Research, Vol. 197, Lott IT, Neurological phenotypes for Down syndrome across the life 
span, Pages No. 101-121, Copyright (2012), with permission from Elsevier. 
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1.3.2.8 Neuropsychiatric morbidity 
Children and adults with ID are more than twice as likely to experience behavioural 
and emotional disturbances than the general population, with around 40% of these 
reaching a clinically concerning level. Around 18% of children with DS have a 
psychiatric disorder, rising to 26-30% in adults. Attention deficit hyperactivity 
disorder (ADHD) and obsessive-compulsive disorder are commonly seen in children 
and adolescents. Around 10% of individuals with DS have a dual diagnosis of autism 
(Kent et al. 2007; Smith 2001; Roizen & Patterson 2003; Dykens 2007; Virji-Babul 
et al. 2007; Bull 2011).  
Depression and anxiety occur frequently in adults with DS; one study reported 
depression or anxiety in 38% of adults aged 31-40 years and 46% of those ≥40 years 
(Virji-Babul et al. 2007), whilst another found anxiety and/or depression in 34% of 
under 50s and 22% in those aged ≥50 years (Kerins et al. 2008). Other studies have 
reported more modest rates of around 6-18% (Holland et al. 1998; Roizen & 
Patterson 2003; McCarron et al. 2005; Mantry et al. 2007). Early-onset dementia, 
similar to Alzheimer’s disease, is well-described in the literature, and is of particular 
relevance given the increasing life expectancy of individuals with DS. It is the most 
common cause of morbidity and mortality in adults with DS, with a standardised 
mortality odds ratio of 21.1 (Yang et al. 2002; Coppus 2013). Overall prevalence is 
estimated at 13-24% (Strydom et al. 2010), but it is clear that prevalence of dementia 
in adults with DS increases significantly with age: 3-10% at 30-39 years; 8-25% at 
40-49 years; 28-55% at 50-59 years; 30-75% at 60-69 years and 100% at ≥70 years 
(Lai & Williams 1989; Visser et al. 1997; Holland et al. 1998; Van Allen et al. 1999; 
Smith 2001; Strydom et al. 2010). Although a clinical diagnosis of dementia is not 
made in the majority of individuals until their early-to-mid 50s (Lai & Williams 
1989; Roizen & Patterson 2003), virtually all adults with DS will have 
neuropathological markers of dementia in the brain by the age of 40 (Lai & Williams 
1989; Van Allen et al. 1999; Lott & Head 2005; Dykens 2007; Zigman & Lott 2007; 
Urv et al. 2008).  
There is clearly a period during which pre-clinical changes are occurring in the 
absence of overt symptoms of dementia, and number of prodromal symptoms have 
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been described. Emotional disturbances, depression and changes in behaviour and 
personality may precede both problems with memory and confusion, and dementia 
per se; the number and severity of maladaptive behaviours increases with 
progression of dementia, and individuals showing sub-clinical changes in personality 
and behaviour are 1.5 times more likely to go on to develop dementia within 5 years 
(Ball et al. 2006; Dykens 2007; Urv et al. 2008; Lott & Dierssen 2010).  
Despite the high prevalence of dementia in adults with DS, few studies have 
evaluated treatment in this group (Lott & Dierssen 2010). Most recently, a 
randomised, placebo-controlled trial of memantine – a drug known to improve 
cognitive function in older adults with Alzheimer’s disease in the general population 
– failed to show an improvement in adults ≥40 years with DS (Hanney et al. 2012). 
 
Figure 4: Cumulative incidence of (a) Alzheimer’s disease type neuropathology in the DS 
population, (b) Alzheimer’s disease dementia in the DS population and (c) Alzheimer’s disease 
dementia in the typically-developing population. Copyright 2007, Wiley. Used with permission, 
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1.3.2.9 Respiratory comorbidities 
As previously noted, individuals with DS often experience frequent respiratory tract 
infections, related to immunodeficiency and structural abnormalities of the airways 
(Kusters et al. 2009; Ram & Chinen 2011). Generalised hypotonia can lead to 
malacia of the airways, which can impact on breathing and increase the risk of 
respiratory infection due to reduced mucus clearance. Sensory problems 
Hearing and visual impairment are common in individuals with DS at every age. 
There is evidence of premature ageing, with early onset of age-related hearing loss 
and senile cataracts, and an increasing prevalence of hearing and visual impairment 
with age  (McCarron et al. 2005; Esbensen 2010; Torr et al. 2010). Regular screening 
across the lifespan is recommended (Henderson et al. 2007; Charleton et al. 2010; 
Bull 2011). 
Importantly, it should be noted that sensory impairment can manifest as behavioural 
and emotional disturbances in individuals with DS due to diminished communication 
skills; an individual who cannot hear may appear stubborn, ignorant or withdrawn 
(Smith 2001; Määttä et al. 2006). However, sensory impairment was not associated 
with mental ill-health in one cohort of adults with DS (Mantry et al. 2007). Learning 
and cognitive function may be affected by visual or hearing loss (Lott 2012). 
 Protective effects of DS 1.3.3
Although associated with a range of comorbidities, there is evidence that DS may 
have a protective effect in other areas.  
1.3.3.1 Cancer 
Rates of most common cancers (excluding leukaemia and testicular cancer) are 
significantly lower in individuals with DS, and tumour-suppressing genes have been 
identified on HSA21 (Yang et al. 2002; Bittles et al. 2002; Kerins et al. 2008; Xavier 
et al. 2009; Esbensen 2010). 
1.3.3.2 Hypertension 
Hypertension is very uncommon, affecting only 0-3% of adults with DS in a number 
of studies (Van Allen et al. 1999; Kerins et al. 2008; van de Louw et al. 2009). This 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Down syndrome: an overview  16 
is much lower than is seen in adults with other forms of ID, estimated at around 17% 
(van de Louw et al. 2009). Prevalence of hypertension in the general population 
worldwide is estimated at 26% (Kearney et al. 2005). 
1.3.3.3 Ischaemic heart disease 
While the incidence of congenital heart disease is high in adults with DS, ischaemic 
heart disease is much less common in this population, occurring in 0-13% (Van 
Allen et al. 1999; Bittles et al. 2002; Kerins et al. 2008; Esbensen 2010; Coppus 
2013). Atherosclerotic protective factors have been associated with genes located on 
HSA21, and are over-expressed in DS, which may explain the low rates of 
atherosclerosis in this population (Vis et al. 2009). 
Reduced exposure to environmental and social factors with known associations with 
these diseases may play a protective role, with rates of alcohol and tobacco use very 
low in adults with DS and ID of other causes, in comparison with the general 
population – 45-96% are non-drinkers  and 85-100% non-smokers  (Robertson et al. 
2000; Jobling & Cuskelly 2009; Haveman et al. 2011; de Winter et al. 2009). 
1.3.3.4 The “Down syndrome advantage” 
DS may confer a benefit to other members of the family. A “Down syndrome 
advantage” has been well-described in the literature; mothers of children with DS 
tend to display better psychological wellbeing (including lower stress levels, more 
close and harmonious family relations, less pessimism and less caregiver burden) 
than mothers of children with other developmental disabilities and ID, across the 
lifespan of their son or daughter (Hodapp et al. 2001; Esbensen & Seltzer 2011). This 
may be related to a number of factors, the most important of which may be the 
behavioural phenotype of the person with ID; higher levels of problem behaviour 
were associated with poorer relationship quality and greater maternal pessimism, and 
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 Intellectual disability in individuals with DS 1.3.4
Alongside the characteristic physical phenotype, one of the hallmark features of DS 
is intellectual disability (ID). DS is the most common genetic cause of ID world-
wide. The most recent edition of the Diagnostic and Statistical Manual of Mental 
Disorders  (DSM-5) defines “intellectual disability” as impairment of general mental 
abilities that impact adaptive functioning in the conceptual, social and practical 
domains, originating in the developmental period (American Psychiatric Association 
2013). This replaces the term “mental retardation”, which is now generally 
considered both outdated and offensive. ID can be classified as mild, moderate, 
severe or profound, based on the level of adaptive functioning displayed by the 
individual. Although intelligence quotient (IQ) test scores were previously used as a 
cut-off for ID level, this is no longer the case, with more emphasis placed on overall 
functioning.  
1.3.4.1 IQ 
Individuals with DS can exhibit a wide range of IQ, typically from around <20 to 70, 
with most in the moderate to severe range (Dierssen et al. 2009; Mégarbané et al. 
2013). As mentioned above, IQ no longer forms a part of the formal diagnostic 
criteria for DS in DSM-5, but IQ testing is still recommended as part of an 
individual’s assessment;  in DSM-5, ID is typically considered to be approximately 
two standard deviations below the general population average, which is equivalent to 
an IQ score ≤70.(American Psychiatric Association 2013). Individuals with mosaic 
DS have significantly higher IQ than those with trisomy 21 (Fishler et al. 1991). IQ 
typically diminishes with age in the general population; a number of studies have 
reported that this process is amplified in adults with DS, though only in verbal, not 
performance, IQ (Carr 2005).  
1.3.4.2 Neurological basis of ID in DS 
A number of characteristic changes occur in the structure and functioning of the 
brain in individuals with the DS. The overall volume of the brain is over 20% smaller 
than that of typically-developing individuals, despite controlling for reduction in 
body size (Contestabile et al. 2010). Although some studies suggest this change is 
evident from the prenatal period an persists into adulthood (Contestabile et al. 2010; 
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Lott 2012), others suggest that brain size is normal at birth, with the relative 
reduction in size occurring postnatally by around 6 months of age (Fidler & Nadel 
2007). Regardless, it is clear that there is an overall shortening of the brain 
(brachycephaly) and reduced total brain volume, with reduced volumes in a number 
of brain areas including the frontal and temporal lobes, hippocampus and cerebellum, 
and that these areas continue to be most affected across the lifespan (Nadel 2003). 
Reduction in cerebellar volume may be related to growth restriction imposed by the 
small cranial vault associated with DS.  
As well as volumetric changes, abnormal development and functioning of the brain 
has been noted. A study of over 100 brains of children with DS found a delay in 
myelination in around a quarter of children, in comparison with 7% of children 
without DS; this was particularly evident in nerve fibres linking the frontal and 
temporal lobes (Wisniewski 1990; Nadel 2003). A number of studies, in both DS and 
ID of other aetiology, have reported abnormal development of dendrites, neuronal 
structures which are vital for synaptic connectivity and brain plasticity. Dendrites are 
shorter and show less branching in the hippocampus and cortex of individuals with 
DS, worsening with age (Contestabile et al. 2010). Minicolumns, the functional units 
of the cerebral cortex, are larger and less dense in individuals with DS (Dierssen et 
al. 2009). Decreased levels of neurotransmitters have been noted, both during foetal 
development and later in life (Contestabile et al. 2010). As discussed earlier, beta-
amyloid plaques and neurofibrillary tangles develop much earlier in individuals with 
DS than in the general population (Lott 2012). 
To summarise, a combination of neuropathological factors – including a reduced 
number of neurons, abnormal neuronal structure and accelerated degeneration – 
contribute to the ID seen in DS, with some brain regions more affected than others. 
The relationship between these regional changes and the cognitive phenotype of 
individuals with DS will be discussed in the following sections. 
1.3.4.3 Motor function 
Children with DS experience delay in gross motor functions such as rolling, sitting, 
walking and running (Palisano et al. 2001), and impaired motor function is evident in 
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a number of mouse models of DS (Contestabile et al. 2010). This delay in motor 
development appears to be more pronounced than the delay in intellectual 
development (Volman et al. 2007), though motor growth curves show that the limit 
appears to be the rate of development and not the level of skills which can be 
acquired, with more complex movements requiring more time to learn (Palisano et 
al. 2001). This is, in part, related to generalised hypotonia (see Section 1.3.2.7), with 
a higher degree of hypotonia related to worse motor function (Volman et al. 2007).  
1.3.4.4 Speech and language 
The development of speech and language is delayed in children with DS, in 
comparison with both typically-developing children and those with ID due to other 
causes (Kernan & Sabsay 1996). This is related to hearing and visual impairments,  
oromotor dysfunction and orofacial anatomical abnormalities, as well as ID per se 
(Roberts et al. 2007; Martin et al. 2009). However, most individuals with DS develop 
at least basic language skills, with many adults with DS being able to communicate 
successfully during their daily routines (Kernan & Sabsay 1996).  
Language deficits in individuals with DS may be related to problems with short-term 
memory (Chapman & Hesketh 2001), and this is discussed further below. 
1.3.4.5 Learning and memory 
There is a huge wealth of literature devoted to learning and memory in individuals 
with DS, which is perhaps unsurprising given the prominence of ID as a feature 
affecting all people with DS. The neurological basis of the learning and memory 
deficits observed in individuals with DS is summarised in Figure 5 (Lott & Dierssen 
2010). This section will focus predominantly on the three main brain areas which 
have been identified as being most affected in DS – the hippocampus, prefrontal 
cortex and cerebellum (Nadel 2003). 
To fully understand the impairment observed in individuals with DS, a basic review 
of the categorisation of memory processes is required, and follows herewith, adapted 
from a description by Robert Stickgold (Stickgold 2005). A visual representation is 
shown in Figure 6. Memories are broadly divided into two categories: declarative, 
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which are facts that can be recalled; and non-declarative, which are unconscious 
memories. Declarative memories are further divided into memories of specific events 
(episodic) and general knowledge memories (semantic). Examples of these include 
what one had for dinner last night (episodic) and the capital city of France 
(semantic). Non-declarative memories are those which are used without conscious 
recollection, such as how to ride a bike. These are further sub-divided into procedural 
skills (step-by-step actions), conditioning (unconscious response to a stimulus), non-
associative (habituation and sensitisation) and priming (related to prior exposure to 
an item, or a related item). All memories are formed through a process of acquisition, 
processing and storage, then recalled at a later date. Memory consolidation refers to 
the neurological processes by which acquired memories are stabilised and stored for 
future recall. 
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Figure 5: The learning circuit in DS. The flow diagram represents the stages of information flow 
relevant to learning and memory which have been reported to be altered in DS. Reprinted from 
The Lancet Neurology, Vol. 9, IT Lott and M Dierssen, Cognitive deficits and associated 
neurological complications in individuals with Down’s syndrome, Page no. 623-33, Copyright 




Figure 6: Categorisation of memory systems. Reprinted by permission from Macmillan 
Publishers Ltd: Stickgold R, Nature; 437, 1272-1278, copyright (2005) 
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The hippocampus is involved in declarative memory, and is important for flexible 
learning and consolidation of learning (Nadel 2003; Teipel & Hampel 2006; Dierssen 
et al. 2009). Spatial cognition also involves hippocampal function (Nadel 2003). 
Individuals with DS exhibit deficits in long-term storage, particularly encoding and 
retrieval, of declarative memory (Lott & Dierssen 2010). One study in children with 
DS found that, whilst they could acquire information almost as quickly as typically-
developing children, they had problems retaining the information, suggesting 
hippocampal impairment. A further study in adolescents found specific evidence of 
hippocampal dysfunction, with individuals with DS performing worse than typically-
developing controls on all five tests used (Wishart 1993; Pennington et al. 2003; 
Fidler & Nadel 2007). The volume of the hippocampus decreases with age in adults 
with DS, and is one of the first areas to be affected by accumulation of Aβ during the 
early stages of dementia. This is associated with a decline in memory function in 
those with and without dementia, and problems with learning, memory and 
visuospatial organisation in those with dementia (Teipel & Hampel 2006; Lott & 
Dierssen 2010).  
The prefrontal cortex is of particular importance in executive function and working 
memory, and also has a role in episodic memory (Nadel 2003; Pennington et al. 
2003).  Impairment in working memory has been noted, particularly in verbal (but 
not visuospatial) information (Jarrold & Baddeley 2001; Fidler & Nadel 2007). 
Children with DS perform poorly on tests of executive function which require 
memory as well as visual-motor organisation (Dierssen et al. 2009).  
The role of the cerebellum is less clear, though it appears to be involved in visual and 
motor skills, conditioning and higher order functioning such as emotion and affect. 
Problems with attention, learning, verbal fluency and working memory are also noted 
(Nadel 2003; Dierssen et al. 2009; Lott & Dierssen 2010). A battery of 
neuropsychological tests has been developed to measure prefrontal, hippocampal and 
cerebellar functioning in children and adults with DS (Edgin et al. 2010), and is 
discussed in more detail in Chapter 8. 
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 Behaviour 1.3.5
A personality or behaviour stereotype of individuals with DS has persisted over time, 
with people with DS being perceived as exhibiting a host of positive personality 
traits, including cheerfulness and affection. This may be, in part, related to an 
increased use of nonverbal social gestures by children with DS (Fidler 2006) and the 
relatively low prevalence of maladaptive behaviours which adults with DS display in 
comparison with adults with ID of other causes (Chapman & Hesketh 2000; Blacher 
& McIntyre 2006). This personality stereotype may also contribute to the “DS 
advantage” discussed previously (Esbensen & Seltzer 2011). However, a wide 
variation in personality traits are exhibited by individuals with DS, and maladaptive 
behaviour and neuropsychiatric problems do occur (see Section 1.3.2.8 above). 
Specific behavioural phenotypes in individuals with DS have been described in some 
detail, and a summary of the emergence of these phenotypes with age is shown in  
 
Table 2 (Chapman & Hesketh 2000). 
 Behavioural and emotional disturbances in adults with DS are commonly related to 
mental health problems, such as depression, pre-clinical and clinical symptoms of 
dementia and, of direct relevance to this thesis, sleep disorders (Capone et al. 2006; 
Dykens 2007).  
1.4 Societal issues 
As well as the physical, mental and emotional difficulties which can be associated 
with DS, there are a number of wider societal issues which people with DS and their 
families face.  
 Education 1.4.1
A detailed review of the educational needs of children and adolescents with DS is 
outwith the scope of this thesis. However, the inclusion of children with DS in 
mainstream schools is now commonplace in most developed countries; for example,   
inclusion in mainstream schooling has been in effect in Italy since the early 1970s 
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(Bertoli et al. 2011), and, by the mid-1990s, fewer than 2% of children in the UK 
were attending “special” schools (Farrell 2000). Mainstream education has been 
shown to have educational and social benefits for individuals with DS, with 
attendance at a mainstream school being a significant predictor of higher academic 
attainment (Laws et al. 2000; Buckley et al. 2006; Turner et al. 2008). 
 
Table 2: Developmental emergence of the behavioural phenotype of Down syndrome. Copyright 
2000, Wiley. Used with permission, from Chapman RS and Hesketh LJ. MRDD Research 
Reviews 2000; 6:84-95. 
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 Employment  1.4.2
The transition from school can be particularly challenging for young people with DS, 
who may face additional barriers to employment due to their ID and comorbidities, 
as well as perceptions relating to their abilities; one survey of over 2000 people in the 
general population in Australia found that only 39% thought that an adult with DS 
was likely to be able to work independently in paid employment (Gilmore et al. 
2003). 
 Daily living 1.4.3
A number of options are available to individuals with DS, ranging from fully 
independent accommodation, supported accommodation, group homes and 
communities to residential care settings. However, an individual’s level of 
independence and ID may determine their living arrangements to a certain extent. 
Individuals with DS in residential care commonly have more comorbidities, and 
accommodation setting may be related to health outcomes including poor diet, 
obesity and inactivity, though causes of death are similar for individuals with DS 
whether they live in the community or in an institutional setting  (Robertson et al. 
2000; Melville et al. 2005; Esbensen et al. 2007; Finlayson et al. 2009; Esbensen 
2010). 
 Healthcare 1.4.4
Given the range of potential health problems which may be associated with DS, it is 
unsurprising that health screening across the lifespan is recommended (Van Allen et 
al. 1999; Smith 2001; Roizen & Patterson 2003; Charleton et al. 2010; Bull 2011). 
However, whilst frequent screening of children is commonplace, less vigilance may 
be paid in adulthood, and the transition from paediatric care to adult services may not 
be straightforward (Hallum 1995; Pueschel 1996; Olsen & Swigonski 2004; 
Schrander-Stumpel et al. 2007).  Specialist multidisciplinary services for adults with 
DS may be beneficial, but few exist (Chicoine et al. 1994; Schrander-Stumpel et al. 
2007).  
People with ID of all causes, including DS, face health inequalities and barriers to 
using health services (Cooper et al. 2004). There is evidence that individuals with DS 
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do not or cannot access adequate healthcare. A study of 151 individuals with ID, 
including 34 with DS, found that, whilst all participants with DS had seen a GP at 
least once within the past year, only 38% of individuals with DS had adequate 
contact with their GP, defined as at a minimum of 4 visits (Howells 1986). The 
benefits of a nurse-led structured health screening programme in people with ID, in 
which 28% of both the intervention and control groups had DS, were demonstrated 
by Cooper et al (Cooper et al. 2006). After 1 year, individuals who underwent the 4 
hour screening process had significantly more new health needs detected and treated, 
as well as higher levels of health promotion and monitoring needs met than 
individuals who received standard care, despite similar underlying health 
surveillance requirements in both groups. 
Some of the lack of screening in adults with DS may be related to “diagnostic 
overshadowing” (Reiss et al. 1982). Although the term was originally used to 
describe the under-diagnosis of mental health problems in individuals with ID, the 
concept can be related to a number of health issues faced by people with DS which 
may go unnoticed or ignored due to the misapprehension that they are “just part of 
the condition”. Many individuals with DS and other forms of ID will have a 
condition diagnosed but not receive treatment due to the mistaken belief of health 
and social care professionals that they cannot or should not be treated.  Most, if not 
all, conditions associated with DS can be corrected or ameliorated, and an underlying 
diagnosis of DS should not preclude treatment in the majority of cases. 
 Advocacy 1.4.5
Charitable organisations play an important part in supporting and advocating for 
people with DS and their families. Such charities – including, in the UK, Down’s 
Syndrome Scotland, the Down’s Syndrome Association and the Down’s Heart Group 
– play a vital role in educating individuals, families, professionals and the general 
public, promoting inclusion for people with DS and influencing policy at a local and 
national level. Peer support for individuals with DS and their families can have 
positive benefits (Mann 1999; Olsen & Swigonski 2004). 
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In the UK, the Down’s Syndrome Association (DSA), a national charity supporting 
people with DS and their families and carers, developed a Health Book for adults 
with DS (Down’s Syndrome Association 2014). This is provided free of charge in 
printed form for DSA members, as well as being available as a free electronic 
download for others. This easy-read book is designed to encourage adults with DS to 
take ownership of their own health and to see their general practitioner (GP) for 
annual health screening. The book contains a checklist of areas which should be 
screened, and supplementary information on DS-related health topics is provided 
online for GPs. This may help adults with DS access regular health screening and 




Although arising from broadly the same genetic abnormality, DS is a complex and 
wide-ranging disorder, with a broad spectrum of cognitive, health and social effects. 
Despite the wide range of known comorbidities, services for adults with DS are 
lacking. As life expectancy continues to rise towards that of the typically-developing 
population and more individuals with DS reach their elder years, further research into 
the health and well-being of adults with DS, as well as the underlying aetiology and 
natural history of DS, is required to ensure that they receive the care and support they 
require and deserve to maintain quality of life across the lifespan. 
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Chapter 2: Obstructive sleep 
apnoea/hypopnoea syndrome: an overview 
Sleep-disordered breathing (SDB) is an umbrella term for a spectrum of sleep-related 
breathing disorders related to narrowing and obstruction of the upper airway. 
Although arising from similar aetiology, there is a continuum of severity, from 
primary snoring to severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS), 
a disorder which can impact significantly on morbidity and mortality. This chapter 
provides an overview of SDB, focussing on the underlying mechanisms, risk factors, 
symptoms and consequences of OSAHS. 
 
2.1 The spectrum of sleep-disordered breathing 
During normal, awake breathing, inspiration is associated with a reduction in 
pressure within the pharynx, making it susceptible to closure, with an open airway 
maintained by the action of the pharyngeal muscles. During sleep, a number of 
factors affect the patency of the upper airway; these are summarised Figure 7 
(Malhotra & White 2002). As one falls asleep, skeletal muscles relax, resulting in an 
overall reduction in muscle tone, reaching total relaxation or atonia in rapid eye 
movement sleep (REM or stage R). This reduced muscle tone (particularly in the 
muscles of the pharynx and tongue), alongside the effects of gravity when 
recumbent, leads to narrowing of the upper airway and an increase in susceptibility 
to airway collapse during inspiration. Additional factors, such as fat deposits around 
the neck, the use of sedative medication or alcohol and comorbid conditions affecting 
muscle tone, can exacerbate this effect, leading to closure of the airway and 
obstruction of breathing. Limitation of the pharyngeal space due to craniofacial 
abnormalities or adenotonsillar hypertrophy can also play a part in airway 
obstruction during sleep. The pathophysiological mechanisms of SDB are discussed 
in further detail in Section 2.2 below. 
 Obstructive sleep apnoea (OSA) 2.1.1
OSA is a condition characterised by repeated cycles of pauses in and resumption of 
breathing. Reduction in breathing due to partial obstruction is known as a 
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hypopnoea, and complete airway obstruction as an obstructive apnoea. Apnoeas and 
hypopnoeas are often associated with oxygen desaturation and arousals from sleep, 
leading to sleep fragmentation. Changes in breathing and other physiological 
parameters during sleep and wake can be studied objectively using a number of 
techniques, with internationally-recognised practice parameters and diagnostic 
criteria used worldwide – these are discussed further in Section 2.6.4.1. An 
apnoea/hypopnoea index (AHI) of ≥5 events per hour of sleep is generally accepted 
as diagnostic of OSA in adults, and can be further categorised as mild (AHI 5-14.9), 
moderate (AHI 15-29.9) or severe (AHI ≥30) (Scottish Intercollegiate Guidelines 
Network 2003; Epstein et al. 2009). 
 
Figure 7: Factors contributing to maintenance and obstruction of the upper airway in sleep-
disordered breathing. Reprinted from The Lancet, Vol. 360, Malhotra A and White DP, 
Obstructive sleep apnoea, Pages No. 237-45, Copyright (2002), with permission from Elsevier. 
 
 
 Obstructive sleep apnoea/hypopnea syndrome (OSAHS) 2.1.2
The term OSAHS is used when OSA results in significant diurnal symptoms. Many 
individuals may demonstrate OSA during objective testing, but there is evidence that 
only those with symptoms benefit from treatment (Barbé 2001). Current guidelines 
recommend treatment only in symptomatic individuals meeting the criteria for 
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moderate to severe OSAHS (Loube 1999; Scottish Intercollegiate Guidelines 
Network 2003; Epstein et al. 2009), although studies have demonstrated 
improvements in sleepiness, mood and daytime function in symptomatic individuals 
with mild OSAHS (Engleman et al. 1997; Engleman et al. 1999; Marshall 2005). 
 Primary snoring 2.1.3
Snoring in the absence of apnoea/hypopnoea is known as primary snoring. While 
snoring is a commonly associated with OSAHS, not every snorer has OSAHS and 
not every individual with OSAHS snores (Bearpark et al. 1995). Although most often 
a complaint of the bed partner rather than the snorer themselves (Hoffstein et al. 
1994), snoring has been associated with an increased risk of all-cause mortality in its 
own right (Rich et al. 2011). Investigation to rule out OSA prior to treatment of 
primary snoring is warranted. 
 Upper airways resistance syndrome (UARS)  2.1.4
Narrowing of the airways which causes sleep fragmentation and symptoms such as 
excessive daytime sleepiness, but does not result in apnoea or hypopnoea per se, is 
known as upper airway resistance syndrome (UARS). There are conflicting views on 
whether this merits the label of a distinct syndrome, or whether it can be thought of 
as sub-clinical or pre-clinical OSAHS (Guilleminault 1993; Rees et al. 2000; 
Velamuri 2006; Pépin et al. 2012). 
 Central sleep apnoea 2.1.5
Although this overview focuses on obstructive breathing problems, it should be 
noted that SDB can also be central in origin. In central apnoea, cessation of airflow 
results from cessation of effort, due to the brain failing to trigger breathing (Eckert et 
al. 2007). This is more common in young children with an immature chemoreceptor 
response and usually diminishes with age, but central apnoea may be seen in older 
children and adults with brain injury, neurological abnormalities, or  genetic 
conditions such as central congenital hypoventilation syndrome  (Urquhart 2013). 
Central apnoea can also be related to obesity hypoventilation (Eckert et al. 2007). 
Central apnoea, and particularly a pathological breathing pattern known as Cheyne-
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Stokes respiration, is commonly found in individuals with congestive heart failure 
(Lieber & Mohsenin 1991; Naughton 1998). 
 
2.2 Pathophysiological mechanism of OSAHS 
The pharynx is composed, essentially, of a flexible tube surrounded by muscle and 
soft tissue, and is, therefore, susceptible to collapse. As detailed in Figure 7, a 
number of factors are involved in balancing maintenance and closure of the 
pharyngeal airway during sleep (Malhotra & White 2002). The pathophysiological 
mechanism of OSAHS has been the subject of a number of excellent reviews 
(Douglas & Polo 1994; Malhotra & White 2002; Patil et al. 2007; Horner 2008; 
Eckert & Malhotra 2008), and a summary of these is given here. 
Collapsibility of the upper airway varies between individuals, and is a determinant of 
pressure and resistance. Critical pressure, or PCRIT, is the point at which airflow 
ceases and the airway collapses. The narrower the airway, the more susceptible it is 
to collapse, and the higher the PCRIT. However, the upper airway is particularly 
narrow at the point where the soft palate and tongue are in alignment, and so is 
vulnerable to obstruction during sleep. A number of anatomical factors, including fat 
deposition, craniofacial structure, retrognathia and adenotonsillar hypertrophy, 
contribute to further narrowing of the airway, and sleep (particularly REM sleep), 
alcohol and sedative drugs inhibit the action of the pharyngeal dilator muscles. These 
combined factors result in partial (hypopnoea) or complete (apnoea) obstruction of 
the airway. 
Apnoea or hypopnoea leads to both reflex stimulation of the pharyngeal dilator 
muscles, and to an increase in respiratory effort related to chemoreceptor response to 
hypoxia/hypercapnia. The increase in respiratory effort results in cortical arousal, 
further stimulating the activity of the dilator muscles and restoring a patent airway. 
However, sleep onset post-arousal leads to narrowing of the airway via the 
mechanisms described above, and the characteristic cycle of repeated obstruction and 
resumption of breathing of SDB continues – see  Figure 8 (Malhotra & White 2002).  
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 Figure 8: Mechanisms of neurocognitive and cardiovascular sequelae of OSAHS. Reprinted 
from The Lancet, Vol. 360, Malhotra A and White DP, Obstructive sleep apnoea, Pages No. 237-
45, Copyright (2002), with permission from Elsevier.  
 
 
2.3 Epidemiology of OSAHS 
A number of studies have assessed prevalence of OSAHS in the adult population 
using subjective and objective measures (Young et al. 1993; Davies & Stradling 
1996; Punjabi 2008; Fuhrman et al. 2012). Although variation is noted between 
studies due to population and methodological differences, it is generally accepted 
that SDB affects around 20% of the general population and the prevalence of 
OSAHS is around 2% in women and 4% in men, based on a middle-aged populations 
(Jennum & Riha 2009). This estimate is mainly based on objective data from the 
Wisconsin Sleep Cohort Study, a large longitudinal study (Young et al. 1993) in the 
USA; a recent follow-up study by the same group reported an increased prevalence 
of 10-17% in men and 3-9% in women, though this is yet to be replicated in other 
populations (Peppard et al. 2013). OSAHS affects up to 6% of the paediatric 
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population (Marcus et al. 2012), with a peak in prevalence at age 2-8 years (Tan et al. 
2013). 
 Risk factors 2.3.1
2.3.1.1 Age 
In adults, OSAHS prevalence increases with age, with one study demonstrating an 
odds ratio of 2.2 for every 10-year increase in age (Duran et al. 2001). A large study 
in the USA found that in men the prevalence of OSAHS increased with age, peaking 
in middle-age, though the severity decreased when controlling for BMI (Bixler et al. 
1998). A further study from the Wisconsin Sleep Cohort found that, whilst the risk of 
SDB increased with age, the association between sleepiness and SDB decreased, 
suggesting that sleepiness may not be the most important symptom in older adults 
with OSAHS, though this association was again observed only in men (Morrell et al. 
2012). Prevalence of OSAHS appears to plateau after the age of 60 years (Duran et 
al. 2001). The age-related increase in OSAHS is related to a number of features of 
the normal ageing process including deposition of adipose tissue, diminishing muscle 
tone, changes to the pharyngeal anatomy and physiology and, in women, menopause 
(Redline et al. 1994; Martin et al. 1997; Malhotra et al. 2006).  
2.3.1.2 Gender 
OSAHS occurs more frequently in men than women, with a ratio in the range of 2:1 
to 8:1 reported in the literature (Punjabi 2008). A community-based random sample 
study in Sweden found that 20% of females aged 20-70 years had moderate OSA 
(Franklin et al. 2013). Studies suggest that men and women may differ not only in 
the symptoms of OSAHS which they experience, but also in the  way in which these 
symptoms are perceived and reported by their spouse or partner (Kingshott et al. 
1995; Punjabi 2008). There is a four-fold increase in the prevalence of OSAHS post-
menopause, and hormone replacement therapy is associated with a reduced 
prevalence of OSAHS (Redline et al. 1994; Bixler et al. 2001; Shahar et al. 2012).  
2.3.1.3 Ethnicity 
Variations in OSAHS prevalence with differing ethnicity has been reported in 
children and adults. However, these differences may be related less to ethnicity per 
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se, but more to factors associated with differing ethnicities, such as craniofacial and 
upper airway structure, obesity, socioeconomic status, health disparity and 
environment (Villaneuva et al. 2005; Genta et al. 2008; Yamagishi et al. 2010; 
Sutherland et al. 2012; Ralls & Grigg-Damberger 2012).  
Ethnicity in relation to SDB is further discussed in Chapter 6 in relation to a 
comparative study of subjective OSAHS prevalence in Scotland and Japan conducted 
as part of this thesis. 
2.3.1.4 BMI and neck circumference 
Being overweight or obese remains the biggest risk factor for OSAHS, with over half 
of all individuals with moderate-to-severe OSAHS having a BMI ≥25 kg/m
2
 (Young 
et al. 2005). Multiple studies around the world have reported an increasing 
prevalence of OSAHS with increasing body weight, with some studies demonstrating 
improvement or resolution of OSAHS with surgical or dietary weight loss (Punjabi 
2008; Romero-Corral et al. 2010). Given that the prevalence of overweight and 
obesity is generally rising, both in the UK and worldwide (see Figure 9), this 
presents a major public health challenge in terms of OSAHS and other comorbidities 
(Wang et al. 2011).  
The relationship between obesity and OSAHS is multifactorial. As well as the 
mechanical effects of reduced airway size related to fat deposition in the neck and 
reduced caudal traction related to central obesity, adipose tissue contributes to 
systemic inflammation and metabolic dysregulation which has been associated with 
OSAHS and can impact on the neuromuscular control of upper airway patency 
(Martin et al. 1997; Malhotra & White 2002; Schwartz et al. 2008; Punjabi 2008; 
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Figure 9: Global trends in obesity, defined as BMI ≥25. Reprinted from The Lancet, Vol. 378, 
Wang CY, McPherson K, Marsh T, Gortmaker SL, Brown M, Health and economic burden of 
the projected obesity trends in the USA and the UK, Pages No. 815-825, Copyright (2011), with 
permission from Elsevier. 
 
 
2.3.1.5 Reduced muscle tone 
Any disorder or factor which reduces muscle tone will impact on the patency of the 
upper airway. This includes the intrinsic effects of sleep (particularly REM sleep), fat 
deposits in the neck, supine posture and normal ageing, as well as extrinsic factors 
such as the use of alcohol and sedative drugs (Mitler et al. 1988; Martin et al. 1997; 
Douglas & Polo 1994; Horner 2008). Comorbid medical conditions associated with 
hypotonia or muscle weakness, such as DS and Duchenne muscular dystrophy, are 
also associated with an increased risk of OSAHS (Primhak & Kingshott 2012). The 
links between DS and OSAHS is discussed in detail in Chapter 3 of this thesis. 
2.3.1.6 Adenotonsillar hypertrophy 
Enlargement of the tonsils and adenoids is the most common cause of OSAHS in 
children. Adenotonsillectomy is considered the standard first-line treatment for 
OSAHS in children, and is curative in 75-100% of cases (Schechter 2002). In adults, 
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large tonsils and adenoids can impact on the pharyngeal space, increasing the risk of 
airway closure during sleep. Tonsillar size is routinely assessed clinically using the 
Mallampati or Friedman rating scales (Mallampati et al. 1985; Friedman 2002), with 
higher scores associated with higher risk of OSAHS (Liistro et al. 2003; Nuckton et 
al. 2006; Rodrigues et al. 2010). 
 
Figure 10: Intermediate phenotypes and heritable factors in OSAHS. Reprinted from Kent BD, 
Ryan S and McNicholas WT, The genetics of obstructive sleep apnoea, Current Opinion in 




The hereditary nature of OSAHS has been demonstrated in a number of studies 
(Redline & Tishler 2000; Riha et al. 2009; Kent et al. 2010), and genetic factors are 
thought to account for around 40% of the variance in AHI seen in OSAHS (Redline 
& Tishler 2000). The heritable factors associated with OSAHS and their contribution 
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to the OSAHS phenotype are summarised in Figure 10 below (Kent et al. 2010), and 
have been discussed in detail elsewhere in this chapter. 
2.3.1.8 Comorbidities 
A number of congenital disorders, including neuromuscular and skeletal disorders 
(e.g. Duchenne muscular dystrophy, scoliosis), craniofacial abnormalities (e.g. Pierre 
Robin sequence, achondroplasia) and genetic disorders (e.g. DS, Prader-Willi 
syndrome) can predispose to OSAHS (Primhak & Kingshott 2012). In the context of 
this thesis, a detailed discussion of the links between DS and OSAHS is provided in 
Chapter 3. 
 
2.4 The OSAHS phenotype 
OSAHS is characterised by a series of nocturnal and diurnal symptoms which are 
summarised in Table 3 and discussed in further detail below.  
 Nocturnal symptoms 2.4.1
Snoring and witnessed apnoeas are the most common nocturnal symptoms of 
OSAHS. The prevalence of these symptoms varies between studies, due to 
population and methodological differences. However, epidemiological studies 
suggest that up to 50% of men and 17% of women in the general population snore 
(Lindberg 2010), rising to up to 100% in those with an AHI ≥15 (Redline et al. 
1994). The percentage of individuals snoring on ≥3 nights per week increases with 
increasing AHI (Young 1996). Witnessed apnoeas rely on spouse or bed partner 
report, and are reported less often in females than males; witnessed apnoeas were 
reported by 8% of males and 5% of females in one community-based study, rising to 
61% of males and 37% of females with an AHI≥15 (Young 1996). Another study 
reported witnessed apnoeas in 42% of males and 12% of females with a similar AHI 
(Redline et al. 1994). In a Danish study, 25% of males and 18% of females with an 
AHI≥5 were habitual snorers, with witnessed breathing pauses noted by 17% and 
13% of males and females respectively (Jennum & Sjøl 1992). A more recent study 
in France reported witnessed apnoeas in 13% of men and 5% of women in the 
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general population, with 14% of men and 6% of women snoring almost every night 
(Fuhrman et al. 2012). 
The repeated cycle of apnoea and arousal results in sleep fragmentation, which may 
manifest as restlessness and unrefreshing sleep. Experimentally-induced sleep 
fragmentation has been shown to impair daytime function (Martin et al. 1996), and 
the neurocognitive impact of untreated OSAHS is discussed further in Section 2.5.4 
below. 
Table 3: Nocturnal and diurnal symptoms of OSAHS. 
Nocturnal symptoms  Diurnal symptoms  
Snoring  Excessive daytime somnolence (EDS)  
Witnessed apnoeas  Morning headache  
Gasping or choking episodes  Dry mouth  
Restlessness  Poor concentration/memory  
Frequent awakenings  Mood disturbances  
Nocturia  Behavioural disturbances  
 
 Diurnal symptoms 2.4.2
Excessive daytime sleepiness (EDS) is the most prominent feature of OSAHS, 
arising from sleep fragmentation due to repeated cycles of arousal during sleep – see  
Figure 8 above and Figure 11 below. EDS is most commonly measured subjectively 
using the Epworth Sleepiness Scale (ESS; Johns 1991), which is discussed in detail 
in Chapter 5, and objectively using the multiple sleep latency test (MSLT; Littner et 
al. 2005). Individuals with EDS related to OSAHS often report daytime napping or 
sleep attacks, as well as falling asleep in social and work situations. This can impact 
negatively on employment, social function and quality of life. Sleepiness when 
driving may occur, and individuals with EDS are more likely to be involved in road 
traffic accidents than the general population (Iranzo 2010). Often, the individual 
themselves is not fully aware of the extent of their sleepiness, and bed partners or 
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proxies tend to give higher ESS scores than patients themselves (Kingshott et al. 
1995; Walter et al. 2002). 
 
Figure 11: Effects of airway narrowing. Reprinted from The Lancet, Vol. 2, Douglas NJ and 
Polo O, Pathogenesis of obstructive sleep apnoea/hypopnoea syndrome, Issue 8923 Page no. 




Daytime cognitive function is impaired, with deficits in attention, concentration and 
memory evident, as well as mood disturbances; again, this is discussed further in 
Section 2.5.4. Dry mouth and nasal congestion are common, related to mouth 
breathing in an attempt to overcome airway obstruction. Morning headaches, related 
to nocturnal hypercapnia, are also frequently reported. 
2.5 Consequences of untreated OSAHS 
Left untreated, OSAHS is associated with a number of deleterious consequences, 
leading to increased morbidity and mortality. 
 All-cause mortality 2.5.1
Untreated OSAHS is associated with increased mortality. A study of over 6,400 
individuals participating in the Sleep Heart Health Study in the USA found a 
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significant association between SDB and all-cause mortality, with hypoxaemia (but 
not sleep fragmentation) independently associated with mortality (Punjabi et al. 
2009). A further large cohort study in Australia, the Busselton Health Study, found 
that moderate/severe, but not mild, OSA was related to increased risk of all-cause 
mortality (Marshall et al. 2008). Self-reported witnessed apnoeas were associated 
with all-cause mortality in the Swedish Obese Subjects study (Marshall et al. 2011). 
 Cardiovascular effects 2.5.2
OSAHS has been associated with cardiovascular sequelae, including hypertension, 
ischaemic heart disease, congestive heart failure and stroke (Parati et al. 2013). In a 
10-year observational study, Marin et al (Marin et al. 2005) demonstrated that severe 
OSAHS in men increased the risk of fatal and non-fatal cardiovascular events in 
comparison with healthy controls, primary snorers, individuals with mild-moderate 
OSAHS and patients on CPAP by an odds ratio of 3 – see Figure 12. Severe SDB in 
men aged 40-70 years was associated with mortality due to coronary artery disease in 
the Sleep Heart Health Study (Punjabi et al. 2009). OSAHS has been shown to be an 
independent risk factor for pulmonary hypertension, with around 20% in one study 
developing mild daytime pulmonary hypertension (Alchanatis et al. 2001). 
As summarised in  Figure 8 and Figure 11, cardiovascular dysfunction in OSAHS is 
in part related to sympathetic nervous system activation secondary to arousal 
(Douglas & Polo 1994; Malhotra & White 2002). However, the relationship between 
OSAHS and cardiovascular morbidity is multifactorial, with intermittent hypoxia, 
endothelial dysfunction, systemic inflammation and disruption of the renin-
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Figure 12: Cumulative percentage of men with new fatal (A) and non-fatal (B) cardiovascular 
events in each of the five groups studied by Marin et al. Reprinted from The Lancet, Vol. 365, 
Marin JM, Carrizo SJ, Vicente E, Agusti AGN, Long-term cardiovascular outcomes in men 
with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive 
airway pressure: an observational study, Pages No. 1046–1053, Copyright (2005), with 





 Endocrine dysfunction 2.5.3
A multitude of studies worldwide have shown an independent association between 
OSAHS and impaired glucose metabolism, abnormal lipid metabolism and metabolic 
syndrome (Lam et al. 2010). As mentioned above, a number of mechanisms are 
thought to be involved in OSAHS and metabolic dysfunction, including sleep 
fragmentation, intermittent hypoxia, oxidative stress, systemic inflammation, 
dysregulation of the leptin/ghrelin system and hormonal effects of adipose tissue 
(Lam et al. 2010). 
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 Neurocognitive sequelae 2.5.4
A meta-analysis by Beebe et al (Beebe et al. 2003) and a more recent meta-review by 
Bucks et al (Bucks et al. 2013) have described the cognitive deficits commonly 
observed in individuals with OSAHS and the possible mechanisms underlying these. 
OSAHS has been associated with a wide range of neurocognitive deficits, 
encompassing learning, memory, attention, executive function and mood, likely 
related to the effects of both intermittent hypoxia and sleep fragmentation. 
Impairment in these areas has clear implications for everyday function and quality of 
life for people with untreated OSAHS. 
A number of brain imaging studies have described changes in brain morphology 
associated with OSAHS, including reduced volumes in the hippocampus, 
cerebellum, prefrontal cortex and temporal lobe (Morrell & Glasser 2012).  As 
discussed in Chapter 1, the hippocampus has a role in declarative memory and 
consolidation of learning, the prefrontal cortex is involved in executive function and 
working memory and the cerebellum has involvement in visual-motor skills, emotion 
and affect, although there is some overlap between functions between brain regions.  
2.5.4.1 Learning and memory 
A relationship between sleep and memory has been well described. In a review of 
sleep-dependent memory consolidation by Stickgold, it was noted that, in a series of 
six experimental studies examining the link between sleep and memory, sleep 
accounted for 69% of the variance in learning/memory task performance, 
demonstrating a very close correlation between the two (Stickgold 2005). It stands to 
reason, therefore, that sleep disruption related to OSAHS may be associated with 
deficits in learning and memory. Memory problems are subjectively reported by 
more than half of patients with OSAHS (Jennum & Sjøl 1992; Flemons & Reimer 
1998). 
The meta-analysis by Beebe et al found inconsistent results in terms of memory 
function in OSAHS, possibly due to methodological differences between studies 
(Beebe et al. 2003), though a previous meta-analysis noted a moderate effect  in 
memory-related performance scores in adults with OSAHS (Engleman et al. 2000). 
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A further meta-analysis of studies assessing the effects of OSAHS on episodic 
memory (Wallace & Bucks 2013)found  impairments in verbal and visuospatial, but 
not visual, memory; the authors proposed that this may be related to dysfunction of 
the prefrontal cortex. Prefrontal cortex dysfunction secondary to OSAHS has been 
implicated in a range of adverse effects on daytime function (Beebe & Gozal 2002), 
and this is discussed further in relation to behaviour below.   
2.5.4.2 Attention 
Individuals with OSAHS commonly complain of problems with concentration; 23% 
of adults with OSAHS in a Swedish cohort (Jennum & Sjøl 1992) and 69% in a 
Canadian study (Flemons & Reimer 1998) reported concentration problems. 
Objective testing of attention and vigilance in individuals with OSAHS also shows 
impairment (Engleman et al. 2000; Beebe et al. 2003; Bucks et al. 2013).  An Italian 
study showed that, whilst reaction time was impaired in individuals with OSAHS 
relative to controls, this was significantly improved after only 15 days on CPAP, 
which was sustained after 4 months of therapy (Ferini-Strambi et al. 2003). 
It has been suggested that individuals with higher IQ have a greater “cognitive 
reserve”, and so are less sensitive to cognitive impairment associated with OSAHS 
(Alchanatis et al. 2005). When individuals with OSAHS underwent tests of attention 
and alertness, individuals with a high IQ performed as well as normal-IQ controls, 
whilst the OSAHS patients with normal IQ showed impairment in comparison with 
controls. However, after a year of CPAP treatment, both groups performed as well as 
controls. 
2.5.4.3 Executive function 
Impaired executive function has been noted in adults with OSAHS in many studies, 
though recent reviews suggest that the this is neither related to OSAHS severity nor 
significantly improved with CPAP therapy (Engleman et al. 2000; Bucks et al. 2013). 
Ferini-Strambi et al demonstrated improvements in tests of executive functioning 
after 15 days of CPAP, though this did not reach significance after 4 months. 
Canessa et al examined the link between morphometric changes and cognitive 
function (Canessa et al. 2011). Reduced volumes in the hippocampus were related to 
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impaired performance on tests of memory and executive function; after treatment 
with CPAP, improved performance on these tests was noted, and was associated with 
increased hippocampal volume. Impaired hippocampal function appears to be related 
to intermittent hypoxia (Feng et al. 2012). The deficits observed in attention and 
vigilance in individuals with OSAHS appear to be related to sleep fragmentation 
more so than hypoxaemia (Engleman et al. 2000; Bucks et al. 2013), and 
experimentally-induced sleep fragmentation results in similar decrements in attention 
and vigilance tasks (Martin et al. 1996). 
2.5.4.4 Motor skills 
Inconsistent effects of OSAHS on motor function skills have been noted (Bucks et al. 
2013), though some studies have shown visuo-motor deficits which may be 
improved by CPAP (Ferini-Strambi et al. 2003; Chen et al. 2012). 
2.5.4.5 Depression 
Irritability and low mood are common symptoms of OSAHS, and just one night of 
sleep fragmentation via experimental methods has been shown to impair mood 
(Martin et al. 1996). Co-existing depression is frequently observed in individuals 
with OSAHS, and overlap between the symptoms of both may hinder diagnosis 
(Harris et al. 2009). In one study in Mexico, 57% of individuals with AHI≥5 had 
symptoms of anxiety and/or depression (Reyes-Zuniga 2012) and, in Australia, 32-
53% of individuals referred for investigation of snoring or OSAHS had symptoms of 
or were receiving treatment for depression (Douglas et al. 2013).. 
2.5.4.6 Behavioural and emotional disturbance 
Particularly in children, sleepiness related to SDB can manifest as hyperactivity or 
behavioural or emotional disturbance, rather than overt sleepiness (Gozal 2000), with 
children with symptoms of SDB more likely to exhibit aggression and bullying 
behaviours (O’Brien et al. 2011). As discussed above, problems with low mood and 
depression are apparent in adults with OSAHS. Beebe and Gozal proposed a model 
whereby OSAHS lead to behavioural and emotional disturbance in both children and 
adults due to the impact of sleep fragmentation and intermittent hypoxia on the 
prefrontal cortex; this is summarised in Figure 13 below (Beebe & Gozal 2002). 
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Prefrontal dysfunction secondary to OSAHS may explain a number of the 
neurocognitive deficits observed in individuals with untreated OSAHS. 
 
Figure 13: Beebe and Gozal’s prefrontal model. Reprinted from Beebe DW and Gozal D (2002), 
Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking 
nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. Journal of 




Despite the clear evidence of a link between cognitive impairment and OSAHS, few 
studies have formally evaluated the role of OSAHS in Alzheimer disease or vascular 
dementia. However, a review of the evidence suggests that a causal link between 
OSAHS and dementia may exist (Bliwise 2013). A prospective study of nearly 300 
older women without dementia found that those with SDB were at higher risk of 
developing mild cognitive impairment or dementia than non-SDB controls, though 
no associations with sleep fragmentation or hypoxia were noted (Yaffe et al. 2011). 
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A recent retrospective study of over 1400 patients in Taiwan suggests that 
individuals with OSAHS have a 1.7 times greater risk of developing dementia within 
5 years of diagnosis when compared to age- and gender-matched controls without 
OSAHS (Chang et al. 2013). It has been suggested the brains of older people may be 
more sensitive to intermittent hypoxia associated with OSAHS, which may 
accelerate cognitive decline in this group (Morrell et al. 2012), potentially 
predisposing to the onset of dementia. However, further investigation in this area is 
required.  
 
2.6 Diagnosis of OSAHS 
This section summarises the range of subjective and objective methods for 
assessment and diagnosis of OSAHS. 
 Clinical history 2.6.1
Although taking a good clinical history is a vital part of the diagnostic process, 
clinical history and physical examination alone has been shown to be a poor indicator 
of OSAHS (Viner 1991) and further subjective and objective screening is usually 
required. 
 Screening questionnaires 2.6.2
A number of screening questionnaires have been validated in the assessment of 
OSAHS. The ESS is a widely-used measure of sleepiness over recent times (Johns 
1991). The Stanford Sleepiness Scale (SSS) provides a point-in-time assessment of 
sleepiness (Hoddes et al. 1973), making it useful for repeated measures across a 
given period, for example prior to each nap of an MSLT. The Karolinska Sleepiness 
Scale offers a similar, Likert-type scale (Åkerstedt & Gillberg 1990). Other 
questionnaires have been developed to assess a wider range of OSAHS symptoms 
beyond sleepiness alone.  One example, the STOP-BANG questionnaire, was 
originally developed to screen for possible OSAHS prior to anaesthesia, and has 
since been found to be useful in a more general sleep clinic setting (Chung et al. 
2008; Vasu et al. 2010; Chung et al. 2012). A review of the full range of screening 
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questionnaires available is outwith the scope of this thesis; however, the 
questionnaires used during the studies described herein are described in the relevant 
Chapters. 
 Objective testing 2.6.3
Although screening questionnaires can be useful, objective measurement of sleep by 
sleep study is required to quantify the underlying level of SDB. A variety of different 
types of sleep study device are available, recording single or multiple channels of 
physiological data during sleep and wake overnight and during the day, at home or in 
a sleep laboratory setting. The American Sleep Disorders Association (ASDA) 
defined four levels of portable device based on the number of channels and quality of 
data recorded  (Ferber et al. 1994). 
2.6.3.1 Level I Devices 
Level I sleep studies, or standard polysomnography (PSG), record a minimum of 
seven channels of data, including EEG, electrooculogram (EOG), electromyogram 
(EMG), electrocardiogram (ECG), airflow, respiratory effort, oxygen saturation and 
body position (Ferber et al. 1994). Since the ASDA guidance was written, the use of 
video recording as part of the PSG study is now commonplace. This combination of 
channels allows the definitive staging of sleep as well as monitoring of respiration, 
oxygenation and body movements associated with SDB and other sleep disorders. 
For this reason, PSG is considered the reference-standard test for diagnosis of 
OSAHS (Penzel et al. 2010). Level I PSG must be fully attended overnight by an 
experienced technologist, and international guidelines and technical specifications 
for the set-up recording and scoring of PSG were published by the American 
Academy of Sleep Medicine in 2007 (Iber et al. 2007); these are discussed further in 
Section 2.6.4 below. Practice parameters for the use of PSG have also been published 
(Kushida et al. 2005). Due to the requirement for costly specialist equipment, an in-
patient bed, and skilled staff in attendance overnight and to score the study, level I 
PSG is the most expensive sleep study, and this may limit its availability. The SIGN 
guidelines for OSAHS state that PSG is not required for diagnosis of OSAHS in the 
majority of cases, but should be available in tertiary centres for the assessment of 
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more complex or equivocal cases (Scottish Intercollegiate Guidelines Network 
2003).. 
2.6.3.2 Level II Devices 
Ambulatory PSG is described as a level II device. This type of device records the 
same channels as level I PSG, but this is unattended and can be carried out in the 
patient’s own home. Although the cost of an in-patient bed is negated, specialist 
equipment and staff are still required to set up the equipment during an outpatient or 
home visit and to score the results. The risk of signal loss is high due to the 
unattended nature of the study. For these reasons, ambulatory PSG is not commonly 
used clinically. However, most modern PSG systems can now be used in both in- and 
outpatient settings, and some systems will allow the recording of digital video at 
home. 
2.6.3.3 Level III Devices 
Level III devices, known as modified portable sleep apnoea testing devices, limited 
studies, cardiorespiratory studies or polygraphy, are frequently used, and practice 
parameters have been published (Collop et al. 2007). By definition, a level III device 
must have a minimum of four channels, including two channels of respiratory effort 
or respiratory effort and airflow, heart rate or ECG and oxygen  saturation (Ferber et 
al. 1994). An important difference between these devices and level I or II PSG is that 
the channels required for sleep staging are absent, and so diagnosis of OSAHS is 
based on time in bed, rather than total sleep time and, additionally, there is no valid 
measure of EEG arousal – this can result in a dilution of the AHI by around 20% 
(Hedner et al. 2011), and this is discussed further in Chapter 7.  Level III devices 
require less specialist knowledge to set up, and patients can be quickly and easily 
instructed in their use, allowing collection of the equipment to set up themselves at 
home. Again, some systems allow the integration of video recording. Although 
signal loss is a risk, patients can easily reattach sensors if they come off, more so 
than with level I or II PSG. Many individuals report a more representative night’s 
sleep at home in their own bed rather than in the hospital environment. The 
combination of an unattended outpatient study, less expensive equipment and far 
quicker and easier scoring mean that polygraphy can offer significant cost savings, in 
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the region of 42-50%, over level I or II studies (Dingli et al. 2003; Juan F. Masa et al. 
2011). Level III polygraphy is indicated as the first-line diagnostic test for 
individuals with a high clinical suspicion of OSAHS and, given its high sensitivity 
and specificity for detection of OSAHS, can be used to exclude as well as diagnose 
the condition, although PSG may still be required if results are equivocal (Ferber et 
al. 1994; Scottish Intercollegiate Guidelines Network 2003; Collop et al. 2007; 
Penzel et al. 2010). Further discussion of level III polygraphy in the context of this 
thesis can be found in Chapter 7. 
2.6.3.4 Level IV Devices 
The most basic sleep study devices record only one or two channels of data, the most 
commonly used level IV device being pulse oximetry. Oximetry has the benefit of 
being portable, easy to use and relatively cheap, allowing quick-turnaround, high-
volume screening, and many clinical sleep services will use this as a first-line test to 
screen all new patients. However, there are significant limitations. A single (or dual) 
channel recording is at very high risk of signal loss – if one channel is lost or affected 
by artefact, the entire study is invalidated, which may result in the requirement for a 
repeat study, incurring additional time and cost. Level IV devices do not record EEG, 
and so no true measure of sleep is recorded, only time in bed. Further, a number of 
validation studies have shown that, whilst sensitivity for diagnosis of OSAHS is 
high, specificity is generally low (Ferber et al. 1994), and so current guidelines 
recommend that oximetry cannot be used to rule out OSAHS, with a “negative” 
study considered equivocal and further testing with a higher level sleep study device 
required (Scottish Intercollegiate Guidelines Network 2003).  
 Scoring and interpretation of sleep studies 2.6.4
2.6.4.1 Scoring criteria and guidelines 
In 1968, Rechtshaffen and Kales introduced the first classification of sleep stages 
based on electrophysiological measures (Rechtschaffen & Kales 1968). These “R&K 
rules” remained the gold-standard guidelines for sleep staging until 2007, when the 
American Academy of Sleep Medicine (AASM) introduced its Manual for the 
Scoring of Sleep and Associated Events (Iber et al. 2007). Unlike the R&K rules, this 
comprehensive manual, for the first time, incorporated guidelines for scoring EEG 
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arousals, respiratory events and movement events alongside sleep staging. The 
Manual is a dynamic document, having been further updated a number of times since 
Version 1, with planned updates on a twice-yearly basis. However, although the 
Manual was generally seen as a step forward in the standardisation of practice in 
sleep medicine, changes to the rules have often been controversial, with studies 
suggesting differences in diagnostic outcomes based on different versions of the 
guidelines and between recommended and acceptable alternative rules within the 
Manual (Ruehland et al. 2009). 
In adults, The American Academy of Sleep Medicine (AASM) Manual for the 
Scoring of Sleep and Associated Events Version 1 (Iber et al. 2007) defines a 
hypopnoea as a ≥30% reduction in a valid measure of airflow of at least 10s duration, 
associated with dip in SpO2 of ≥3% and/or an EEG arousal. An obstructive apnoea is 
defined as a ≥90% reduction in airflow for a minimum duration of 10s, with no 
arousal or desaturation requirement. Further discussion of the scoring rules and 
recording equipment can be found in the Methods section of Chapter 7 of this thesis. 
2.6.4.2 Diagnostic thresholds 
The International Classification of Sleep Disorders 2
nd
 edition defines the diagnostic 
threshold for OSAHS as an AHI or respiratory disturbance index (RDI) ≥5 events per 
hour of sleep in association with symptoms including sleepiness, hypersomnolence, 
insomnia, arousals with feeling of asphyxiation/ suffocation, snoring or witnessed 
apnoeas, where the disorder cannot be attributed to other conditions, use of 
medicines or other substances (American Academy of Sleep Medicine 2005). Both 
the ICSD-2 and SIGN guidelines classify the severity of OSAHS as: mild: 5-15 
events per hour; moderate: 15-30 events per hour; and severe: more than 30 events 
per hour (Scottish Intercollegiate Guidelines Network 2003; American Academy of 
Sleep Medicine 2005). SIGN recommends treatment of all symptomatic patients with 
moderate-to-severe OSAHS. It should, however, be noted that differing thresholds 
are used between studies in the literature, which may account for some of the 
differences observed between them. 
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2.7 Treatment of OSAHS 
A range of treatment options are available for SDB and OSAHS, and are briefly 
described here. 
 Continuous positive airway pressure 2.7.1
Continuous positive airway pressure therapy (CPAP) is recognised as the first-line 
treatment for OSAHS in adults, and, since its introduction in 1981, has changed the 
lives of millions of people world-wide.  
2.7.1.1 History and mechanism 
CPAP was invented by Professor Colin Sullivan and introduced via a landmark paper 
in 1981(Sullivan et al. 1981). A simple, non-invasive treatment, CPAP involves 
delivering pressurised room air via a mask positioned over the nose (or nose and 
mouth) to reverse the negative intrathoracic pressure generated during an apnoea by 
providing pneumatic splinting of the airway, as shown in Figure 14. Despite its 
simplicity, Sullivan and colleagues demonstrated an instant and dramatic 
improvement in oxygen saturation and AHI in a cohort of five patients, aged 13 to 
55, with severe OSAHS. An example is shown in Figure 15, where the saturation 
trace of one individual who had previously shown repeated desaturations into the 
80%s was normalised by the application of CPAP. 
2.7.1.2 Benefits 
Since this original landmark study, the efficacy of CPAP has been demonstrated in a 
range of trials, including randomised controlled trials using placebo or sham CPAP. 
These trials have shown CPAP to be effective in ameliorating many of the 
consequences discussed above, including EDS, cognitive dysfunction and metabolic 
and cardiovascular outcomes ( Engleman et al. 1994; McFadyen et al. 2001; 
Engleman et al. 2002; Patel et al. 2003; Ferini-Strambi et al. 2003; Marin et al. 2005; 
Weaver et al. 2007; West et al. 2007; Coughlin et al. 2007; Antic et al. 2011; Kylstra 
et al. 2013).  
All-cause mortality is improved by the use of CPAP; a study of 444 individuals with 
SAHS over 10 years found that those with untreated OSAHS had significantly higher 
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mortality than those using CPAP, with use of CPAP therapy reducing the risk of all-
cause mortality to a similar level as the general, non-OSAHS, population (Marti et al. 
2002). Further retrospective reviews have continued to support these observations  
(Marin et al. 2005).  
 
Figure 14: Mechanism of upper airway occlusion and its prevention by CPAP. During wake, 
muscle tone prevents airway collapse during inspiration (top panel); during sleep, the tongue 
and soft palate collapse due to negative intrathoracic pressure (middle panel). CPAP provides a 
pneumatic splint, keeping the airway open (lower panel). Reprinted from The Lancet, Vol. 317, 
Issue 8225, Sullivan CE, Berthon-Jones M, Issa FG, Eves L, Reversal of obstructive sleep 
apnoea by continuous positive airway pressure applied through the nares, Pages no. 862-865, 
Copyright (1981), with permission from Elsevier.  
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Figure 15: Normalisation of oxygen saturation during sleep after one night of CPAP therapy. A 
single patient’s control night (upper panel) and CPAP night (lower panel) are shown. CPAP at 
7.0cmH2O was applied at arrow A and sustained for the remainder of the night. Reprinted from 
The Lancet, Vol. 317, Issue 8225, Sullivan CE, Berthon-Jones M, Issa FG, Eves L, Reversal of 
obstructive sleep apnoea by continuous positive airway pressure applied through the nares, 
Pages no. 862-865, Copyright (1981), with permission from Elsevier.  
 
 
2.7.1.3 Side-effects and compliance issues 
Although CPAP is simple, non-invasive and effective, it does have some side effects. 
A proportion of users will struggle to tolerate CPAP, and many will discontinue the 
therapy. There is evidence that many make the decision to continue or quit CPAP 
within the first 1-2 weeks (Hoy et al. 1999; Ye et al. 2012; Balachandran et al. 2013), 
and intensive education and support has been shown to improve compliance in the 
longer term (Hoy et al. 1999). Psychological and behavioural interventions may be 
effective in improving CPAP compliance (Engleman & Wild 2003). The choice of 
CPAP interface is also important (Parthasarathy 2008; Borel et al. 2013). 
Side effects can be a barrier to compliance with CPAP; common side effects of 
CPAP include nasal dryness or congestion, skin irritation or discomfort related to the 
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mask interface and aerophagia, which can result in bloating and flatulence, and 
claustrophobia (H. M. Engleman et al. 1994; Stepnowsky et al. 2002; Chasens et al. 
2005; Weaver & Grunstein 2008). Dryness and congestion can be easily remedied by 
the addition of heated humidification, though this does not necessarily improve 
compliance with treatment (Massie et al. 1999; Martins de Araújo 2000; Neill et al. 
2003; Worsnop et al. 2010; Koutsourelakis et al. 2010). Other factors affecting 
compliance include age, gender,  ethnicity, low socioeconomic status and 
psychological factors ( Engleman et al. 1994; Weaver & Grunstein 2008; Olsen et al. 
2008; Simon-Tuval et al. 2009; Ye et al. 2012). CPAP may be ineffective or 
minimally effective in individuals who are asymptomatic or have only mild OSAHS 
(Engleman et al. 1997; Barbé 2001) 
2.7.1.4 Guidelines 
CPAP is recommended as the first-line treatment for OSAHS in adults by a number 
of guidelines and reports, including those published by SIGN, National Institute for 
Clinical Excellence and the AASM (Scottish Intercollegiate Guidelines Network 
2003; National Institute for Clinical Excellence 2008; Epstein et al. 2009).  
 Non-CPAP therapies 2.7.2
Although treatments other than CPAP are available, there is a paucity of evidence to 
support their use as a standalone treatment for OSAHS in most cases and CPAP 
remains the first-line treatment for most. However, these may be useful as an adjunct 
to CPAP therapy, or as a first-line treatment for sub-OSAHS SDB. The use of 
alternative therapies may also be indicated in the event of inability to tolerate CPAP. 
2.7.2.1 Weight reduction 
In individuals who are overweight, weight loss can be effective in reducing the 
severity of OSAHS, though this can be difficult to achieve and maintain. In a 3-way 
randomised trial of CPAP versus mandibular advancement device (see 2.7.2.4 below) 
versus weight loss, weight loss was associated with a reduction in AHI, but did not 
significantly improve OSAHS, daytime sleepiness or quality of life (Lam et al. 
2007). A recent European Respiratory Society Task Force concluded that the 
available evidence for weight loss as a standalone treatment for OSAHS was 
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inconsistent (Randerath et al. 2011). However, given the health and economic 
benefits of weight loss generally (Oster et al. 1999), all overweight and obese 
individuals with OSAHS should be advised to lose weight, irrespective of other 
treatment for OSAHS.  
2.7.2.2 Pharmacological intervention 
Although a number of pharmacological treatments for OSAHS have been proposed, 
including theophylline, acetazolamide, selective serotonin reuptake inhibitors, 
cholinergic agents and nocturnal oxygen, no single medication has been consistently 
effective in treating OSAHS (Hedner & Zou 2010; Randerath et al. 2011). 
2.7.2.3 Surgical intervention 
A number of surgical options for treatment of OSAHS are available. Removal of the 
uvula and soft palate using laser, radiofrequency ablation or by 
uvulopalatopharyngoplasty (UPPP) are not recommended as a sole treatment for 
OSAHS and, indeed, can make future CPAP treatment problematic (Mortimore et al. 
1996; Han et al. 2006). A less invasive technique, known as Pillar implants, uses 
short fibre rods which are inserted into the soft palate under local anaesthetic. This 
stiffens the soft palate and has been shown to be effective in individuals with primary 
snoring and mild/moderate OSAHS, and can be used in conjunction with CPAP 
(Maurer et al. 2005; Bertoletti et al. 2009). 
Maxillofacial surgery to reposition the upper and/or lower jaw and thereby increase 
the pharyngeal airspace has been shown to be effective in individuals where 
craniofacial abnormality is the primary cause of OSAHS (Mehra & Wolford 2000), 
though the invasive nature of this procedure makes it less desirable as a standard 
treatment for the majority of OSAHS patients.  
Surgical weight loss via bariatric surgery is a treatment option in super-obese 
patients. However, long-term follow-up data on the effect of bariatric surgery on 
OSAHS in these patients is limited, and perioperative complications appear common 
(Chang et al. 2010). Further studies are required, though the ethics of randomised 
trials in this high-risk population have been questioned (Greenburg et al. 2009). 
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2.7.2.4 Oral appliances 
Mandibular advancement devices (MAD) are considered the best alternative for 
individuals who are unwilling or unable to tolerate CPAP (Fleetham & Almeida 
2010), and are the usual first-line treatment for primary snoring. An orthodontic 
gumshield-type device is worn over the teeth at night, pulling the lower jaw and 
attached soft tissues (including the tongue) forward, increasing the pharyngeal space. 
This is particularly useful in cases where snoring is caused by retrognathia. Side- 
effects including orofacial pain, excessive salivation and inability to retain the device 
have been described (Izci et al. 2005), and MAD use has been shown to be less 
effective than CPAP in individuals with mild/moderate OSAHS (Lam et al. 2007). 
However, in a recent randomised crossover trial of MAD in symptomatic individuals 
with mild/moderate OSAHS who had declined or did not require CPAP therapy, 
treatment with MAD was found to be effective, both in terms of clinical outcomes 
and health economics, in comparison to no treatment (Quinnell et al. 2014). 
Other oral appliances which increase the pharyngeal space, including tongue 
retention devices which pull the tongue forward during sleep (Lazard et al. 2009) and 
oral pressure therapy which is applied over the lower teeth to protrude the jaw 
(Colrain et al. 2013) are available, though evidence for their efficacy is currently 
scant. 
2.7.2.5 Positional therapy 
The gravitational effect of lying in the supine position can impact on airway patency 
during sleep. Some individuals experience positional OSAHS in which 
apnoea/hypopnoea only occurs when lying on their back. In this instance, positional 
therapy may be appropriate. A positional training device, which vibrates whenever 
the patient turns onto their back and stops when they return to a non-supine position, 
has been shown to reduce AHI in individuals with mild/moderate positional OSAHS 
(Van Maanen et al. 2012). 
2.7.2.6 Hypoglossal nerve stimulation 
Stimulation of the hypoglossal nerve during inspiration using an implantable device 
triggers contraction of the genioglossus muscle, and the resulting tongue protrusion 
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counteracts airway narrowing. This has been shown to be both safe and effective in 
individuals with moderate/severe OSAHS for whom CPAP has been intolerable 
(Eastwood et al. 2011), though further studies are required. 
2.8 Conclusion 
OSAHS is a common condition which is related to increased morbidity and 
mortality. However, simple, effective treatment in the form of CPAP is available 
and, in most cases, significantly reduces or normalises the risks associated with the 
disorder. Whilst alternative treatments are available and desirable to patients, these 
are less effective than CPAP in most cases and are, therefore, only recommended for 
specific patient subpopulations, as an adjunct to CPAP therapy or in individuals who 
are non-compliant with CPAP. 
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Chapter 3: The relationship between DS and 
OSAHS 
As the preceding chapters have shown, there is significant overlap between the DS 
phenotype and factors which contribute to OSAHS. This chapter outlines the 
relationship between the two disorders, and provides the context for the studies 
described within the remainder of thesis. 
 
3.1 Prevalence of OSAHS in DS 
The prevalence of OSAHS in adults with DS was undetermined at the outset of this 
work. However, there were a number of smaller studies in children with DS.  
The first large study of over 100 children with DS aged 1-18 years used inpatient 
polygraphy to screen for OSA, independent of clinical suspicion of OSAHS (de 
Miguel-Díez et al. 2003). Fifty-five percent of children had OSA, defined as ≥3 
apnoea/hypopnoea (AH) events per hour in bed. A gender effect was noted, with 
65% of males and 39% of females exhibiting OSA. AH per hour in bed showed a 
significant association with younger age, male gender and tonsillar (but not 
adenoidal) hypertrophy; there was no correlation with obesity, congenital heart 
disease or previous adenotonsillectomy. An AHI of ≥1 event per hour of sleep is 
considered abnormal in children when using PSG. However, since AH can be diluted 
when using polygraphy (see Chapter 2), a higher AH cut-off may be required; in this 
study, use of an AH cut-off of ≥5 events per hour gave a prevalence of 42%, 23% at 
AH≥10 and 12% at AH≥15. Despite methodological and population differences 
across studies, the objective prevalence of OSAHS in the typically-developing 
paediatric population is estimated at 0.1-13.0% (Lumeng & Chervin 2012), much 
lower than was reported in the study of children with DS by de Miguel-Diez, 
regardless of AH cut-off.   
To date, only two studies have used PSG to assess the prevalence of OSAHS in 
adults with DS. In a study in Italy (Resta et al 2003), six adults (3 male, 3 female) 
aged 28-53 with DS years from a residential facility underwent inpatient PSG after 
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an acclimatisation night. Using a diagnostic threshold of AHI≥10 events per hour, 5 
of the 6 participants (83%) had OSA. Severity of OSA, measured by AHI or ODI, 
was not associated with age, BMI or neck circumference. A prevalence of 83% 
represents a substantial increase over the 2-4% observed in the general adult 
population (Young et al. 1993). However, this study has a number of significant 
limitations. Firstly, the very small number of participants should be noted. All 
participants lived in residential care and so the results may not be generalisable to the 
wider DS population, particularly given that residential status can affect health 
outcomes, including physical activity and BMI (Prasher 1995; Finlayson et al. 2009). 
Only two of the six individuals included in this study were overweight or obese using 
WHO criteria (World Health Organization 2006), the remaining four participants all 
being of normal BMI; again, this suggests that this data may not be generalisable to 
the wider DS population, where overweight and obesity affects up to three-quarters 
of individuals and differs according to gender (Prasher 1995; Van Allen et al. 1999; 
Melville et al. 2005; Melville et al. 2007; Henderson et al. 2007). Data relating to 
symptoms of OSAHS and ethnicity were not collected. None of the participants were 
taking any medication or had significant comorbidities, which, again, may not be 
representative of the DS population as a whole.  
The second published study included 16 adults with DS aged 19-56 years recruited 
from a DS-specific clinic and DS advocacy groups in the USA (Trois et al. 2009). 
Except for one Asian participant, all were Caucasian. There was an even gender split, 
and 4 of the 8 females were post-menopausal. Three-quarters of participants were 
obese and 13% were overweight. The mean ESS was 12 (range = 3-20)/24, and 63% 
reported EDS. Using an AHI cut-off of >15 events  per hour, all but 2 of the 
participants (88%) had OSAHS, with no significant gender difference. AHI was 
highly correlated with obesity, but not with age. Only one of the 16 participants had 
been referred for evaluation of possible OSAHS, despite the majority of participants 
being found to have severe OSAHS. Although this more rigorous study is slightly 
more representative of the DS population than the study by Resta et al (Resta et al. 
2003), the major limitation is, again, the very small number of participants.  
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One further study recruited 12 young adults with DS from a DS day centre in Greece 
and conducted PSG in the participants’ own homes (Andreou et al. 2002). Using an 
AHI threshold of >10 events per hour, 100% of participants had OSA, though the 
ESS was normal in all cases. 
These studies suggest that the prevalence of OSAHS in the DS population is greatly 
elevated, but small participant numbers and methodological issues underline the need 
for larger, population-based studies. This is the basis for the studies discussed in 
Chapter 5-7 of this thesis. 
 
3.2 Comorbidities 
 Anatomy and physiology 3.2.1
The characteristic craniofacial phenotype of individuals with DS, with midface 
hypoplasia and brachycephaly, results in an anatomically reduced pharyngeal space. 
Generalised hypotonia increases the risk of airway collapse, and is compounded by 
other factors including a thick neck, obesity, relative macroglossia, adenotonsillar 
hypertrophy and increased mucosal secretions. This has been demonstrated using 
MRI in children with DS (Uong et al. 2001; Shott & Donnelly 2004; Donnelly et al. 
2004; Guimaraes et al. 2008). Being overweight or obese is the most important risk 
factor for OSAHS, and up to three-quarters of adults with DS fall into this category. 
It is likely that premature ageing evident in individuals with DS exacerbates the age-
related increase in OSAHS risk seen in the general population, and the increasing life 
expectancy of individuals with DS means that the number of adults with DS living 
with OSAHS is likely to increase over the coming years. 
 Cognitive impairment 3.2.2
As discussed in Chapter 2, untreated OSAHS leads to cognitive impairment. Given 
that adults with DS are already cognitively impaired by virtue of their ID, the impact 
of OSAHS in this population may be even more pronounced. A study in children 
aged 7-12 years with DS using the Arizona Cognitive Test Battery found that those 
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with comorbid OSAHS performed less well on a test of executive function and had a 
mean verbal IQ score 9 points lower than those without; no association with age or 
BMI was noted (Breslin et al. 2014). In a small sample of adults with DS, AHI was 
associated with poorer performance in right hemisphere-related visuoperceptual 
skills tasks (Andreou et al. 2002). 
Individuals with high IQ exhibit some resilience to the cognitive effects of untreated 
OSAHS due to an increased cognitive reserve, while those in the normal IQ range do 
not (Alchanatis et al. 2005); therefore, it is likely that those with DS who have IQ 
below the normal range will be more susceptible to the cognitive impact of OSAHS 
due to their reduced reserve. There is evidence that higher cognitive reserve can 
reduce the risk of Alzheimer’s disease in the ageing general population (Stern 2012), 
while, in adults with DS, early-onset Alzheimer’s-type dementia is almost universal 
by the age of 40 years (Lai & Williams 1989). There appears to be overlap between 
the brain regions which are structurally and functionally affected in DS with those 
which are impaired in OSAHS in the general population, particularly the 
hippocampus and prefrontal cortex. Overall, the combination of ID, early-onset 
dementia and OSAHS may leave adults with DS extremely vulnerable to cognitive 
impairment. Fernandez and Edgin proposed the hypothesis that untreated OSAHS 
accelerates the cognitive decline associated with ageing in adults with DS (Fernandez 
& Edgin 2013). They suggest that sleep fragmentation disrupts sleep-dependent 
memory consolidation during slow wave sleep, whilst intermittent hypoxia causes 
neuronal damage and promotes amyloid deposition. It is possible that CPAP therapy 
may decelerate age-related cognitive decline in adults with DS and OSAHS by 
alleviating sleep fragmentation and intermittent hypoxia. While there are no formal 
studies in this population, CPAP has been shown to reduce sleep fragmentation and 
increase the percentage of slow wave sleep in non-DS adults with mild/moderate 
Alzheimer’s disease and OSAHS (Cooke et al. 2009). 
Untreated OSAHS is related to behavioural and emotional disturbances in children 
and adults with DS (Capone et al. 2006; Dykens 2007), and depression is common in 
both individuals with DS and in typically-developing adults with OSAHS. A survey 
of twenty eight adolescents and young adults with DS diagnosed with major 
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depression by a mental health clinic for people with DS found that 86% had OSAHS 
when tested by PSG, in comparison with 44% of non-depressed controls; 
moderate/severe OSAHS was evident in 54% of cases and 11% of controls (Capone 
et al. 2013). Though this study had not been published at the time that our work 
commenced, this suggests that the coexistence of both DS and OSAHS may increase 
the risk of mood disturbance and depression, given that rates of depression have been 
quoted as 6-46% in DS irrespective of OSAHS (Holland et al. 1998; Roizen & 
Patterson 2003; McCarron et al. 2005; Mantry et al. 2007; Virji-Babul et al. 2007; 
Kerins et al. 2008) and 32-57% in those with OSAHS in the non-DS population 
(Harris et al. 2009; Reyes-Zuniga 2012; Douglas et al. 2013). 
DS and OSAHS are both independently associated with cognitive impairment, and it 
appears that the presence of both may amplify the level of impairment observed. 
 Pulmonary Hypertension 3.2.3
Pulmonary hypertension can result from or be worsened by untreated OSAHS in 
individuals with DS, and should be considered as a possible underlying cause when 
unexplained pulmonary hypertension is noted (Levine & Simpser 1982; Marcus et al. 
1991; Lefaivre et al. 1997). 
 Genetic predisposition 3.2.4
OSAHS is known to have a hereditary component, as discussed in Chapter 2, with 
genetic factors explaining around 40% of the variance in AHI in the general 
population (Redline & Tishler 2000). Since individuals with DS display phenotypic 
features of both familial genes and the DS genotype, it could be posited that a family 
history of OSAHS might compound the risk of OSAHS in these individuals.  
 Immune dysfunction 3.2.5
Individuals with DS have impaired immune function from birth which can lead to 
recurrent infections (Charleton et al. 2010). OSAHS can contribute to recurrent 
infections in individuals with DS due to sleep disruption (Ram & Chinen 2011). 
Sleep disruption has been associated with immune dysfunction in the general 
population (Bryant et al. 2004). 
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3.3 Treatment of OSAHS in DS 
To date, there are no randomised, controlled trials assessing the effects of CPAP 
treatment in children or adults with DS and OSAHS.  
In children, the first-line treatment for OSAHS is adenotonsillectomy (Schechter 
2002). A small study of 11 children with DS and OSAHS, mean age 8.5 years, found 
that adenotonsillectomy resulted in a significant decrease in AHI, though to a lesser 
degree than in a control group  children without DS (Shete et al. 2010). The SpO2 
nadir was improved in children without DS, but not in the DS group.  Neither group 
showed an improvement in arousal index post-tonsillectomy. No further treatment 
was required in the non-DS group, but 55% of the DS group required CPAP therapy 
for residual OSAHS. 
A study of the effect of 3 months of CPAP therapy in children with OSAHS included 
a subset of 10 children with neurodevelopmental disorders – 6 with DS and one child 
each with Prader-Willi syndrome, cerebral palsy, autism and a complex 
chromosomal disorder (Marcus et al. 2012). In the developmentally delayed group, 
CPAP use was associated with significant improvements in subjective sleepiness, 
behaviour and quality of life. However, the anthropometric data, sleep characteristics 
or CPAP compliance of this subgroup were reported separately, and the small sample 
number and heterogeneity of neurodevelopmental disorders mean that this cannot 
necessarily be generalised to the wider paediatric DS population. 
Trois et al reported anecdotally on the outcome of CPAP therapy in 14 adults with 
DS identified as having OSAHS (Trois et al. 2009). Of the 14 individuals, 9 were 
followed up clinically by the study team, 1 sought treatment elsewhere and the 
outcome of the remaining 4 was unknown.  Eight of the 9 individuals underwent 
CPAP titration (one did not attend); of these, 7 commenced fixed-pressure CPAP at a 
pressure of 7-10cmH2O and one individual with severe OSAHS commenced bilevel 
ventilation. Five of the 8 adults on treatment had an excellent compliance of 6-8 
hours per night, with their families reporting a subjective improvement in sleepiness 
and daytime function. One participant had a compliance of only 2 hours per night, 
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one refused treatment due to anxiety and one quit CPAP due to nasal congestion. No 
formal subjective or objective measures of CPAP efficacy were made. 
Given that over half of children with DS and OSAHS require CPAP despite 
adenotonsillectomy and that the likely prevalence of OSAHS in adults with DS is so 
high, it is perhaps surprising that so little evidence relating to efficacy or 
acceptability of CPAP exists. 
 
3.4 Screening for OSAHS 
Guidelines published by the Royal College of Paediatrics and Child Health  
recommend that all children with DS should be offered a screening test using at least 
overnight oximetry at least once in infancy and annually until the age of 3-5years 
(Royal College of Paediatrics and Child Health 2009). In the event of an abnormal 
oximetry study, polygraphy or polysomnography should be performed. Screening 
until 3-5 years was chosen arbitrarily in the absence of any evidence that further 
screening of asymptomatic children was warranted, and in the belief that covers the 
period of highest risk for OSAHS. However, it is important that families are made 
aware of the symptoms of OSAHS and that these are not overlooked by parents or 
professionals, or subject to diagnostic overshadowing (Reiss et al. 1982). Symptoms 
of OSAHS should continue to be monitored across the lifespan (Van Allen et al. 
1999; Smith 2001; Roizen & Patterson 2003; Charleton et al. 2010; Bull 2011). The 
Down’s Syndrome Association published a DS Health Book for adults with DS to 
carry with them to annual health checks with their GP (Down’s Syndrome 
Association 2014). This allows the individual to take ownership of their own health 
and wellbeing and acts as a guide for GPs regarding required health checks; this 
includes reference to sleep problems including OSAHS, and additional guidance for 
GPs is provided via a website (Hill 2013). However, given the healthcare inequalities 
facing  adults with DS and the fact that guidelines for health surveillance in adults 
with DS are not always adequately followed (see Section 1.4.4 for discussion),  
education of individuals with DS, their families and healthcare professionals by 
providing  an adequate evidence to support this endeavour is vital. 
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3.5 Conclusion 
Despite a clearly increased risk of OSAHS in adults with DS and some overlap 
between the deleterious consequences of both disorders, neither prevalence of 
OSAHS in adults with DS nor the effect of treatment with CPAP in this population 
has been systematically documented in a large cohort.  The remaining chapters of 
this thesis document our attempts to address these gaps in the evidence. 
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Chapter 4: Aims, research questions and ethics 
This chapter summarises the aims and objectives of the study, and the ethical 
approval required. 
 
4.1 Study design 
The study was designed in two parts. The first part of the study was an assessment of 
the prevalence of SDB across the target population using subjective and objective 
measures. The second part of the study was a single-blind, randomised 
parallel/crossover trial of CPAP therapy versus conservative lifestyle measures for 
treatment of OSAHS, allowing both between-groups and within-groups comparisons. 




The aims of this study was two-fold: 
1. To systematically document the prevalence of OSAHS in a population of adults 
with DS.  
2. To assess the efficacy of CPAP therapy in adult patients with OSAHS and DS, 
including formal assessment of symptomatic relief, treatment response and 
functional status. 
 
4.3 Research questions 
To meet these aims, three research questions were considered: 
1. What is the prevalence of OSAHS in adults with DS in Scotland (and the UK)? 
2. Does CPAP use in DS adults with OSAHS improve sleepiness and quality of life 
more effectively than lifestyle measures alone? 
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3. What are the potential barriers to implementing CPAP effectively in DS adults 
with OSAHS? 
 
4.4 Primary and secondary outcomes 
 
 Primary outcomes 4.4.1
The primary endpoint of the treatment phase of the study was the change in 
subjective sleepiness, as measured by the Epworth Sleepiness Scale (ESS) (Johns 
1991), from baseline to 1month. The ESS is a robust index, widely used in both 
clinical practice and clinical trials. A change of 1 point on the ESS is the smallest 
detectable shift in the score (which is a categorical scale with one point increments) 
and is the minimum clinically significant change since it is indicative of one 
symptom state shift on one domain of the score. A pictorial version of the ESS, 
designed for use with patients with diminished literacy skills, has been shown to 
produce scores comparable with the traditional ESS (Ghiassi et al. 2010), and was 
implemented during this study. Both questionnaires will be discussed in more detail 
in Chapter 5. 
 Secondary outcomes 4.4.2
A number of secondary outcomes were assessed. All instruments are discussed in 
further detail in Chapters 5 and 8. 
1. Change in subjective sleepiness (pESS) from baseline to 3, 6 and 12 month visits.  
2. Objective changes in emotional and behavioural function, measured using a 
modified version of the Developmental Behaviour Checklist for Adults (Mohr et 
al. 2005). 
3. Health status and quality of life, measured by the RAND-36 instrument (Hays et 
al. 1993).  
4. Cognitive function, measured using the Arizona Cognitive Test Battery (Edgin et 
al. 2010). 
5. Adverse events, including side effects associated with CPAP usage. 
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6. Compliance with CPAP, reported as the average hours of use per night, along 
with other data recorded by in-built machine software. Periods for which the 
machine is on and being used are recorded, and provide the gold standard method 
for monitoring CPAP compliance. 
7. Carer burden, measured using a modified version of the Zarit Burden Inventory 
(Bédard et al. 2001), 12-item version of the General Health Questionnaire 
(Goldberg 1972) and open-ended qualitative questions about the experience of 
caring. 
 Sample size 4.4.3
An estimate of required sample size was made with the input of the trial statistician. 
Given that the likely effect size was unknown, a conservative estimate of effect size 
related to variability was made. A sample size of 70 participants was proposed, based 
on a previous repeated measures, parallel-arm, intention-to-treat study within the 
department, investigating the effects of CPAP on daytime function in adults with 
OSAHS in the general population (McFadyen et al. 2001). It was calculated that this 
sample size would provide 90% power to detect large differences of 0.8 SD between 
treatment groups and 90% power to show moderate r-values of >0.5 within the 
CPAP-only group. Given the finite population of adults with DS, we aimed to recruit 
a minimum of 26 participants into each arm of the study to achieve a power of 80%, 
with 34 participants in each arm giving a power of 90%. It was thought that this 
number should be achievable, given expertise of the study team in recruiting for 
previous studies and estimating that over 50% of the adult DS population would have 
OSAHS. With no available data on CPAP compliance in individuals with DS, a non-
compliance rate of 10% was estimated, based on previous studies within the 
department, with any participant withdrawals resulting in a small decrement in study 
power. 
4.5 Ethical approval and informed consent 
Ethical approval was sought from the Scotland A Research Ethics Committee (REC), 
the national NHS REC specialising in review of studies involving adults with 
incapacity to give consent (AWI).  
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The initial ethics application sought approval to include a full cross-section of the 
target population, including adults with capacity to consent and AWI. However, the 
ethics committee felt that there was insufficient evidence that the inclusion of AWI 
could be permitted within the scope of the Adults With Incapacity (Scotland) Act 
2000 (Scottish Parliament 2000), and approval for the study was given only with the 
exclusion of AWI from the treatment phase of the study. The questionnaire study 
was approved for people with and without capacity to consent, and no formal 
informed consent was required for this phase of the study; return of a completed 
questionnaire was considered implicit consent. 
Substantial amendment notices with additional evidence supporting the inclusion of 
AWI in the treatment study were submitted, but not successfully approved until 
March 2013, at the third attempt (15 months from first recruitment). This proved to 
be a significant obstacle to study progress, and is discussed in further detail in 
Chapter 9. 
Prior to March 2013, informed consent to participate in the treatment study was 
obtained prior to the initiation of any study-specific procedures (i.e. prior to issue of 
the home sleep study equipment) using a written consent form signed by the 
participant (see Appendix 2). On the first visit, the study procedures were reviewed 
with the participant and their relative/carer, using simple language and augmented 
with signs and gestures to enhance understanding. Prior to the first visit, the families 
received a copy of the patient and carer information sheets by post; care was taken to 
ensure that the families had read these documents, and spare copies were offered if 
required. The consent form, written in easy-read format, was explained to the 
participant and relative/carer. All parties were invited to ask any questions and raise 
any concerns prior to signing the consent form. Assessment of the participant’s 
ability to give informed consent was made on a case-by-case basis by the researcher, 
and anyone deemed unable to consent was excluded from the study. Individuals who 
were subject to a guardianship order or whose relative/carer held welfare power of 
attorney for the individual were automatically excluded from participation since both 
of these legal positions are only granted when a person lacks capacity to consent.  
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After the ethics decision to allow inclusion of AWI, additional consenting procedures 
were required, which varied depending on where the participants study procedures 
were conducted and whether they were able to give consent for themselves. All 
participants assessed as having capacity to consent signed a consent form as above. 
For all Scotland-based patients lacking capacity, and patients lacking capacity from 
outwith Scotland travelling to Edinburgh to participate in the research, consent was 
obtained on their behalf in keeping with the Adults with Incapacity (Scotland) Act 
(Scottish Parliament 2000) using a separate consent form for AWI (see Appendix 2). 
Consent was taken from their nearest relative if they had one, and if they did not, 
from their welfare attorney. Although the term welfare attorney is not used in 
England, Wales or Northern Ireland, the principle is the same in that there will be a 
person nominated who takes care of the person’s affairs, and who, when they are in 
Scotland, can be considered, in principle, a welfare attorney. 
For patients lacking capacity from outwith Scotland who will be visited in their home 
or another non-NHS location, appropriate ethical approval was sought from a 
relevant ethics committee in England and/or Northern Ireland as required. Advice 
was sought from the participant's consultee in line with the Mental Capacity Act 
2005 in England and Wales (HM Government 2005), or assent sought from a close 
relative or friend of the person lacking capacity to consent in line with Northern 
Ireland common law (NHS Health Research Authority 2015).  
In line with the recommendations of the Duke Down’s Syndrome Research Team 
(Heller et al. 2006), informed consent was obtained at a visit where no other test 
procedures were to be carried out (other than issue of home sleep study kit), allowing 
the investigators to establish a rapport with the participant and their relative/carer, 
familiarising them with the study environment and reducing anxiety. 
The original signed copy of the consent form was filed and stored securely within the 
Sleep Research Unit, with a photocopy of the signed form sent to the participant and 
their carer for their records. Further copies were filed in the participant’s case report 
form and NHS Lothian patient casenotes as appropriate.  
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Chapter 5: Subjective assessment of 
prevalence – Questionnaire study 
The first part of the study was a cross-sectional population study designed to assess 
prevalence of SDB/OSAHS in adults with DS using subjective measures. 
 
5.1 Methods 
The study prevalence questionnaire is included in Appendix 1. Since, as discussed in 
Chapter 1, there is a wide spectrum of ID in DS and, commonly, visual impairments, 
it was important to ensure the questionnaire was as accessible to as many people with 
DS as possible; although the questionnaire states that the participant may seek help 
from a relative or carer if required, we were keen to obtain a response from the 
participant themselves wherever possible. The questionnaire, therefore, was written 
in easy-read format. There is evidence that the use of easy-read information can 
enhance understanding and retention of medical and health information, and improve 
compliance (Houts et al. 2006). 
Guidance on easy-read formats was sought from FAIR Advice 
(www.fairadvice.org.uk), an Edinburgh-based charitable organisation providing an 
information and advice service for people with ID, parents, carers and professionals. 
The organisation also publishes easy-read health information booklets specifically 
designed for people with ID, including a number of booklets commissioned by NHS 
Scotland. Two FAIR booklets were subsequently included in the lifestyle advice 
package for the randomised treatment study, and are discussed in further detail in 
Chapter 8. Guidance published by the Department of Health was also considered 
(Department of Health 2010).  
A minimum 14-point font was used to enhance visibility for those with visual 
impairments. Simple language was used as far as possible, although some elements 
of the questionnaire could not be simplified without losing functionality. Where 
possible, pictorial information was used to enhance accessibility and understanding. 
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All study documents were reviewed for ease of understanding by a group of people 
with DS assembled via and facilitated by Down’s Syndrome Scotland (DS Scotland; 
www.dsscotland.org.uk), a national charity supporting individuals with DS and their 
families. Changes suggested by the group and DS Scotland staff were used to refine 
the questionnaire and other study documentation prior to distribution. 
The questionnaire was designed in two parts, with one section for completion by the 
participant with DS and a second section for completion by a relative or carer who 
knew the participant well. 
 Demographics and general health 5.1.1
The participant section of the questionnaire asked about demographic information 
including age, height, weight, collar size and smoking status. Presence of 
comorbidities associated with DS and sleep disturbances, including thyroid status, 
previous ENT surgery, diabetes and cardiovascular, respiratory and gastro-intestinal 
problems was assessed via tick-box, and participants were asked to list any current 
prescribed and non-prescribed medications. Medications were categorised using the 
World Health Organisation Anatomical Therapeutic Chemical Classification System 
(ATC-DDD) (WHO Collaborating Centre for Drug Statistics Methodology 2011). 
Participants were asked to note any diagnosed sleep disorders, along with current or 
previous treatment of these. 
 Modified sleep questionnaire 5.1.2
Sleep disturbances were recorded using a modified version of an in-house sleep 
questionnaire. Although not formally validated, this questionnaire has been used 
routinely in our Department for over 30 years as a pre-assessment tool in patients 
referred clinically for assessment of possible sleep disorders including SDB, 
OSAHS, narcolepsy and parasomnias, as well as in a number of research studies         
( Engleman et al. 1994; Kingshott et al. 1995; Kingshott et al. 1998; Engleman et al. 
1998; McArdle et al. 1999). Elements of the questionnaire relating to sleep duration 
and phenomena of disturbed sleep were selected and presented in easy-read format. 
Participants were asked to document the number of hours per twenty-four hours that 
they spent asleep during the night and during the day. Presence of snoring, witnessed 
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apnoeas, nocturnal choking episodes, frequent awakenings, unrefreshing sleep and 
daytime sleepiness were rated on a Likert-type scale based on the number of nights 
per week each phenomenon occurred.  
 Pictorial Epworth Sleepiness Scale 5.1.3
The Epworth Sleepiness Scale (ESS) (Johns 1991) is a standard instrument used to 
assess daytime sleepiness in the general population. This validated tool has been 
routinely employed in clinical and research practice since its development in the 
1990s. Advantages of the ESS include its brevity and simplicity. The single-page 
questionnaire (Figure 16) can be quickly and easily completed by most patients, and 
easily scored and interpreted by the clinician. The ease of use of the ESS and its 
reliability as a repeated measure to track changes in subjective sleepiness over time 
and pre/post-intervention has resulted in its widespread use. 
The individual is asked to rate their likelihood of dozing or falling asleep (in contrast 
to just feeling tired) on a scale of 0-3, where 0 = would never doze and 3 = would 
definitely doze, in a set of eight everyday scenarios: sitting reading; watching TV; 
sitting inactive in a public place; as a passenger in a car for an hour without a break; 
lying down to rest in the afternoon; sitting talking to someone; sitting quietly after a 
lunch without alcohol; and in a car whilst stopped for a few minutes in traffic. The 
reference period relates to “recent times”. Individual scores for each of the eight 
items are added together to give a total score in the range 0-24. The generally-
accepted cut-off for an abnormal score on the ESS is >10/24 (Johns 1993; Rosenthal 
& Dolan 2008). 
Sensitivity and specificity of the ESS have been shown to be high (sensitivity 93.5%, 
specificity 100%) in individuals with narcolepsy (Johns 2000), a population which 
has been shown to be 5 times sleepier than controls (Parkes et al. 1998). Sensitivity 
and specificity are lower in patients with OSA (66% and 48% respectively) with an 
area under the ROC curve of 0.6 when OSA is defined as an AHI>5 (Rosenthal & 
Dolan 2008). ESS scores show good test-retest reliability, with no significant 
difference and high correlation between scores in control participants over time, and 
a reduction in individuals with OSAHS treated with CPAP (Johns 1992). A meta-
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analysis (n=706) of the effect of CPAP therapy on sleepiness associated with OSA 
showed a significant reduction in ESS overall, with CPAP use reducing the ESS by a 
mean of 3 points more than placebo overall and by 5 points in individuals with 
severe OSA (Patel et al. 2003). 
Although the ESS is generally well understood and completed, understanding is 
reliant upon the ability to read and write; persons with diminished literacy skills, 
including people with ID may have problems understanding and completing the 
questionnaire. To address these issues, a pictorial version of the ESS (pESS) was 
devised (Ghiassi et al. 2010), aiming to enhance understanding and accessibility of 
the ESS in people with and without diminished literacy in the general population. 
Both the original ESS and the pESS are shown in Figure 16.  
In the original validation study, scores on the pESS show good agreement with those 
on the original ESS, with 55% of participants who completed both scales expressing 
a preference for the pictorial version. The study did not specifically assess the utility 
of the pESS in persons with ID. However, given the known benefits of easy-read 
literature  (Houts et al. 2006) and pictorial information in this patient group (van 
Schrojenstein Lantman-de Valk & Walsh 2008), we opted to use the pESS in our 
prevalence study.  
Although designed to be self-completed, the ESS is frequently used as a proxy 
measure in clinical practice, for example by asking both the patient and their spouse, 
bed partner or relative to rate the patient’s sleepiness. A number of studies (Johns 
1994; Kingshott et al. 1995; Walter et al. 2002; Kumru et al. 2004) have examined 
use of the ESS as a proxy measure. Results suggest that, whilst neither patient nor 
proxy ESS scores are accurate predictors of objective sleepiness,  obtaining both a 
patient and proxy ESS rating may give a more accurate picture of the patient’s 
sleepiness. These studies have shown that scores on the ESS as rated by the patient 
or their proxy either do not significantly differ (Johns 1994; Kingshott et al. 1995) or 
tend to be higher when rated by a partner (Walter et al. 2002; Kumru et al. 2004), 
suggesting an element of underscoring of the severity of sleepiness by patients 
themselves. Therefore, it was anticipated that pESS scores provided via the 
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prevalence questionnaire would be either an accurate reflection of the person with 
DS’s sleepiness or a conservative estimate, regardless of whether the questionnaire 
was completed by the individual or their relative/carer.  
Although the ESS has not been specifically validated in the DS population, it has 
been used as a proxy measure in a previous study in adults with DS (Trois et al. 
2009). 
 
Figure 16: The original Epworth Sleepiness Scale (Johns 1991)and Pictorial Epworth Sleepiness 
Scale (Ghiassi et al. 2010). Original ESS used with written permission from MW Johns. Pictorial 
ESS reproduced from Thorax, Ghiassi R et al, 66: 97-100, 2011 with permission from BMJ 
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 Modified Developmental Behaviour Checklist for Adults 5.1.4
The final section of the questionnaire, directed at the carer or relative of the person 
with DS, was an abbreviated version of the Developmental Behaviour Checklist for 
Adults (DBC-A). The Developmental Behaviour Checklist (DBC) (Einfeld & Tonge 
1995) is a suite of instruments for assessment of behavioural and emotional 
disturbances in children, adolescents and adults with developmental disabilities and 
ID. It has been used to track changes in behavioural/emotional disturbances over 
time in young people with ID, including people with DS (Tonge & Einfeld 2000; 
Clarke et al. 2003). 
Originally comprising the Primary Carer Version (DBC-P) and Teacher Version 
(DBC-T) (Einfeld & Tonge 2002), a revised version for adults with ID, the DBC-A, 
was published in 2004 (Mohr et al. 2005). The DBC-A was adapted from the DBC-P, 
and comprises 107 items examining a range of behavioural and emotional 
disturbances, designed to be answered by a relative or carer who knows the person 
with ID well. Each item is scored on a scale of 0-2, where 0 = “not true as far as you 
know”, 1 = “somewhat or sometimes true” and 2 = “very true or often true”, based 
on the person’s behavioural and emotional state over the preceding 6 months. Items 
are grouped into 6 subscales representing different dimensions of disturbance: 
Disruptive; Self-absorbed; Communication Disturbance; Anxiety/Antisocial; Social 
Relating; Depressive.  
The DBC-A can be scored at 3 broad levels: the overall score, individual subscale 
scores or individual item scores. To keep the prevalence questionnaire as concise as 
possible, we opted to include three of the six subscales, which, based on a previous 
study (Riha et al. 2006) were most closely related to sleep disturbance: Disruptive, 
Anxiety/Antisocial and Depressive. Behaviours in the Disruptive category include 
irritability, impatience and impulsivity. Antisocial behaviours include stealing, 
stubbornness and being bossy. Depressive behaviours include poor self-esteem, 
becoming withdrawn and loss of appetite. The full list of questions included is shown 
in the questionnaire in Appendix 1. 
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The DBC-A has been shown to be both reliable and valid, with specificity = 0.69, 
specificity = 0.79 and area under the ROC curve of 0.77. Scores on the DBC-A have 
been shown to correlate highly with other validated measures of behavioural and 
emotional disturbances in adults with ID, including the Aberrant Behaviour Checklist 
(ABC) and Psychiatric Assessment Schedule for Adults with Developmental 
Disability (PAS-ADD).Validation studies have shown the DBC-A has acceptable 
test-retest and inter-rater reliability, as well as high internal consistency, in both 
family members and paid carers (Mohr et al. 2005). 
The DBC-A subscale totals are calculated by adding the scores for all questions in 
each domain, except the Anxiety/Antisocial subscale, in which all scores were 
totalled with the exception of “Poor sense of danger”, which was subtracted.  
Data from each DBC-A subscale can be compared in a number of ways. Although 
reporting the total score (sum of item scores; SIS) on each subscale is a very simple 
method of comparing an overall summary of problem behaviours within and between 
individuals, it does not give information on the number of individual items checked 
or the scale at which these items are scored or the severity at which each behaviour is 
rated. For example, a total score of 10 could result from 10 individual behaviours 
scored at 1, 5 behaviours scored at 2 or a combination of 0, 1 and 2 scores, and it can 
be argued that an individual exhibiting a wider range of mildly problematic 
behaviours has a different profile from that of an individual with fewer but more 
severe behavioural problems. To extract more meaningful information on the extent 
and intensity level of problem behaviours from the DBC than total scores alone, 
Taffe et al (Taffe et al. 2008) describe the use of mean item scores (MIS), proportion 
of items checked (PIC) and intensity index (II). 
The mean item score (MIS) is calculated by dividing the SIS by the number of items 
in the subscale, and represents the average level of overall problem behaviour. The 
proportion of items checked (PIC) is the number of positive responses (scores of 1 or 
2) divided by total number of items in scale, which indicates the breadth of range of 
behaviours exhibited. The MIS and PIC Scores can be combined to give an intensity 
index (II; MIS/PIC-1); MIS = PIC(1 + II); this represents the proportion of 
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positively-scored items scored as somewhat or often true, and gives a measure of the  
intensity of problem behaviour. 
Normative data on the DBC-A for adults with ID aged 18-85 years, stratified by level 
of ID, were collected in 2009 and released in 2011(Mohr et al. 2012), allowing 
comparison  of total problem behaviour scores, mean item scores and individual 
subscale scores to the population norms. At this time, the subscales and factors of the 
questionnaire were updated and renamed on the basis of the new data. Since this 
change was made after commencement of our study, we used the original DBC-A 
(Mohr et al. 2005) rather than the new version. Unfortunately, the published 
normative data are not applicable to the original version of the DBC-A, and so 
normative data are unavailable the version of the checklist used in this study. 
 Symptoms suggestive of OSA 5.1.5
Symptoms highly suggestive of OSA were defined using 3 algorithms based on those 
validated in a recent questionnaire-based survey of prevalence of OSA in the French 
general population (Fuhrman et al. 2012). These algorithms use combinations of 
recognised symptoms to identify individuals who have a high probability of OSA: 
1. Snoring ≥3 nights per week plus (witnessed apnoeas, or pESS>10). 
2. Snoring ≥3 nights per week plus (witnessed apnoeas, or unrefreshing 
sleep ≥3 nights per week). 
3. Snoring ≥3 nights per week plus (witnessed apnoeas, or daytime 
sleepiness ≥3 nights per week). 
 Identification of participants and distribution of 5.1.6
questionnaires 
Easy-read invitation leaflets and questionnaires (see Appendix 1) were sent initially 
to a community-based sample of adults (age ≥16 years, the age of legal adulthood in 
Scotland (Scottish Government 1991)) with DS in Scotland, commencing in 
February 2011. Participants and their relative/carers were invited to complete and 
return a questionnaire, indicating via a check box if they did not wish to be contacted 
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with regards to undergoing a home sleep study at a future date. A pre-paid return 
postage envelope was provided.  
All questionnaires, return postage envelopes and mailing envelopes were 
individually numbered to allow identification of participants whilst maintaining 
anonymity. Numbers were allocated sequentially from DSQ0001-DSQ5430 (with 
DSQ an acronym for Down syndrome questionnaire). The numbered questionnaires 
were mailed out on behalf of the research team by a number of third-party 
organisations working with people with DS. The research team did not have access 
to the personal details of any potential participants identified by these outside 
organisations until such time as a completed questionnaire was returned, if the 
participant chose to disclose this. Each outside organisation was asked to keep an on-
site list of participants contacted and their individual questionnaire numbers to ensure 
that each participant could be tracked and contacted again as required on behalf of 
the study team. Numbers on return envelopes allowed identification of individual 
participants for further contact even if they did not provide their name and/or address 
on the questionnaire.  
Individuals with DS aged ≥16 years were primarily identified by DS Scotland from 
their membership database. Further individuals were identified and contacted by the 
NHS Greater Glasgow and Clyde Primary Care Liaison Team, who hold a database 
of adults with ID in the Greater Glasgow and Clyde area, and Sleep Scotland 
(www.sleepscotland.org), a charity providing support to families of children and 
young people with additional support needs and severe sleep problems, who hold a 
database of individuals who have accessed their service. A number of other 
organisations working with people with DS also identified smaller groups of 
participants. Current and previous clinical patients attending or known to the 
Department of Sleep Medicine, Royal Infirmary of Edinburgh, who met the study 
criteria were contacted directly by the research team. Patients known to be on CPAP 
treatment were sent prevalence questionnaires regardless of their ineligibility for the 
treatment phase of the study. Any eligible participants contacting the researchers as a 
result of publicity, advertising or word of mouth were sent a questionnaire directly 
by the study team.  
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A reminder letter and second questionnaire were sent out to anyone not returning a 
questionnaire within 2 months of the original mail-out, again by the distributing 
organisations to maintain anonymity. Prior to sending a postal reminder, DS Scotland 
sent an email reminder to anyone who had not returned a questionnaire for whom 
they had an email address. No further reminders were sent if no response was 
received after the second questionnaire. 
In an extension to the original prevalence questionnaire study in Scotland, the same 
questionnaire was sent out to adults aged ≥16 years with DS across the rest of the 
UK (England, Wales and Northern Ireland), commencing May 2012. As per the 
Scotland survey, questionnaire distribution was completed anonymously on behalf of 
the research team by charitable organisations supporting people with DS and their 
families: the Down’s Syndrome Association (DSA; www.downs-syndrome.org.uk) 
and the Down’s Heart Group (www.dhg.org.uk). Again, a reminder letter and second 
questionnaire were sent out anonymously by the distributing organisations to anyone 
not returning a questionnaire in response to the original mailing, with no further 
reminders or contact made if no response was received after the second 
questionnaire. DSA declined to send a second questionnaire or email reminder.  
The final prevalence questionnaires were posted out in June 2014. 
As well as direct participant identification as described above, a number of publicity 
strategies were employed. Information on the study was included in publications by a 
number of organisations working with people with DS, allowing individuals 
interested in participating to contact the study team directly to have a questionnaire 
sent out and raising awareness of the study amongst professionals. This included the 
DS Scotland website, e-bulletins and magazine, FAIR Advice newsletter and 
Blackburn Support Services newsletter. A paid advertisement was placed in Third 
Force News (TFN), Scotland’s only dedicated weekly newspaper for charities and 
voluntary organisations, with a readership of over 19000 people. A press release 
through the University of Edinburgh press office in April 2011 resulted in articles in 
local and national publications, including TFN, Metro, Edinburgh Evening News, 
Dalkeith Advertiser and Edinburgh University Science Magazine (EU:Sci). Posters 
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advertising the study were displayed on noticeboards throughout the Royal Infirmary 
of Edinburgh. Flyers promoting the study were distributed to professional groups and 
at meetings relating to sleep and/or DS, including: the Edinburgh Sleep Medicine 
Course; Scottish Sleep Forum; Scottish Senior Nurse Group; Down’s Syndrome 
Medical Interest Group (DSMIG); Royal Society of Medicine meeting – “Dementia 
in people with intellectual disabilities: Getting it right”; and the London Dementia in 
Intellectual Disabilities Special Interest Group national conference.  
As the study progressed, visibility of the study was enhanced via a number of 
professional presentations and public engagement activities. These are detailed in 
Appendix 4 and included: Royal Infirmary of Edinburgh Grand Rounds; DSMIG 
meeting, Winchester; European Society of Sleep Technologists meeting, Paris; and a 
workshop for people with DS, parents and carers at the DS Scotland conference, 
Cumbernauld. Longer articles related to the study were published in the British Sleep 
Society Newsletter and the DS Scotland magazine, Full Potential. 
A number of abstracts were submitted and accepted for oral and poster presentations 
at national and international conferences; these are collated in Appendix 4. 
 Statistical analysis 5.1.7
All statistical analysis was overseen by an experienced Trial Statistician, Dr Linda J. 
Williams, Centre for Population Health Sciences, The University of Edinburgh (see 
Acknowledgements). Basic statistical analysis was conducted by the Investigator 
under the guidance of the Trial Statistician. More complex analyses were conducted 
by the Statistician for demonstration, with the Investigator replicating these tests and 
the Statistician checking for accuracy. 
Standard statistical analyses were conducted using SPSS Statistics version 19 (IBM 
Corp., USA). All analyses were two-tailed, with significance set at p=0.001 to allow 
for the effects of multiple testing, where the number of significant findings by chance 
increases with the number of comparisons run. A value of p=0.001 was thought 
unlikely enough to be a chance finding (Bauer 1991). 
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All variables were checked for normality. Discrete variables were evaluated using 
the Chi-square test and continuous variables using the Student’s T-test. The Mann-
Whitney-U test was used for non-parametric variables. Results are presented as mean 
± standard deviation for normally-distributed variables or as a median with 
interquartile range (IQR 25-75%) for non-normally distributed data as appropriate, or 
as number and percentage. 
Pearson’s and Spearman’s rank correlations were used to explore the correlations 
between continuous variables, presented as Pearson’s r and p-value or Spearman’s ρ 
and p-value as appropriate.  
Regression analysis was undertaken to explore significant associations between 
variables, using binary logistic regression (reported as odds ratio (OR) with 95% 
confidence interval (CI)) for categorical variables and generalised linear modelling 
(reported as β-coefficient with 95% CI) for continuous variables. Variables of 
interest generated by exploration were entered into the appropriate regression model, 
with the least significant variables then removed from the model in a stepwise 
fashion. Age and gender were allowed to remain in the model, even if non- 
significant, to control for the effect of these variables, which are known to be 
significant risk factors for OSAHS (see Section 2.3.1). Where a significant gender 
difference was noted during exploration, regression/modelling was conducted 




Of 5270 questionnaires sent to adults with DS across the UK (74% England, 14% 
Scotland, 5% Wales, 7% Northern Ireland), 1321 responses were received (25%). A 
summary of study participation is shown in Figure 17. The proportion of responses 
received after initial and subsequent waves of contact are summarised in Table 4. 
Of the responses received, 1105 (21%) were valid for analysis (see Figure 17). The 
overall valid response rate excluding participants on CPAP was 20% (England 19%, 
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Scotland 37%, Wales 17%, Northern Ireland 15%). When compared with the average 
population distribution of the UK during the period of the study (Office for National 
Statistics 2013; Office for National Statistics 2014), England appears to be under-
represented in our sample (66% of responses v. 84% of UK population), whilst 
Scotland is over-represented (25% v. 8%). The percentage of responses received 
from participants in Wales and Northern Ireland were broadly representative (4% v. 
4%, 5% v. 3% respectively).  
 Anthropometric data 5.2.1
The anthropometric characteristics of all remaining valid questionnaire responders 
(n=1067) are shown in Table 5.  
There was an even gender split (54.8% males, 45.0% females; 2 responders did not 





; p<0.0001), although collar size was larger in 
males than females (males 41.3±3.8cm, females 38.2±4.5cm; p<0.0001). No other 
significant gender differences were observed. 
Responders were primarily young adults who were overweight (34%) or obese (40%) 
according to the World Health Organisation BMI classification (World Health 
Organization 2006). WHO BMI categories are only valid for individuals aged ≥20 
years, and as such were reported for 70% of our cohort. 
There was a significant correlation between BMI and collar size (r=0.533, 
p<0.0001). Weak but significant associations between age and BMI (r=0.137, 
p<0.0001), and age and collar size (r=0.179, p<0.0001) were also noted. 
Seven percent of responders reported a formal diagnosis of OSA (53 males, 28 
females). Of these, just under half (38 responders) reported that they were receiving 
treatment with continuous positive airway pressure (CPAP) therapy and were 
excluded from further analysis. Other reported sleep disorders included insomnia 
(n=2), narcolepsy (n=1), behavioural sleep problems (n=1), parasomnia (n=1), 
headbanging (n=1), myoclonic jerks (n=1), nightmares (n=1) and somniloquy (n=1).  
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Questionnaires sent = 5270 
 
England = 3895 (74% of total) 
Scotland = 752 (14%) 
Wales = 260 (5%) 
Northern Ireland = 363 (7%) 
Invalid = 216 
 
Undeliverable = 105 
Duplicate questionnaire = 55 
Declined to participate = 27 
Deceased = 16 
Not completed = 11 
Completed but lost in post = 2 
Non-responders = 3949 
 
England = 3025  
Scotland =425 
Wales = 205 
Northern Ireland = 294 
Responses received = 1321 (25%) 
 
England = 870 (22% response rate) 
Scotland = 327 (44%) 
Wales = 55 (21%) 
Northern Ireland = 69 (19%) 
Valid for analysis = 1105 (21%) 
 
England = 725 (19% of total) 
Scotland = 277 (37%) 
Wales =44 (17%) 
Northern Ireland = 59 (15%) 
Treated with CPAP = 38 (3%) 
 
England = 24 (3% of responders) 
Scotland = 10 (4%) 
Wales = 1 (2%) 
Northern Ireland = 3 (5%) 
 
FINAL ANALYSIS = 1067 (20%) 
adults with Down syndrome, not 
receiving treatment with CPAP 
 
England = 701 (66% of total) 
Scotland = 267 (25%) 
Wales = 43 (4%) 
Northern Ireland = 56 (5%) 
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Table 4: Summary of questionnaire distribution by different organisations, including number of 
questionnaires received in initial and subsequent waves of distribution.  
* Second questionnaire sent by all except DS Scotland, who sent a reminder email.                      
** Second questionnaire. 
Organisation Total sent Responses 
wave 1 
Responses 
wave 2 * 
Responses 




Down's Syndrome Association 4019 809 - - 809 
Down's Heart Group 521 128 55 - 183 
Down's Syndrome Scotland 450 64 112 35 211 
Greater Glasgow & Clyde 
Primary Care Group 
142 44 21 - 65 
Department of Sleep Medicine, 
Royal Infirmary of Edinburgh 
98 37 6 - 43 
Sleep Scotland 17 2 3 - 5 
Other 23 3 2 - 5 
TOTAL 5270 1087 199 35 1321 





Reported comorbidities are summarised in Table 6.  
Heart problems and thyroid problems were common (37% and 36% respectively), 
and occurred significantly more frequently in females (heart 31% males, 45% 
females; thyroid 29% of males, 44% of females; both p<0.0001). No other gender 
differences were evident. Prevalence of other comorbidities potentially related to 
OSA or affecting sleep was low: hay fever (18%); asthma (13%); epilepsy (6%); 
diabetes (3%); hypertension (2%); stroke (2%).  
 Sleep symptoms  5.2.3
Self-reported sleep and behaviour characteristics are summarised in Table 6.  
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Males were significantly sleepier than females (p=0.02), although mean ESS scores 
across the cohort were within the normal range (7±5; scores of >10 are consistent 
with excessive daytime somnolence (EDS), and scores ≤10 are considered normal). 
Overall, 23% of responders were classified as having EDS on the pESS (no 
significant gender difference), although 11% did not complete the pESS. 
Overall, the mean self-reported total sleep time (TST) was 9.1±1.3hr in 24hr, with 
8.6±1.2hr nocturnal sleep. The majority of participants (72%) did not nap in the 
daytime. Of those participants reporting daytime napping, 8% napped for <1hr, 18% 
napped for 1-3 hours and 2% napped for >3hr per day. TST in 24hr and nocturnal 
TST were significantly higher in females (8.9±1.4hr males, 9.2±1.3hr females, 
p=0.004; 8.5±1.3hr males, 8.8±1.2hr females, <0.0001). There was no significant 
gender difference in the estimated duration of daytime naps. 
No significant gender differences were observed in the reporting of symptoms of 
SDB, including snoring, witnessed apnoeas, nocturnal choking, unrefreshing sleep, 
frequent night wakenings and daytime sleepiness. Snoring was reported by 830 
responders (79%); with snoring occurring frequently (≥3 nights per week) in 434 
(41%). Apnoeas were witnessed in 309 participants (30%); frequent apnoeas in 149 
(15%). Unrefreshing sleep was noted in 760 participants (73%); frequent 
unrefreshing sleep in 332 (32%). Daytime sleepiness was reported by 787 
participants (75%); 287 (27%) reporting this frequently. Over a third of respondents 
(34%) did not know whether or not they had witnessed apnoeas, much higher than 
compared with the other sleep symptoms (7% snoring, 10% choking, 6% night 
wakenings, 7% unrefreshing sleep, 2% daytime sleepiness). 
When assessed for probable OSAHS using the French algorithms (Fuhrman et al. 
2012), 366 (35%) of responders met the criteria for probable OSAHS on ≥1 of the 
three algorithms (henceforth referred to as “probable OSAHS”).  
The characteristics of those with probable OSAHS are summarised in Table 8. 
Responders with probable OSAHS were significantly younger, had a higher BMI, 
higher mean total pESS and were more likely to have pESS>10 (all p<0.0001). 
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Although TST overall was similar between those with probable OSAHS and those 
without (p=0.10), the distribution of TST across the day differed, with significantly 
longer daytime naps (p<0.0001) and shorter nocturnal sleep (p=0.02) in those with 
probable OSAHS. Snoring, witnessed apnoeas, nocturnal choking episodes, night 
awakenings, unrefreshing sleep and daytime sleepiness were all significantly more 
common in those with probable OSAHS (all p<0.0001). All of the probable OSAHS 
group were frequent snorers (this was a common variable in all 3 algorithms), in 
contrast to 67.0% of the group where OSAHS was not suspected. 
Total pESS was significantly associated with longer TST in 24hr (r=0.206, 
p<0.0001), longer daytime TST (ρ=0.549, p<0.0001) and, inversely, with nocturnal 
TST (r=-0.131, p<0.0001). Total pESS was also associated with BMI (r=0.220, 
p<0.0001), collar size (r=0.180, p<0.0001) and, weakly, with age (r=0.077, p=0.02). 
Weak inverse correlations were noted between nocturnal TST and age (r=-0.066, 
p=0.04), and nocturnal TST and collar size (r=-0.104, p=0.01). BMI was associated 
with increased daytime TST (ρ=0.198, p<0.0001) and weakly associated with 
increased TST in 24hr (r=0.096, p=0.04). Daytime TST was also weakly but 
significantly associated with age (ρ=0.091, p=0.009) and collar size (ρ=0.120, 
p=0.009). 
Determinants of pESS, EDS and probable OSAHS were explored using regression 
analysis and the results summarised in Table 9a/b. For pESS, age, BMI, hay fever, 
category G and N medications, and pause frequency remained in the model after 
stepwise forward selection, of which all but age were significant. Witnessed apnoeas 
were the most significant determinant of pESS score, with apnoeas seen 1-2 
nights/week giving an OR of 2 (CI 0.8-2.8, p=0.001) and ≥3 nights per week 
increasing the OR to 6 (CI 4.4-6.6, p<0.0001). Witnessed apnoeas also predicted a 
small but significant increase in likelihood of EDS (OR 0.3, CI 0.2-0.6, p<0.0001). 
Use of neurological drugs was associated with a higher pESS score (OR 2.0, CI 0.8-
3.1, p=0.001) and EDS (OR 0.1, CI 0.1-0.2, p<0.0001). Use of respiratory 
medications was a small but significant determinant of probable OSAHS (OR 0.6, CI 
0.4-0.9, p=0.01). Category G drugs (genito-urinary and sex hormones), were 
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associated with a doubling in chance of higher pESS scores (OR 2.2, CI 0.5-3.9, 
p=0.01). 
BMI was a significant determinant of higher pESS score (OR 0.1, CI 0.0-0.2, 
p=0.004) and probable OSA (OR 1.1, CI 1.1-1.1, p<0.0001), but did not predict 
EDS. Hay fever and epilepsy were the only comorbidities predicting sleepiness or 
OSAHS, with small but significant increases in likelihood noted for increased pESS 
score (OR 1.3, CI 0.2-2.4, p=0.02) and probable OSAHS (OR 0.2, CI 0.1-0.5, 
p<0.0001) respectively. 
 Behavioural and emotional disturbances 5.2.4
Gender differences in behaviour are summarised in Table 6. Females had 
significantly higher raw (p=0.003) and mean (p=0.002) Disruptive scale scores and 
exhibited a wider range of Disruptive behaviours (p=0.001), although the intensity of 
behaviour did not differ significantly from males (p=0.55). A floor effect was 
observed in the Anxiety/Antisocial subscale, with very low mean responses reported. 
No significant gender differences were noted. No significant gender differences were 
apparent in terms of the intensity of Depressive behaviours or raw scores, although 
women had higher mean scores (p=0.04) and checked more behaviours (p=0.03) than 
men. 
Those with probable OSAHS scored significantly higher on all three DBC-A 
domains, at all 4 scoring levels (all p<0.0001, except: Anxiety/Antisocial SIS 
p=0.047, II p=0.001; Depressive II p=0.002) – see Table 8.  
Higher total pESS score was significantly associated with increased scores on all 
three behaviour subscales, regardless of scoring method (all p<0.0001), as was self-
reported duration of daytime napping (all p<0.0001). Longer estimated TST in 24hr 
was weakly associated with higher Disruptive (ρ=0.147, p=0.001) and Depressive 
(ρ=0.118, p=0.01) SIS/MIS/PIC/II scores. BMI was weakly but significantly 
associated with increased Anxiety/Antisocial SIS and Depressive SIS/MIS scores. 
Age showed weak but significant negative associations with Disruptive scale SIS, 
and MIS/PIC/II in the Disruptive and Anxiety/Antisocial domains (data not shown). 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Subjective assessment of prevalence – Questionnaire study  89 
The significance of sleepiness, symptoms of SDB and probable OSAHS as 
determinants for behavioural and emotional disturbance based on SIS was explored 
using regression analysis (Table 9a/b and Table 10). Determinants of Disruptive 
behaviour were analysed separately for men and women due to the significant 
difference noted in scores between genders. The decision to split the data rather than 
adjust for gender was made since the significantly different variables did not appear 
to behave in a similar manner in males and females at baseline, suggesting a possible 
interaction. Use of nervous system (category N) medication was a predictor of 
Disruptive behaviour, with men 3 times more likely (CI 1.2-4.8, p=0.001) and 
women 4 times more likely (CI 2.6-5.6, p<0.0001) to have higher scores in this 
subscale when taking these drugs. Category N medication was also a significant 
determinant of Depressive (OR 2.3, CI 1.6-3.0, p<0.0001), but not 
Anxiety/Antisocial behaviour scores (OR 0.1, CI -0.2-0.4, p=0.56). 
Snoring 1-2 nights/week reduced the likelihood of Disruptive behaviour in males 
(OR -1.8, CI -3.4--0.1, p=0.04), but snoring did not influence scores in women or in 
the other subscales. Witnessed apnoeas 1-2 nights/week predicted increased 
Disruptive behaviour scores in men (OR 2.0, CI 0.3-3.7, p=0.02), but lower scores in 
women (OR -1.6, CI -3.1--0.1, p=0.04). Choking episodes did not affect Disruptive 
scores in men, but resulted in an OR of 3 (OR1.1-4.1, p=0.001) to 4 (OR1.0-6.7, 
p=0.01) in women, depending on severity of symptoms. Frequent awakenings 1-2 
nights/week doubled the likelihood of higher Disruptive scores in males (OR 2.0, CI 
0.3-3.7, p=0.02), with the OR increasing to 4 (CI 1.7-5.7, p<0.0001) with 
awakenings ≥3 nights per week, but had no significant effect in females. 
Unrefreshing sleep ≥3 nights per week increased the chance of higher scores on the 
Anxiety/Antisocial (OR 0.5, CI 0.1-1.0, p=0.03) and Depressive (OR 2.3, CI 1.4-3.3, 
p<0.0001) subscales. Daytime sleepiness ≥3 nights per week was associated with 
increased risk of Anxiety/Antisocial behaviour (OR 0.5, CI 0.1-0.9, p=0.01). 
 Medication 5.2.5
Self-reported medication use is detailed in Table 11 and Table 12. Medication use 
was frequent, reported by 63% of males and 75% of females (p=<0.0001). The 
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female predominance in medication use remained evident regarding the types of 
medication; drugs within ATC-DDD categories G (genitourinary and sex hormones), 
category H (systemic hormonal preparations excluding sex hormones and insulin), 
and category N (nervous system) were all used more frequently by females. The 
difference in category G drug use may be partly explained by the use of hormonal 
contraceptives in 62 females (13%). Females were more likely to take 
antidepressants (18 (3%) males, 37 (8%) females, p=0.001), classified under 
category N. 
There were no significant differences between genders in use of medications which 
might have influenced sleep, including benzodiazepines/Z-drugs, antihistamines, 
antiepileptics, opiates or melatonin.  
Responders with probable OSAHS were significantly more likely to be on 
medication of any type, with three-quarters using at least one drug. Those with 
probable OSAHS were significantly more likely to be taking drugs in categories G, 
N, and R (respiratory system), antihistamines and anti-epileptic medication. 
 Adenotonsillectomy 5.2.6
Removal of tonsils and adenoids was common, with 249 (23%) responders reporting 
removal of tonsils and/or adenoids and 124 (12%) reporting adenotonsillectomy. 
Characteristics of responders by surgery status is summarised in Table 13. Those 
who had undergone surgery were significantly younger, but there was no significant 
difference in surgery status between genders. Surgery did not result in lower mean 
pESS scores (8±6 v. 7±5; p=0.25), and there was no significant improvement in self-
reported subjective sleepiness (p=0.18). Indeed, those who had previously undergone 
surgery were significantly more likely to exhibit symptoms of OSAHS, including 
snoring, witnessed apnoeas, nocturnal choking episodes and frequent night 
wakening. Participants who had undergone surgery were significantly more likely to 
exhibit EDS (p=0.02), with 28% scoring >10 on the pESS. 
Individuals who had previously had surgery were more likely to have a formal 
diagnosis of OSA (7% v. 2%; p=0.04), as well as being more likely to meet the 
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criteria for probable OSAHS (42% v. 32%; p=0.002). Those with probable OSAHS 
were significantly more likely to have had adenoidectomy (23%; p=0.001), 
tonsillectomy (22%; p=0.01) or adenotonsillectomy (16%; p=0.001) than those in 
whom OSAHS was not suspected (14%, 15%, and 9% respectively). 
Previous surgery was associated with higher scores on the Disruptive (p=0.04) and 
Depressive (p=0.02), but not Anxiety/Antisocial (p=0.22), subscales of the DBC-A. 
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Table 5: Anthropometric characteristics of all valid questionnaire responders, with responders 
on CPAP therapy excluded. Chi-square test used for parametric categorical variables, t-test for 
continuous categorical variables and Mann-Whitney U test for non-parametric variables. 
Values presented as mean±SD or n % unless otherwise stated.  
* Gender of 2 responders unknown.            
** Difference between males and females          
*** WHO BMI category calculated for participants aged ≥20 years only   
    
p **
Age (years) 1062 0.99
Body Mass Index (kg/m
2
) *** 911 <0.0001
Underweight (<18.5kg/m
2
) 6 0.8% 3 0.7% 3 0.9%
Normal weight (18.5-24.99kg/m
2
) 187 25.1% 124 30.1% 63 19.0%
Pre-obesity (25.0-29.99kg/m
2
) 255 34.3% 147 35.7% 107 32.3%
Obesity class I (30.0-34.99kg/m
2
) 154 20.7% 74 18.0% 80 24.2%
Obesity class II (35.0-39.99kg/m
2
) 91 12.2% 43 10.4% 48 14.5%
Obesity class III (≥40.00kg/m
2
) 51 6.9% 21 5.1% 30 9.1%
Collar size (cm) 579 <0.0001
Smoker 1 0.1% 1 0.2% 0 0.0%
Ex-smoker 5 0.5% 2 0.4% 3 0.6%
Non-smoker 1011 99.4% 548 99.5% 462 99.4%
Any medication 1067 728 68.2% 369 63.1% 359 74.8% <0.0001
Asthma 1067 135 12.7% 75 12.8% 60 12.5% 0.93
Stroke 1067 16 1.5% 7 1.2% 9 1.9% 0.45
Broken nose 1067 8 0.7% 6 1.0% 2 0.4% 0.31
Diabetes 1067 29 2.7% 13 2.2% 16 3.3% 0.34
Heart problems 1067 37.2 3.5% 182 31.1% 215 44.8% <0.0001
Hay fever 1067 193 18.1% 104 17.8% 89 18.5% 0.75
Thyroid problems 1067 379 35.5% 168 28.7% 210 43.8% <0.0001
Epilepsy 1067 62 5.8% 31 5.3% 31 6.5% 0.43
Liver problems 1067 17 1.6% 13 2.2% 4 0.8% 0.09
Hypertension 1067 19 1.8% 9 1.5% 10 2.1% 0.64
Nasal surgery 1067 15 1.4% 8 1.4% 7 1.5% 1.00
Kidney problems 1067 23 2.2% 11 1.9% 12 2.5% 0.53
Gluten intolerance 1067 61 5.7% 26 4.4% 35 7.3% 0.06
Adenoidectomy 1067 185 17.3% 103 17.6% 182 37.9% 0.87
Tonsillectomy 1067 188 17.6% 106 18.1% 182 37.9% 0.69
Adenotonsillectomy 1067 124 11.6% 73 12.5% 51 10.6% 0.39
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Table 6: Self-reported sleep and behaviour characteristics of valid questionnaire responders, 
with responders on CPAP therapy excluded. Chi-square test used for parametric categorical 
variables, t-test for continuous categorical variables and Mann-Whitney U test for non-
parametric variables. Values presented as mean±SD, median(IQR) or n % unless otherwise 
stated.  
* Gender of 2 responders unknown.              
** Difference between males and females  
 
        
p **
Disruptive behaviour subscale (scale range 0-34) 1050 0.003
Mean item score (possible score 0-2) 1050 0.002
Proportion of items checked (possible score 0-1) 1050 0.001
Intensity index  (possible score 0-1) 920 0.55
Anxiety/Antisocial subscale (scale range -2-14) 1035 0.96
Mean item score (possible score 0-2) 1035 0.66
Proportion of items checked (possible score 0-1) 1035 0.64
Intensity index  (possible score 0-1) 783 0.91
Depressive subscale (scale range 0-18) 1050 0.17
Mean item score (possible score 0-2) 1050 0.04
Proportion of items checked (possible score 0-1) 1050 0.03
Intensity index  (possible score 0-1) 735 0.99
Pictorial Epworth Sleepiness Scale (pESS) 954 0.02
Pictorial Epworth Sleepiness Scale score >10 954 215 22.5% 124 23.8% 90 20.9% 0.31
Estimated total sleep time (TST) in 24 hours (hr) 559 0.004
Estimated TST during night (hr) 1011 <0.0001
Estimated TST during daytime (hr) 834 0.96
Naps in daytime 834 235 28.2% 125 27.9% 109 28.3% 0.94
Snoring - ever (≥1 night/week) 830 78.9% 462 80.1% 366 77.4% -
Never 149 14.2% 75 13.0% 74 15.6%
Rarely/sometimes (1-2 night/week) 396 37.6% 224 38.8% 171 36.2%
Often/frequent (≥3 nights/week) 434 41.3% 238 41.2% 195 41.2%
Don't know 73 6.9% 40 6.9% 33 7.0% -
Witnessed apnoeas - ever (≥1 night/week) 309 30.0% 175 30.8% 133 29.0% -
Never 370 36.0% 200 35.2% 169 36.8%
Rarely/sometimes (1-2 night/week) 160 15.5% 83 14.6% 76 16.6%
Often/frequent (≥3 nights/week) 149 14.5% 92 16.2% 57 12.4%
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Nocturnal choking episodes - ever (≥1 night/week) 282 27.1% 142 24.9% 140 29.9% -
Never 656 63.0% 362 63.4% 292 62.3%
Rarely/sometimes (1-2 night/week) 221 21.2% 111 19.4% 110 23.5%
Often/frequent (≥3 nights/week) 61 5.9% 31 5.4% 30 6.4%
Don't know 104 10.0% 67 11.7% 37 7.9% -
Frequent night wakenings - ever (≥1 night/week) 743 71.2% 393 68.7% 349 74.3% -
Never 237 22.7% 235 41.1% 101 21.5%
Rarely/sometimes (1-2 night/week) 484 46.4% 262 45.8% 222 47.2%
Often/frequent (≥3 nights/week) 259 24.8% 131 22.9% 127 27.0%
Don't know 64 6.1% 44 7.7% 20 4.3% -
Unrefreshing sleep - ever (≥1 night/week) 760 72.6% 413 72.3% 470 73.0% -
Never 210 20.1% 114 20.0% 95 20.0%
Rarely/sometimes (1-2 night/week) 428 40.9% 236 41.3% 192 40.5%
Often/frequent (≥3 nights/week) 332 31.7% 177 31.0% 154 32.5%
Don't know 77 7.4% 44 7.7% 33 7.0% -
Daytime sleepiness - ever (≥1 night/week) 787 75.0% 443 93.1% 342 72.5% -
Never 244 23.2% 121 25.4% 123 26.1%
Rarely/sometimes (1-2 night/week) 500 47.6% 276 58.0% 224 47.5%
Often/frequent (≥3 nights/week) 287 27.3% 167 35.1% 118 25.0%
Don't know 19 1.8% 12 2.5% 7 1.5% -
Prior diagnosis of OSA 1067 44 4.1% 29 5.0% 15 3.1% 0.16
Probable OSA using definition 1 1038 350 33.7% 199 34.9% 150 32.2% 0.39
Probable OSA using definition 2 1042 356 34.2% 200 35.1% 155 33.0% 0.51
Probable OSA using definition 3 1038 352 33.9% 200 35.1% 151 32.4% 0.39
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Table 7: Anthropometric characteristics of responders meeting criteria for probable OSAHS on 
≥1 of the 3 algorithms, with responders on CPAP therapy excluded.  Chi-square test used for 
parametric categorical variables, t-test for continuous categorical variables and Mann-Whitney 
U test for non-parametric variables. Values presented as mean±SD or n % unless otherwise 
stated.   
* Gender of 2 responders unknown.              
** Difference between males and females 
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p 
Age (years) 1004 <0.0001
Gender (males : females) 1037 0.47
Collar size (cm) 565 0.02
Body Mass Index (kg/m
2
) ** 884 <0.0001
Underweight (<18.5kg/m
2
) 0 0.0% 6 1.3%
Normal weight (18.5-24.99kg/m
2
) 42 17.3% 140 29.3%
Pre-obesity (25.0-29.99kg/m
2
) 81 33.3% 168 35.1%
Obesity class I (30.0-34.99kg/m
2
) 48 19.8% 100 20.9%
Obesity class II (35.0-39.99kg/m
2
) 44 18.1% 42 8.8%
Obesity class III (≥40.00kg/m
2
) 28 11.5% 22 4.6%
Any medication 1039 273 74.6% 473 70.3% 0.001
Benzodiazepines/Z-drugs 1039 7 1.9% 6 0.9% 0.24
Opiates 1039 6 1.6% 6 0.9% 0.36
Antidepressants 1039 21 5.7% 33 4.9% 0.56
Antiepileptics 1039 24 6.6% 19 2.8% 0.005
Antihistamines 1039 35 9.6% 36 5.3% 0.01
Contraceptives 1039 29 7.9% 33 4.9% 0.06
Melatonin 1039 7 1.9% 9 1.3% 0.60
Oxygen 1039 4 1.1% 6 0.9% 0.75
Comorbidities:
Asthma 1039 64 17.5% 68 10.1% 0.001
Stroke 1039 1 0.3% 14 2.1% 0.03
Broken nose 1039 1 0.3% 6 0.9% 0.43
Diabetes 1039 7 1.9% 20 3.0% 0.42
Heart problems 1039 152 41.5% 231 34.3% 0.02
Hay fever 1039 79 21.6% 111 16.5% 0.04
Thyroid problems 1039 130 35.5% 242 36.0% 0.95
Epilepsy 1039 35 9.6% 25 3.7% <0.0001
Liver 1039 2 0.5% 13 1.9% 0.10
Hypertension 1039 10 2.7% 8 1.2% 0.08
Nasal surgery 1039 6 1.6% 8 1.2% 0.58
Kidney problems 1039 13 3.6% 9 1.3% 0.02
Gluten intolerance 1039 20 5.5% 39 5.8% 0.89
Surgery status:
Adenoidectomy 1039 84 23.0% 96 14.3% 0.001
Tonsillectomy 1039 81 22.1% 101 15.0% 0.005
Adenotonsillectomy 1039 60 16.4% 62 9.2% 0.001





206 : 159 363 : 309
Characteristics
Probable OSA
n = 366 (34.3%) *
26±8
OSA not suspectedTotal 
responses n = 673 (63.1%) *
40.1±4.0
30.0±1.3
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Table 8: Sleep and behaviour characteristics of responders meeting criteria for probable 
OSAHS on ≥1 of the 3 algorithms, with responders on CPAP therapy excluded. Chi-square test 
used for parametric categorical variables, t-test for continuous categorical variables and Mann-
Whitney U test for non-parametric variables. Values presented as mean±SD, median(IQR) or n 
% unless otherwise stated. 
p
Prior diagnosis of obstructive sleep apnoea (OSA) 1039 31 8.5% 13 1.9% <0.0001
DBC-A Disruptive  subscale (scale range 0-34) 1023 <0.0001
Mean item score (possible score 0-2) 1023 <0.0001
Proportion of items checked (possible score 0-1) 1023 <0.0001
Intensity index  (possible score 0-1) 895 <0.0001
DBC-A Anxiety/Antisocial subscale (scale range -2-14) 1021 0.047
Mean item score (possible score 0-2) 1021 <0.0001
Proportion of items checked (possible score 0-1) 1021 <0.0001
Intensity index  (possible score 0-1) 766 0.001
DBC-A Depressive subscale (scale range 0-18) 1024 <0.0001
Mean item score (possible score 0-2) 1024 <0.0001
Proportion of items checked (possible score 0-1) 1024 <0.0001
Intensity index  (possible score 0-1) 718 0.002
Pictorial Epworth Sleepiness Scale (pESS) 933 <0.0001
Pictorial Epworth Sleepiness Scale score >10 933 126 38.8% 89 14.6% <0.0001
Estimated total sleep time (TST) in 24 hours (hr) 545 0.10
Estimated  TST during night (hr) 988 0.02
Estimated TST during daytime (hr) 834 <0.0001
Naps in daytime 812 111 40.8% 123 22.8% <0.0001
Snoring - ever (≥1 night/week) 366 100.0% 450 67.0% -
Never 0 0.0% 149 22.2%
Rarely/sometimes (1-2 night/week) 0 0.0% 396 58.9%
Often/frequent (≥3 nights/week) 366 100.0% 54 8.0%
Don't know 0 0.0% 73 10.9% -
Witnessed apnoeas - ever (≥1 night/week) 206 56.9% 103 15.7% -
Never 20 5.5% 339 51.8%
Rarely/sometimes (1-2 night/week) 82 22.7% 78 11.9%
Often/frequent (≥3 nights/week) 124 34.3% 25 3.8%
Don't know 136 37.6% 213 32.5% -












n = 366 (34.3%) *
OSA not suspected







0.42 (0.18-0.71) 0.24 (0.06-0.50)
0.41 (0.18-0.59) 0.24 (0.06-0.41)
0.10 (0.00-0.33) 0.00 (0.00-0.22)
0.22 (0.11-0.44) 0.11 (0.00-0.33)
0.22 (0.11-0.33) 0.11 (0.00-0.22)
0.25 (0.00-0.50) 0.00 (0.00-0.50)
0.33 (0.11-0.67) 0.11 (0.00-0.44)
0.33 (0.11-0.56) 0.11 (0.00-0.33)
0.00 (0.00-0.39) 0.00 (0.00-0.25)
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Nocturnal choking episodes - ever (≥1 night/week) 160 44.9% 117 17.6% -
Never 145 40.7% 495 74.4%
Rarely/sometimes (1-2 night/week) 111 31.2% 105 15.8%
Often/frequent (≥3 nights/week) 49 13.8% 12 1.8%
Don't know 51 14.3% 53 8.0% -
Frequent night wakenings - ever (≥1 night/week) 292 81.1% 434 65.7% -
Never 36 10.0% 195 29.5%
Rarely/sometimes (1-2 night/week) 158 43.9% 316 47.8%
Often/frequent (≥3 nights/week) 134 37.2% 118 17.9%
Don't know 32 8.9% 32 4.8% -
Unrefreshing sleep - ever (≥1 night/week) 313 86.2% 431 64.9% -
Never 18 5.0% 188 28.3%
Rarely/sometimes (1-2 night/week) 118 32.5% 299 45.0%
Often/frequent (≥3 nights/week) 195 53.7% 132 19.9%
Don't know 32 8.8% 45 6.8% -
Daytime sleepiness - ever (≥1 night/week) 322 88.7% 448 67.3% -
Never 36 9.9% 205 30.8%
Rarely/sometimes (1-2 night/week) 150 41.3% 335 50.3%
Often/frequent (≥3 nights/week) 172 47.4% 113 17.0%
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Table 9a: Determinants of sleepiness as assessed by generalised linear modelling, reported as β-
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Table 9b: Determinants of sleepiness and probable OSAHS as assessed by binary logistic 
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Table 10: Determinants of behaviour as assessed by generalised linear modelling, reported as β-
coefficient with 95% CI. . DBC-A Disruptive subscale analysed separately for males and females 
due to significant difference in scores at baseline (adjusting for gender inappropriate due to 
noted possibility of interaction effect).  
 
  








Category N medication 3.0 1.2 4.8 0.001
Snoring - rarely/sometimes (1-2 nights/week) -1.8 -3.4 -0.1 0.04
Snoring - often/frequently (≥3 nights/week) -1.4 -3.3 0.6 0.16
Witnessed apnoeas - rarely/sometimes (1-2 nights/week) 2.0 0.3 3.7 0.02
Witnessed apnoeas - often/frequently (≥3 nights/week) 1.5 -0.5 3.5 0.14
Nocturnal choking - rarely/sometimes (1-2 nights/week) 1.4 -2.1 3.0 0.09
Nocturnal choking - often/frequently (≥3 nights/week) -0.4 -3.2 2.4 0.77
Frequent awakenings - rarely/sometimes (1-2 nights/week) 1.8 0.3 3.3 0.02
Frequent awakenings - often/frequently (≥3 nights/week) 3.7 1.7 5.7 <0.0001
Unrefreshing sleep - rarely/sometimes (1-2 nights/week) -0.1 -1.7 1.4 0.85
Unrefreshing sleep - often/frequently (≥3 nights/week) 2.1 -0.2 4.3 0.07
Category N medication 4.1 2.6 5.6 <0.0001
Snoring - rarely/sometimes (1-2 nights/week) 0.6 -1.0 2.2 0.47
Snoring - often/frequently (≥3 nights/week) 0.5 -1.2 2.3 0.54
Witnessed apnoeas - rarely/sometimes (1-2 nights/week) -1.6 -3.1 -0.1 0.04
Witnessed apnoeas - often/frequently (≥3 nights/week) -0.8 -3.2 1.5 0.48
Nocturnal choking - rarely/sometimes (1-2 nights/week) 2.6 1.1 4.1 0.001
Nocturnal choking - often/frequently (≥3 nights/week) 3.9 1.0 6.7 0.01
Frequent awakenings - rarely/sometimes (1-2 nights/week) 1.4 -0.1 2.9 0.08
Frequent awakenings - often/frequently (≥3 nights/week) -0.2 -2.1 1.7 0.85
Unrefreshing sleep - rarely/sometimes (1-2 nights/week) 1.5 0.0 3.0 0.06
Unrefreshing sleep - often/frequently (≥3 nights/week) 6.2 4.3 8.1 <0.0001
DBC-A Disruptive - Female
DBC-A Disruptive - Male
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Category R medication 0.3 0.0 0.6 0.09
Category N medication 0.1 -0.2 0.4 0.56
Snoring - rarely/sometimes (1-2 nights/week) 0.0 -0.4 0.3 0.82
Snoring - often/frequently (≥3 nights/week) -0.3 -0.7 0.1 0.13
Witnessed apnoeas - rarely/sometimes (1-2 nights/week) 0.2 -0.2 0.5 0.32
Witnessed apnoeas - often/frequently (≥3 nights/week) -0.1 -0.5 0.3 0.67
Nocturnal choking - rarely/sometimes (1-2 nights/week) 0.3 0.0 0.7 0.03
Nocturnal choking - often/frequently (≥3 nights/week) 0.5 -0.1 1.1 0.11
Frequent awakenings - rarely/sometimes (1-2 nights/week) 0.1 -0.2 0.4 0.55
Frequent awakenings - often/frequently (≥3 nights/week) 0.0 -0.4 0.4 0.87
Unrefreshing sleep - rarely/sometimes (1-2 nights/week) 0.0 -0.3 0.3 1.00
Unrefreshing sleep - often/frequently (≥3 nights/week) 0.5 0.1 1.0 0.03
Daytime sleepiness - rarely/sometimes (1-2 nights/week) 0.2 -0.1 0.5 0.20
Daytime sleepiness - often/frequently (≥3 nights/week) 0.5 0.1 0.9 0.01
Category R medication 0.0 -0.7 0.7 1.00
Category N medication 2.3 1.6 3.0 <0.0001
Snoring - rarely/sometimes (1-2 nights/week) -0.2 -0.9 0.5 0.50
Snoring - often/frequently (≥3 nights/week) -0.2 -1.0 0.5 0.55
Witnessed apnoeas - rarely/sometimes (1-2 nights/week) 0.4 -0.3 1.1 0.22
Witnessed apnoeas - often/frequently (≥3 nights/week) 0.9 0.0 1.8 0.06
Nocturnal choking - rarely/sometimes (1-2 nights/week) 0.5 -0.2 1.1 0.16
Nocturnal choking - often/frequently (≥3 nights/week) 0.5 -0.7 1.6 0.46
Frequent awakenings - rarely/sometimes (1-2 nights/week) 0.5 -0.2 1.1 0.15
Frequent awakenings - often/frequently (≥3 nights/week) 0.3 -0.6 1.1 0.52
Unrefreshing sleep - rarely/sometimes (1-2 nights/week) 0.5 -0.2 1.1 0.19
Unrefreshing sleep - often/frequently (≥3 nights/week) 2.3 1.4 3.3 <0.0001
Daytime sleepiness - rarely/sometimes (1-2 nights/week) -0.1 -0.7 0.5 0.67
Daytime sleepiness - often/frequently (≥3 nights/week) 0.5 -0.3 1.3 0.23
DBC-A Depressive
DBC-A Anxiety/Antisocial
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Table 11: Self-reported medication status of valid questionnaire responders, by gender, based 
on World Health Organisation Anatomical Therapeutic Chemical Classification System (WHO 
ATC) category. Drugs types known to affect sleep are also listed. Responders on CPAP therapy 
are excluded. Chi-square test used for all variables. Results presented as n % unless otherwise 
stated. 
 
* Gender of 2 responders unknown 
** Difference between males and females with DS 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prevalence and treatment of OSAHS in adults with Down syndrome 
Subjective assessment of prevalence – Questionnaire study  104 
Table 12: Self-reported medication status of valid questionnaire responders, by probable 
OSAHS status, based on World Health Organisation Anatomical Therapeutic Chemical 
Classification System (WHO ATC) category. Drugs types known to affect sleep are also listed. 
Responders on CPAP therapy are excluded.  Chi-square test used for all variables. Values 
presented as n % unless otherwise stated.  
* Gender of 2 responders unknown 
** WHO BMI categories calculated for participants aged ≥20 years only   
   
  
p 
A - Alimentary tract and metabolism 1039 77 21.0% 148 22.0% 0.75
B - Blood and blood forming organs 1039 14 3.8% 26 3.9% 1.00
C - Cardiovascular system 1039 22 6.0% 54 8.0% 0.26
D - Dermatologicals 1039 48 13.1% 71 10.5% 0.22
G - Genito-urinary system and sex hormones 1039 40 10.9% 44 6.5% 0.02
H - Systemic hormonal preparations, excluding sex hormones and insulins 1039 129 35.2% 235 34.9% 0.95
J - Antiinfectives for systemic use 1039 8 2.2% 9 1.3% 0.31
L - Antineoplastic and immunomodulating agents 1039 5 1.4% 3 0.4% 0.14
M - Musculo-skeletal system 1039 19 5.2% 23 3.4% 0.19
N - Nervous system 1039 85 23.2% 108 16.0% 0.01
P - Antiparasitic products, insecticides and repellents 1039 0 0.0% 0 0.0% -
R - Respiratory system 1039 77 21.0% 86 12.8% 0.001
S - Sensory organs 1039 10 2.7% 22 3.3% 0.71
V - Various ** 1039 5 1.4% 6 0.9% 0.53
Over-the-counter medications with no clear WHO ATC category 1039 27 7.4% 42 6.2% 0.52
Opiates 1039 6 1.6% 6 0.9% 0.36
Antidepressants 1039 21 5.7% 33 4.9% 0.561
Benzodiazepines / Z-drugs 1039 7 1.9% 6 0.9% 0.24
Antiepileptics 1039 24 6.6% 19 2.8% 0.01
Antihistamines 1039 35 9.6% 36 5.3% 0.01
Contraceptives (% of females) 1039 29 18.4% 33 10.7% 0.06
Oxygen 1039 4 1.1% 6 0.9% 0.75
Melatonin 1039 7 1.9% 9 1.3% 0.60
WHO ATC category
Probable OSA
n = 366 (34.3%) *
OSA not suspected
n = 673 (63.1%) *
Total 
responses
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Table 13: Self-reported sleep and behaviour characteristics of valid questionnaire responders by 
surgery status, with responders on CPAP therapy excluded.  Chi-square test used for 
parametric categorical variables, t-test for continuous categorical variables and Mann-Whitney 
U test for non-parametric variables. Values presented as mean±SD, median(IQR) or n % unless 
otherwise stated. 




Age (years) 1062 0.002
Gender (males : females)* 1065 0.94
Body Mass Index (kg/m
2
) ** 911 0.24
Underweight (<18.5kg/m
2
) 0 0.0% 6 1.1%
Normal weight (18.5-24.99kg/m
2
) 51 29.3% 135 23.7%
Pre-obesity (25.0-29.99kg/m
2
) 53 30.5% 195 34.2%
Obesity class I (30.0-34.99kg/m
2
) 34 19.5% 118 20.7%
Obesity class II (35.0-39.99kg/m
2
) 21 12.1% 68 11.9%
Obesity class III (≥40.00kg/m
2
) 14 8.0% 37 6.5%
Collar size (cm) 579 0.11
Disruptive behaviour subscale (scale range 0-34) 1050 0.04
Mean item score (possible score 0-2) 1050 0.01
Proportion of items checked (possible score 0-1) 1050 0.01
Intensity index  (possible score 0-1) 920 0.07
Anxiety/Antisocial subscale (scale range -2-14) 1035 0.22
Mean item score (possible score 0-2) 1035 0.03
Proportion of items checked (possible score 0-1) 1035 0.03
Intensity index  (possible score 0-1) 783 0.08
Depressive subscale (scale range 0-18) 1050 0.02
Mean item score (possible score 0-2) 1050 0.02
Proportion of items checked (possible score 0-1) 1050 0.02
Intensity index  (possible score 0-1) 735 0.30
Pictorial Epworth Sleepiness Scale (pESS) 954 0.002
Pictorial Epworth Sleepiness Scale score >10 954 62 28.3% 153 20.8% 0.02
Estimated total sleep time (TST) in 24 hours (hr) 559 0.42
Estimated  TST during night (hr) 1011 0.76
Estimated TST during daytime (hr) 834 0.87












136 : 113 449 : 367
Anthropometric, sleep and behaviour characteristics
TA Surgery
n =  249 (23.3%)
No TA surgery















0.29 (0.18-0.53) 0.29 (0.12-0.47)
0.00 (0.00-0.33) 0.00 (0.00-0.25)
0.22 (0.11-0.44) 0.22 (0.00-0.33)
0.22 (0.11-0.33) 0.11 (0.00-0.25)
0.00 (0.00-0.50) 0.00 (0.00-0.50)
0.22 (0.11-0.67) 0.22 (0.00-0.56)
0.22 (0.11-0.56) 0.22 (0.00-0.44)
0.00 (0.00-0.38) 0.00 (0.00-0.33)
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Snoring - ever (≥1 night/week) 208 84.6% 622 77.2% -
Never 24 9.8% 125 15.5%
Rarely/sometimes (1-2 night/week) 85 34.6% 311 38.6%
Often/frequent (≥3 nights/week) 123 50.0% 311 38.6%
Don't know 14 5.7% 59 7.3% -
Witnessed apnoeas - ever (≥1 night/week) 102 43.0% 207 26.1% -
Never 72 30.4% 298 37.6%
Rarely/sometimes (1-2 night/week) 44 18.6% 116 14.6%
Often/frequent (≥3 nights/week) 58 24.5% 91 11.5%
Don't know 63 26.6% 287 36.2% -
Nocturnal choking episodes ever (≥1 night/week) 83 34.3% 199 24.9% -
Never 139 57.4% 517 64.6%
Rarely/sometimes (1-2 night/week) 64 26.4% 157 19.6%
Often/frequent (≥3 nights/week) 19 7.9% 42 5.3%
Don't know 20 8.3% 84 10.5% -
Frequent night wakenings - ever (≥1 night/week) 186 76.2% 557 69.6% -
Never 49 20.1% 188 23.5%
Rarely/sometimes (1-2 night/week) 106 43.4% 378 47.3%
Often/frequent (≥3 nights/week) 80 32.8% 179 22.4%
Don't know 9 3.7% 55 6.9% -
Unrefreshing sleep - ever (≥1 night/week) 195 80.2% 565 70.3% -
Never 34 14.0% 176 21.9%
Rarely/sometimes (1-2 night/week) 98 40.3% 330 41.0%
Often/frequent (≥3 nights/week) 97 39.9% 235 29.2%
Don't know 14 5.8% 63 7.8% -
Daytime sleepiness - ever (≥1 night/week) 192 79.0% 595 73.7% -
Never 49 20.2% 195 24.2%
Rarely/sometimes (1-2 night/week) 115 47.3% 385 47.7%
Often/frequent (≥3 nights/week) 77 31.7% 210 26.0%
Don't know 2 0.8% 17 2.1% -
Prior diagnosis of OSA 1067 24 9.6% 20 2.4% 0.04
Probable OSA on ≥1 definition 1039 105 42.2% 261 31.9% 0.002
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5.3 Discussion 
This is the first large-scale prevalence study of OSAHS in adults with DS. Based on 
self-reported symptoms categorised using the French algorithms (Fuhrman et al. 
2012), the prevalence of OSAHS in this population of UK adults with DS is 
approximately 35%. This is significantly higher than the 2-4% prevalence reported in 
the general population (Young et al. 1993). There was no gender difference in 
OSAHS prevalence in young adults with DS. 
A mean prevalence of 35% is modest in comparison with the >80% quoted in 
previous prevalence studies for the DS population (Resta et al. 2003; Trois et al. 
2009). Although both of these studies used polysomnography to collect objective 
prevalence data, participant numbers were small. Resta et al included only 6 
participants, recruited from a single residential home. Similarly to our study, Trois et 
al recruited via local DS associations and clinics; however, only 16 adults with DS 
were included. A large population-based cohort study of adults with intellectual 
disability in the west of Scotland (n=1023, including 186 with DS) examined 
subjective prevalence of sleep problems (Boyle et al. 2010). Of 87 responders with 
DS, problems initiating and maintaining sleep were reported by 7-9%, but symptoms 
of SDB/OSAHS were not assessed. A further questionnaire study in Canada (Virji-
Babul et al. 2007) found that 19-23% of 59 adults with DS enrolled with a voluntary 
national register of people with DS had been diagnosed with a sleep disorder by a 
clinical psychologist. However, the precise nature of these sleep disorders is not 
stated. OSA was reported by 21% of the whole group (n=223), but this included 
participants aged 1 month to >40 years and prevalence data for adults was not 
reported. 
 Anthropometric Data 5.3.1
Study participants ranged in age from 16 to 65 years, although the majority (69%) 
were aged between 20 and 40 years. The paucity of older responders may be related 
to a number of factors including increased risk of early-onset Alzheimer’s-type 
dementia noted in adults with DS after age 50 (Lai & Williams 1989) and the 
generally reduced life expectancy (mean 51 years, median 58 years) in this 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Subjective assessment of prevalence – Questionnaire study  108 
population  (Wu & Morris 2013). Older adults with DS may be more likely to live in 
residential care, or less likely to have a living relative to assist with questionnaire 
completion. 
The majority of participants in this study were overweight or obese, with females 
significantly heavier than males. Interestingly, the level of obesity in males was the 
same as that of the general population (24%), whilst 36% of females with DS were 
obese in comparison to 25% in the general population (Moody 2014). These 
observations support previous studies in DS and ID populations (Melville et al. 2005; 
Melville et al. 2007).  
A number of factors may contribute to the raised mean BMI in women with DS. 
Females were significantly more likely to be on medication of any type, including  
antidepressants (8%) and hormonal contraceptives (13%) which are known to be 
associated with weight gain (Blumenthal et al. 2014).  Thyroid problems were also 
significantly more prevalent in females (44%). Changes in thyroid function are 
associated with fluctuations in body weight. In our study, thyroid problems were 
significantly more prevalent in females (44%). Interestingly, a recent study in the 
general population in Greece demonstrated a significant link between thyroid 
function in BMI in women, but not men (Milionis & Milionis 2013). Thyroid 
dysfunction may be a contributor to the increased BMI in this group, although further 
investigation is required. 
 Comorbidities 5.3.2
Prevalence of comorbidities potentially related to OSAHS or potentially affecting 
sleep was generally in line with that reported in the general population and previous 
studies in the DS population. One paper (Upton et al. 2000) estimated the prevalence 
of hay fever and asthma in the UK as 20% and 8% respectively, and similar rates are 
noted in this study (18% and 13% respectively). Six percent of our cohort reported 
epilepsy, similar to previous studies in DS (9%) (McVicker et al. 1994), but much 
higher than the general population (<1%) (Forsgren et al. 2005). The prevalence of 
diabetes in the general population is estimated at 3% (Wild et al. 2004), also 
reflected in our study (3%).  A study in the Netherlands reported hypertension in 
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17% of a cohort of adults with ID, however none of the subset of participants with 
DS were hypertensive (van de Louw et al. 2009). Unsurprisingly, hypertension was 
noted in only 2% of our cohort. Stroke is generally rare in young adults (<1%) 
(Smajlovic & Smajlović 2015), and this was again reflected in our data in young 
adults with DS (1%).  
Participants with probable OSAHS were more likely to have asthma, heart problems, 
hay fever, epilepsy or kidney problems than those with low probability of OSA. This 
may be a reflection of sleep disturbance caused by these disorders, or the 
contribution of such disorders to the aetiology of OSAHS. Further investigation is 
warranted. 
 Sleep symptoms 5.3.3
A discrepancy was noted between self-reporting of daytime sleepiness per se (74%; 
27% frequently) with the percentage of those reporting EDS via the pESS (20%). 
Although the pESS appears to be a useful measure in this population, overall scores 
may be reduced due to unsuitability of some of the questions. Particularly, the 
question relating to sitting down and reading may not be appropriate given the levels 
of diminished literacy in this population, and may be problematic in those with visual 
impairment, common in DS. In this study, over 70% of respondents noted that they 
did not nap during the daytime despite 20% exhibiting EDS. This may reflect a lack 
of opportunity to nap (due to employment, education or other daytime commitments) 
rather than absence of sleepiness. Modification of the pESS to improve its utility in 
this specific population may be appropriate and is an area for further investigation. 
A large percentage of responders did not know whether or not they had apnoeas, 
which may have resulted in underestimation of the prevalence of this symptom. This 
may reflect the relative complexity of the description (people are generally more 
familiar with snoring than “pauses in breathing”), but may also relate to the 
availability of a second individual to witness the apnoeas; many people with DS live 
in supported accommodation without a live-in carer or family member and, whereas 
snoring may be heard outside the bedroom, apnoeas are not. This may also explain 
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the relatively young mean age of respondents, who may still reside at home. 
Information on living arrangements was not recorded in this study. 
It should be noted that all responders with probable OSAHS reported snoring ≥3 
nights per week, as this variable was common to all three algorithms. Sleep apnoea 
without snoring is rare in the literature, though one polysomnographic study in adults 
with DSDS (Andreou et al 2002) noted snoring in only 7 of 12 participants with 
studies diagnostic of sleep apnoea. The algorithms used in the current study may 
result in under-estimation of prevalence of OSAHS by excluding those who snore <3 
nights per week. 
 Behavioural and emotional disturbances 5.3.4
Generally, scores on the subscales of the DBC-A were low. A floor effect was noted 
on the Anxiety/Antisocial subscale, with mean scores of 0/14 in both males and 
females, regardless of sleep symptoms, and those with and without probable 
OSAHS. There may be an element of selection bias, with families of individuals with 
more severe behavioural and emotional problems less likely to respond. However, 
probable OSAHS was associated with a significant increase in raw and mean scores 
as well as breadth and intensity of problem behaviours in all 3 subscales, supporting 
the hypothesis of SDB impacting negatively on behaviour and emotion in adults with 
DS.  
Cognitive and behavioural deficits in adults and children with untreated SDB are 
well documented in the general adult population, as is reversal of these deficits with 
treatment (Engleman et al. 1994; Engleman et al. 1997; Engleman 1999; Engleman 
& Douglas 2004). Beebe and Gozal (Beebe & Gozal 2002) proposed that the 
neurocognitive deficits associated with untreated SDB can be explained by 
dysfunction of the prefrontal cortex, leading to impairment of daytime function in a 
range of areas including attention, motivation, control of emotion and decision-
making. Since adults with DS already exhibit impairment in this and other brain 
regions (as discussed in Chapter 1),  untreated SDB may present a “double-hit” on 
cognition in these individuals. It is possible that untreated SDB may contribute to 
acceleration of the cognitive decline seen in early-onset dementia, which is common 
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in adults with DS (Lai & Williams 1989; Holland et al. 1998); a recent review by 
Fernandez and Edgin suggests that sleep disruption might lead to both earlier onset 
of dementia and more rapid deterioration (Fernandez & Edgin 2013).  
Breslin et al (Breslin et al. 2014) reported a 9-point IQ deficit in children with SDB 
and DS versus controls. Marcus et al (Marcus et al. 2012) showed an improvement in 
behaviour scores in subset of 10 children with neurodevelopmental disability (6 with 
DS) with CPAP use. However, to date, no published studies have investigated the 
effect of SDB on cognitive function in adults with DS, or the effect of CPAP therapy 
in this group.  
 Medication  5.3.5
High rates of medication use were reported, with 75% of those with probable 
OSAHS using at least one medication. Untreated OSAHS may have health economic 
implications in terms of prescription rates (Jennum & Kjellberg 2011), but, in this 
population, may also reflect the increased number of comorbidities related to DS. 
 Adenotonsillectomy 5.3.6
Adenotonsillectomy is the first-line treatment for OSAHS in the majority of 
typically-developing children, curative in 75-100% (Schechter 2002). However, less 
favourable results are reported in children with DS, with 30-73%  exhibiting residual 
OSAHS despite adenotonsillectomy (Donnelly et al. 2004; Shete et al. 2010).  
In this study, previous surgery did not result in a lower rate of EDS, and those who 
had previously had adenoids and/or tonsils removed were more likely to exhibit 
symptoms of OSAHS and Disruptive and Depressive behaviour. Whilst surgery may 
result in a partial or initial improvement, the multifactorial nature of the aetiology of 
OSAHS in individuals with DS must be borne in mind; multiple factors mean results 
are not sustained into adulthood in the DS population (Donnelly et al. 2004; Shott & 
Donnelly 2004). This is supported by Capone et al, who noted that prior 
tonsillectomy was not associated with presence or absence of OSAHS in a 
population of adolescents and young adults (age 14-30 years) with DS (Capone et al. 
2013). However, an element of selection bias may be present, with families who 
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have previously had a child diagnosed with OSAHS and treated via 
adenotonsillectomy more likely to complete and return a questionnaire, and more 
vigilant regarding the recurrence of symptoms of OSAHS. 
 
 Limitations  5.3.7
Limitations of this work include the subjective nature of the study. Inherent non-
responder bias in questionnaire studies is well-documented, and difficult to avoid 
(Pannucci & Wilkins 2010), however we believe that the questionnaire was designed 
in such a way as to minimise this. An element of selection bias may be evident, with 
those individuals and families with concerns about sleep more likely to respond. 
There was some regional variation in methodology. An England-based charity which 
sent out the majority (3895; 74%) of the questionnaires declined to send out a second 
questionnaire to individuals who did not respond initially. A repeat mailout was 
conducted by all other services involved in the study. This may have contributed to 
the reduced response rate in England, Wales and Northern Ireland. Making contact a 
second time has been shown to increase response rates by ~20% in other studies 
(Hoffman et al. 1998; Nakash et al. 2006). 
Although the questionnaire was designed to be completed by the individual with DS, 
it is likely that a large proportion of the questionnaires were completed by a proxy on 
the participant’s behalf. A “proxy effect” has been reported in the literature (Tennant 
et al. 1991). However, since this more often results in under-reporting of 
characteristics, it is likely that our estimates of prevalence, sleepiness and behaviour 
are conservative.   
The majority of participants were identified through patient support groups, and so 
may not be representative of the DS population as a whole. Older adults may be 
under-represented, possibly due to inability to complete the questionnaire on account 
of comorbidities such as dementia, or absence of a living relative or family member 
to assist with completion. 
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Information on ethnicity was not collected, and so our prevalence data may not be 
transferable to other countries with divergent ethnicity. However, comparison of the 
prevalence of OSAHS in adults with DS in Scotland with that in Japan, as discussed 
in Chapter 6, showed similar prevalence of symptoms despite the ethnic and 
anthropometric differences between these two populations (Sawatari et al. 2013). 
This questionnaire focussed only on symptoms of SDB/OSAHS. However, a number 
of symptoms such as EDS, unrefreshing sleep and frequent night wakenings are 
common to other sleep disorders, and circadian rhythm disorders, insomnia or 
parasomnias cannot be ruled out as co-morbid or alternative causes for these 
symptoms. 
Building on this work, obtaining objective sleep study data would further quantify 
the severity of SDB in adults with DS. This forms the basis of our further study, 
described in Chapter 7.   
 
5.4 Conclusion 
In conclusion, this first large-scale study of OSAHS prevalence in adults with DS 
showed an estimate of 35% – nearly 9 times higher than in the general adult 
population. Unfortunately, neither assessment nor treatment of OSAHS appears to be 
commonplace in this population clinically - as evidenced by only 7% of the study 
population having a prior diagnosis of OSA and only 3% receiving CPAP treatment - 
despite the potential benefits for improved cognitive function, health and wellbeing. 
This study provides evidence for advocating for improved guidelines for monitoring 
of SDB/OSAHS in DS adults and potentially specialised clinics or services for adults 
with DS and other forms of ID. In the UK, there is currently a dearth of such 
services, with poor transitioning from paediatric services to adult care being 
commonplace. Screening of adults with DS for SDB is recommended, as are 
measures to improve awareness of this disorder amongst people with DS, their 
families and all professionals involved in their care. 
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Chapter 6: Subjective prevalence of OSAHS in 
the UK and Japan – a comparative study 
This study was a collaboration between our team in Edinburgh and a group of 
researchers from Kyushu University, Fukuoka, Japan (see Acknowledgements). This 
new collaboration was formed as a result of networking during the European Society 
of Sleep Technologists meeting in Paris in 2012, at which early results of the study 
described in Chapter 5 were presented (see Appendix 4). 
Sleep-disordered breathing has been the subject of interethnic comparison in a 
number of studies in the general population. Though anatomical differences in 
craniofacial structure can predispose to SDB (Cistulli 1996), this is further 
exacerbated by differing ethnicity (Villaneuva et al. 2005). To our knowledge, there 
have been no studies comparing the effects of ethnicity on OSAHS prevalence in DS.  
We hypothesised that the presence of DS may supercede the effect of ethnicity as a 
risk factor for OSAHS. Therefore, the aim of this study was to compare the 
prevalence of self-reported OSAHS in adults with DS in two nations with differing 
ethnicity - Scotland and Japan. 
 
6.1 Methods 
A comparative study was conducted using subsets of data from two cross-sectional 
studies conducted contemporaneously in Scotland (See Chapter 5) and Japan 
(Sawatari et al. 2015). Both studies received individual ethical approval from the 
relevant local research ethics body (Scotland A Research Ethics Committee; Ethics 
Committee of the Faculty of Medicine at Kyushu University, Japan, and Japan Down 
Syndrome Society). Written informed consent was not required, with return of a 
completed questionnaire considered implicit consent to participate. 
In Scotland, easy-read questionnaires were sent to adults aged ≥16 years with DS and 
their caregivers between February 2011 and June 2014 as part of a wider study 
across the UK, as described in detail in Chapter 5. In Japan, questionnaires were sent 
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to children and adults with DS and their caregivers between May 2011 and 
September 2013. All individuals were members of the Japan Down Syndrome 
Society. Since the Japanese questionnaire surveyed both adults and children, 
responders aged <16 years were excluded from the comparison study analysis.  
Questionnaires were completed by either the individual with DS themselves or their 
caregiver, dependent upon ability. Both questionnaires captured basic anthropometric 
data, along with more focussed questions on sleepiness and symptoms of OSAHS. 
Body mass index (BMI) was calculated from weight and height provided in the 
questionnaire, and classified according to standard classifications for overweight and 
obesity (World Health Organization 2006). Although alternative cut-off values have 
been proposed to control for differing body fat compositions between European and 
Asian populations (Wang et al. 1994), a World Health Organization expert review 
recommended that the standard cut-offs should be retained as the international 
classification, but with additional points included to facilitate international 
comparison (World Health Organization 2004). 
Subjective sleepiness was rated using the pictorial Epworth Sleepiness Scale (Ghiassi 
et al. 2010) in English, or the Japanese version of the Epworth Sleepiness Scale 
(Takegami et al. 2009) as appropriate (referred to henceforth as (p)ESS). Symptoms 
of OSAHS (snoring, witnessed apnoeas, frequent night awakening and daytime 
sleepiness) were classified as occurring frequently (5–7 nights/week), sometimes (1–
4 nights/week) or never (<1 night/week).  
Likely diagnosis of OSAHS was determined using previously published algorithms 
which have been used in both the general population (Fuhrman et al. 2012) and 
adults with DS (see Chapter 5): 
1. Frequent snoring + (witnessed apnoeas ≥1 night/week or (p)ESS>10) 
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 Analysis 6.1.1
Standard statistical analyses were undertaken using SPSS Statistics 19, (IBM Corp., 
USA). Analysis was conducted independently by the investigators in Scotland and 
Japan using a combined SPSS database of subsets of data from both studies. 
Significance was set at p<0.05 and all analyses were two-tailed. All variables were 
checked for normality. The Chi-square test was used for normally-distributed 
discrete variables, Student’s t-test for normally-distributed continuous variables, and 
Mann-Whitney-U test for non-normally distributed data. Results are presented as 
mean ± standard deviation for normal variables, or as number and percentage. 
 Pearson’s rank correlations were used to explore associations between continuous 
variables, with results shown as Pearson’s r and p-value.   
Regression analysis was undertaken to explore significant associations between 
variables, using binary logistic regression (reported as odds ratio (OR) with 95% 
confidence interval (CI)) for categorical variables and generalised linear modelling 
(reported as β-coefficient with 95% CI) for continuous variables. Variables of 
interest generated by exploration were entered into the appropriate regression model, 
with the least significant variables then removed from the model in a stepwise 




A summary of the questionnaires sent, responses received and questionnaires valid 
for analysis is shown in Figure 18. Of a total of 2752 questionnaires sent (752 in 
Scotland, 2000 in Japan), 789 were valid for analysis – 267 (34%) from participants 
in Scotland and 522 (66%) from participants in Japan. Thirteen responders had a 
prior diagnosis of OSAHS and were using CPAP therapy (4% of all responders in 
Scotland and 1% in Japan); these individuals were excluded from further analysis. 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Subjective prevalence of OSAHS in the UK and Japan – a comparative study  117 
The characteristics of valid responders in Scotland and Japan are summarised in 
Table 14. Responders were generally young adults, 56% of whom were male. Mean 
(p)ESS scores were broadly within the normal range (6±5/24). No significant 
differences were noted between the two populations in terms of gender, (p)ESS or 
proportion of individuals exhibiting excessive daytime sleepiness (EDS). However, 
the Scottish cohort were significantly older than the Japanese population, and had a 
higher mean BMI. Three-quarters of the Scottish group were overweight or obese, in 
comparison with 43% of the individuals in Japan. Fifty-six percent of the responders 
in Japan met the WHO criteria for increased or high risk BMI. 
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Figure 18: Summary of questionnaires sent, received and valid for inclusion in the study from 







Questionnaires sent = 2752 
 
Scotland           752    (27% of total) 
Japan             2000  (73%) 
Invalid = 747 
            Scotland    Japan 
Undeliverable    7 0 
Duplicate             25 0 
Declined  7 0 
Deceased  4 0 
Not completed  5 0 
Reply lost in post 2 0 
Aged <16 years  0         697
  
Non-responders = 1203  
 
Scotland  425  
Japan  778  
 
Responses received = 1549 (56%) 
 
Scotland           327   (44% response) 
Japan             1222 (61%) 
 
Treated with CPAP = 13 (2%) 
 
Scotland  10 (4%) 
Japan  3   (1%) 
 
FINAL ANALYSIS = 789 (29%) 
adults with Down syndrome, not 
receiving treatment with CPAP 
 
Scotland           267  (34% of total) 
Japan             522  (66%) 
 
Valid for analysis = 802 (29%) 
 
Scotland           277  (37% response) 
Japan             525  (26%) 
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Symptoms of OSAHS were common in both cohorts. Snoring (Scotland 68%, Japan 
79%; p=0.001) and frequent night awakenings (Scotland 50%, Japan 59%; p=0.04) 
were significantly more prevalent in the Japanese group. Daytime sleepiness per se 
was more frequently reported in the Scottish population (Scotland 54%, Japan 33%; 
p<0.0001), despite no significant difference in scores on the (p)ESS between the two 
countries. Witnessed apnoeas were reported by around a third of responders, with no 
significant differences between the two cohorts noted. 
Gender differences between and within the two populations of adults with DS were 
explored, and are summarised in Table 15. Participants in Scotland were older than 
in Japan, irrespective of gender (p<0.0001); however, responders in both countries 
were predominantly young adults. Mean age did not differ significantly between 
genders in either country. In Scotland, women had a higher BMI than men, and both 
men and women in Scotland had a significantly higher BMI than their Japanese 
counterparts, with higher percentages of individuals in the pre-obese/obese category. 
Japanese men and women did not differ significantly in terms of BMI risk 
categorisation. Males were significantly sleepier than females in both Japan and 
Scotland, with similar mean (p)ESS scores noted within genders in both countries. A 
higher percentage of men exhibited EDS in the Scottish cohort, a difference not 
observed in Japan. In Japan, a significantly higher proportion of men than women 
reported witnessed apnoeas and daytime sleepiness; in Scotland, no significant 
gender differences in reporting of OSAHS symptoms were noted. Snoring and 
frequent night awakenings were more common in Japanese than Scottish males. 
Significantly higher rates of self-reported daytime sleepiness were evident in both 
males and females in Scotland. 
OSAHS prevalence in adults with DS was estimated at 20% in Scotland and 14% in 
Japan (p=0.08; Table 16). No significant gender differences were noted between or 
within countries (data not shown). 
Regression analysis results for Scotland and Japan are shown in Table 17a/b, Table 
19a/b and  Table 20a/b respectively. In Japan, male gender was a risk factor for 
likely OSAHS, though this was not evident in the Scottish cohort. Being male was 
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the predictor of higher scores on the (p)ESS and EDS in Japan; in Scotland, being 
younger and being male were also predictive. Age and elevated BMI predicted 
snoring in both Scotland and Japan, but no significant determinants for witnessed 
apnoeas were found in either population. 
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Table 14: Anthropometric and sleep characteristics of responders in Scotland and Japan. 
Results are shown as mean±SD or number (%) as appropriate.  
* WHO BMI categories valid for individuals aged ≥19 years only. 
 
Whole group Scotland Japan
n = 789 n = 267 n = 522
434 : 346 149 : 118 285 : 228
(56% : 44%) (56% : 44%) (56% : 44%)
Age (years) 789 27±10 32±11 25±8 <0.0001
BMI (kg/m
2
) 730 25.8±5.8 29.8±7.0 24.0±4.0 <0.0001
     Underweight (<18.5kg/m
2
) *                     16 (3%) 1 (0.5%) 15 (4%)
     Normal weight * 242 (44%) 52 (25%) 190 (57%)
     Pre-obese * 177 (32%) 63 (31%) 111 (34%)
     Obese class I * 76 (14%) 47 (23%) 29 (9%)
     Obese class II * 29 (5%) 26 (13%) 3 (1%)
     Obese class III * 16 (3%) 16 (8%) 0 (0%)
     Increasing but acceptable risk (18.5-23.0kg/m
2
) * - - 136 (39%)
     Increased risk (23.0-27.5kg/m
2
) * - - 125 (35%)
     Higher risk (≥27. 5kg/m
2
) * - - 74 (21%)
Epworth Sleepiness Score (Pictorial or Japanese) 691 6±5 6±5 6±5 0.39
Excessive daytime sleepiness, i.e. (p)ESS >10/24 691 134 (19%) 46 (20%) 88 (19%) 0.76
ever (≥1 night/week) 560 (76%) 163 (68%) 397 (79%) 0.001
Frequently (5-7 nights/week) 154 (21%) 57 (24%) 97 (19%)
Sometimes (1-4 nights/week) 406 (55%) 106 (44%) 300 (60%)
Never (<1 night/week) 181 (24%) 77 (32%) 104 (21%)
ever (≥1 night/week) 183 (33%) 57 (35%) 126 (31%) 0.49
Frequently (5-7 nights/week) 48 (9%) 22 (13%) 26 (7%)
Sometimes (1-4 nights/week) 135 (24%) 35 (21%) 100 (25%)
Never (<1 night/week) 382 (68%) 107 (65%) 275 (69%)
ever (≥1 night/week) 405 (56%) 118 (50%) 287 (59%) 0.04
Frequently (5-7 nights/week) 81 (11%) 35 (15%) 46 (9%)
Sometimes (1-4 nights/week) 324 (45%) 83 (35%) 241 (49%)
Never (<1 night/week) 322 (44%) 118 (50%) 204 (42%)
ever (≥1 night/week) 308 (40%) 136 (54%) 172 (33%) <0.0001
Frequently (5-7 nights/week) 49 (6%) 38 (15%) 11 (2%)
Sometimes (1-4 nights/week) 259 (34%) 98 (39%) 161 (31%)

















Gender (Male : Female) 780 1.00
<0.0001
-
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Table 15: Gender differences in anthropometric and sleep characteristics of valid questionnaire 
responders in Scotland and Japan. Results are shown as mean±SD, or number (%) as 
appropriate.  
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Table 16: Likely OSAHS prevalence in Scotland and Japan. Results are shown as number (%). 
 
 
Table 17a: Determinants of sleepiness, witnessed apnoeas and likely OSAHS in adults with DS 






Frequent snoring with witnessed apnoeas ≥1 night/week or 
(p)ESS>10
717 36 (16%) 59 (12%) 0.24
Frequent snoring with witnessed apnoeas ≥1 night/week or 
daytime sleepiness ≥1 night/week
726 46 (20%) 66 (13%) 0.04
Likely OSAHS (either) 728 46 (20%) 70 (14%) 0.08
Criteria for likely OSAHS p
Total 
responses
Scotland          
n = 267
Japan                      
n = 522
Total included Odds Ratio 95% CI lower 95% CI upper p
     Age 0.99 0.95 1.03 0.47
     Gender (male) 1 0.47 2.12 0.99
     Pre-obese or obese 1.1 0.47 2.57 0.83
     Age 1.03 0.99 1.07 0.17
     Gender (male) 3.63 1.46 9.05 0.006
     Pre-obese or obese 2.17 0.76 6.19 0.15
     Age 0.96 0.93 0.99 0.01
     Gender (male) 1.06 0.55 2.03 0.86
     Pre-obese or obese 2.08 1.02 4.25 0.04
     Age 0.96 0.92 1 0.07
     Gender (male) 1.15 0.53 2.48 0.72
     Pre-obese or obese 1.26 0.53 2.02 0.6
Snoring ≥1 night/week 
185
Witnessed apnoeas ≥1 night/week
125




Excessive daytime sleepiness, i.e. (p)ESS >10/24 
178
Dependent variable
Prevalence and treatment of OSAHS in adults with Down syndrome 
Subjective prevalence of OSAHS in the UK and Japan – a comparative study  124 
Table 17b: Determinants of sleepiness in adults with DS in Scotland, assessed by generalised 






Table 18a: Determinants of snoring, witnessed apnoeas and likely OSAHS in adults with DS in 
Japan, assessed by binary logistic regression with estimate reported as odds ratio. 
 
Total included β- coefficient 95% CI lower 95% CI upper p
     Age 0.08 0.01 0.15 0.03
     Gender (male) 3.12 1.56 4.57 <0.0001
     Pre-obese or obese 2.45 0.78 4.12 0.004
Dependent variable
Scotland                                                                                                                                                                       
n=267
Epworth Sleepiness Score **
178
Total included Odds Ratio 95% CI lower 95% CI upper p
     Age 1 0.96 1.05 0.84
     Gender (male) 1.98 1 3.9 0.049
     Increased or high risk BMI 1.73 0.89 3.39 0.11
     Age 1.03 1 1.07 0.08
     Gender (male) 2.11 1.14 3.91 0.02
     Increased or high risk BMI 1.44 0.79 2.63 0.23
     Age 0.95 0.91 0.98 0.004
     Gender (male) 1.67 0.95 2.96 0.08
     Increased or high risk BMI 1.8 1.02 3.17 0.04
     Age 1 0.97 1.04 0.99
     Gender (male) 1.41 0.82 2.41 0.22
     Increased or high risk BMI 0.83 0.49 1.41 0.49
Snoring ≥1 night/week 
326
Witnessed apnoeas ≥1 night/week 
259




Excessive daytime sleepiness, i.e. (p)ESS >10/24 
301
Dependent variable
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Table 18b: Determinants of sleepiness in adults with DS in Japan, assessed by generalised linear 




In this first international, comparative, cross-sectional study of OSAHS symptoms in 
adults with DS, the overall likely prevalence of OSAHS was 16%. Prevalence of 
OSAHS was much higher in both countries than is noted in the general population, 
supporting previous reports of increased risk of OSAHS in adults with DS. However, 
prevalence did not differ significantly between countries, supporting our hypothesis 
that ethnicity does not affect the prevalence of OSAHS in adults with DS.  
Cephalometric data in Caucasian and Japanese populations have identified a number 
of craniofacial features which may predispose to OSAHS (Villaneuva et al. 2005), 
and cephalometric studies have found differences between adolescents with DS and 
typically-developing controls of the same ethnic background (Suri et al. 2010). Given 
that the characteristic craniofacial differences observed in individuals with DS are 
evident regardless of ethnicity, it appears that the DS craniofacial phenotype over-
rides underlying ethnicity. Indeed, mouse models of DS exhibit changes to 
craniofacial dimensions which are directly proportional to those seen in humans, 
suggesting that the DS phenotype may even transcend species differences 
(Richtsmeier et al. 2002). 
Some gender effects were noted, though these were not uniform between cohorts. 
Male gender was a significant determinant of likely OSAHS in Japan, but not 
Total included β-coefficient 95% CI lower 95% CI upper p
     Age 0.62 -0.12 0.14 0.1
     Gender (male) 1.8 0.77 2.87 0.001
     Increased or high risk BMI 0.46 -0.59 1.52 0.39
Dependent variable
Japan                                                                                                                                                                                 
n=525
Epworth Sleepiness Score (Pictorial or Japanese)
301
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Scotland; in Scotland, being male predicted higher (p)ESS scores and EDS. Men 
were more likely to exhibit EDS than females in both countries. Male gender is a 
known risk factor for OSAHS in the general population (Young et al. 1993; Malhotra 
& White 2002), and it would appear that gender exerts an effect in those with DS 
also. A further gender difference was noted in the Scottish cohort, with women 
having higher BMI than men, supporting previously published data in adults with DS 
in Scotland (Melville et al. 2005). This may be related to a number of factors, 
including underlying thyroid disease and use of oral contraceptives, both of which 
are associated with weight gain in the general population (Frye 2006; Milionis & 
Milionis 2013). Hormonal contraception was used by 8% of females in Scotland, but 
this is not commonplace in women with DS in Japan, reflecting an important cultural 
difference.  
Mean BMI was much lower in Japan than in Scotland regardless of gender. A 
previous study in the general population (Genta et al. 2008) comparing OSAHS in 
males of Caucasian and Japanese descent in Brazil found that ethnicity was not 
associated with severity of OSAHS when Asian-specific obesity cut-offs were used 
(World Health Organization 2004). Using these thresholds in the current study, 
raised BMI was a risk factor for higher sleepiness scores in Scotland, but not Japan, 
which may reflect the effect of differences in the underlying distribution of body fat 
with ethnicity in the aetiology of OSAHS (Wang et al. 1994). Differences in diet 
between Japan and Western cultures have been described; the Western diet is high in 
animal fat and sugar, predisposing to obesity, whilst the Japanese diet is higher in 
low-fat foods such as rice, soy and fish (Ogce et al. 2008). Environment plays a role, 
with the diet of Japanese migrants to the US noted to become more “Westernised”.  
Further, information on living arrangements were not collected during this study. 
Previous studies have noted variation in BMI with residential status (Prasher 1995), 
which may contribute to the differences in BMI observed here. Individuals living in 
residential care are likely to have a more controlled diet that those living at home 
with family, and so are less likely to be overweight or obese. 
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Snoring and/or intermittent nocturnal hypoxia due to apnoeas during sleep are known 
to affect cognitive function, emotion and behaviour in both the general population 
and in individuals with DS (Engleman & Douglas 2004; Andreou et al. 2002). People 
with DS are predisposed to early-onset Alzheimer’s-type dementia, with 
neuropathological changes in the brain, such as beta-amyloid plaques and 
neurofibrillary tangles, evident in nearly all adults with DS by 40 years of age 
(Wisniewski et al. 1985). It has been proposed that untreated OSAHS may accelerate 
cognitive decline in adults with DS (Fernandez & Edgin 2013), and so early 
recognition and treatment of OSAHS may not only improve diurnal behaviour and 
diminish sleepiness, but may also play a role in slowing cognitive decline and 
improving overall quality of life. 
This study has limitations which come with every self-reported questionnaire study, 
including responder bias and lack of objective data. Though the response rate was 
high (56%), selection bias cannot be ruled out. As discussed in Chapter 5, there may 
be a proxy effect due to caregivers, rather than individuals with DS completing the 
questionnaire; however, this is more likely to result in conservative estimation of the 
prevalence of OSAHS. 
Increasing age is a known risk factor for OSAHS (Malhotra & White 2002). As life 
expectancy in individuals with DS continues to rise, with many adults with DS living 
into their 60s and 70s (Wu & Morris 2013), this may impact on the prevalence of 
OSAHS in this population. The majority of responders in both cohorts in this study 
were young adults, and, therefore, the true prevalence of OSAHS in adults with DS 
may be underestimated. Given that there may be around 47,000 individuals with DS 
in the UK alone (Wu & Morris 2013), diagnosing and treating OSAHS in this group 
may impact on economic aspects of healthcare in this group, as well as overall health 
economic importance.  
Future large-scale studies using polygraphy or polysomnography to objectively 
assess prevalence would be ideal, and this is the focus of Chapter 7 of this thesis. 
Previous studies using polysomnography in adults with DS have reported an OSAHS 
prevalence of >80% (Resta et al. 2003; Trois et al. 2009); however, both of these 
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studies included only small numbers of participants (24 adults across the two studies) 
and so may not be representative of the DS population as a whole.  
6.4 Conclusions 
This study is the first to compare self-reported symptoms of OSAHS in two 
ethnically diverse populations of adults with DS. Although differences were noted 
with respect to symptoms between countries, the overall prevalence of OSAHS did 
not differ significantly, and was raised in comparison with that of the general 
population. 
Both gender and ethnic differences may play a role in the expression of OSAHS 
across different groups of people and cultural differences may affect its reporting. 
However, many factors predisposing to OSAHS are common to all those with DS, 
irrespective of where they are born, and the aetiology of OSAHS in DS is complex 
and multifactorial.  
This study highlights that the evaluation and treatment of OSAHS in adults with DS 
are limited in both countries. Given the elevated prevalence of OSAHS in adults with 
DS, there is a real need for this to be addressed; in doing so, the potential for 
improving the health, cognitive function and quality of life of adults with DS of all 
ethnicities would be much enhanced. 
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Chapter 7: Objective assessment of prevalence 
– sleep studies 
Following on from the subjective assessment of prevalence via questionnaire, the 
second phase of the study was designed to assess prevalence of SDB in adults with 




 Sleep study invitation 7.1.1
All eligible questionnaire responders who did not check the box to decline further 
participation were invited to undergo a home sleep study. In order to accurately 
assess prevalence of SDB/OSAHS by sampling as true a cross-section of the target 
population as possible, responders were considered eligible if aged ≥16 years with 
DS and not currently using CPAP; sleep studies were offered regardless of subjective 
sleepiness, sleep-related symptoms, previous sleep diagnoses or any other variables 
reported in the questionnaire. However, as discussed in Chapter 5 and on account of 
the study topic, selection bias was difficult to avoid. 
Where the responder had provided contact details on their completed questionnaire, 
an invitation pack (see Appendix 2), including invitation letter, participant 
information sheet, carer information sheet, consent form (for information only), reply 
slip and pre-paid return postage envelope, was sent directly by the study team. All 
invitation packs were numbered using the participant’s individual identification 
number as per the questionnaire. Questionnaire responders who had indicated 
willingness to be contacted further but had not provided contact details were sent an 
invitation pack by the third-party distributor who had sent their original 
questionnaire, using their individual questionnaire number. Questionnaire responders 
were asked to complete and return a reply slip, indicating via a simple check-box 
whether or not they wished to have a home sleep study, or whether they would like to 
discuss the study with the research team before making a decision. Responders were 
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not asked to give a reason if indicating that they did not wish to have a sleep study, 
although, in practice, many responders annotated reasons on the form. 
Where a reply slip was not received within 3 months of posting, a reminder was sent. 
At this point, no further contact was made in the event of no response to the reminder 
being received. 
Initially, only responders in Scotland were invited for sleep studies. Due to the 
ongoing ethical review around the inclusion of AWI and the number of questionnaire 
responders from England, Wales and Northern Ireland, it was decided that 
responders from outwith Scotland would not be contacted until a final decision had 
been reached. Upon receipt of a favourable ethical opinion allowing inclusion of 
AWI in March 2013, invitation packs were sent to responders across the whole of the 
UK, commencing May 2013. These packs included the original invitation letter, 
updated versions of the participant and carer information sheets, an information sheet 
for the relative/carer/welfare attorney of AWI, a copy of the informed consent form 
for AWI (for information only) and a revised reply slip (see Appendix 2). As well as 
asking whether or not the responder wished to undergo a sleep study, the revised 
reply slip contained questions regarding the patient’s geographical location 
(Scotland, England, Wales, Northern Ireland) and ability to give consent. The 
purpose of these questions was to aid the research team in the logistics of scheduling 
and delivering home sleep studies, since different study-specific procedures applied 
depending upon the participant’s ability to consent and which part of the country in 
which they resided (see Chapter 4).   
With the approval of the ethics committee, all questionnaire responders from 
Scotland who had previously either declined a sleep study or failed to return a reply 
slip were sent an updated invitation with a new covering letter, along with the 
information sheet and consent form for AWI, explaining the change in entry criteria 
to allow inclusion of AWI (see Appendix 2). Again, this was followed up by a 
reminder if a reply was not received, with no further contact made to non-responders 
after this time. 
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 Home sleep study equipment 7.1.2
Home sleep studies were conducted using the Embletta
®
 Gold™ (Embla Systems 
LLC, Amsterdam, Netherlands) portable sleep diagnostic device – see Figure 19. 
This is a level III device (Ferber et al. 1994), with capacity to record multiple 
channels of physiological data. The Embletta
®
 Gold™ and its predecessor, 
Embletta
®
, has been used and validated in a number of studies (Dingli et al. 2003; 
Abdelghani et al. 2007; Smith et al. 2007; Gjevre et al. 2011; Ng et al. 2010).  
 
Figure 19: The Embletta
®
 Gold™ equipment in situ: 1) nasal pressure cannula; 2) thoracic 
























As discussed in Chapter 2, current guidelines (SIGN 2003) state that llimited sleep 
studies to assess respiratory events are an adequate first-line method of diagnostic 
assessment for OSAHS and that full PSG with EEG-based sleep staging is not 
required for most patients. It was felt that the less obtrusive nature of a limited study 
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device, with fewer sensors than a PSG and not requiring an in-patient hospital stay, 
would be more acceptable to people with DS, many of whom have experienced high 
levels of medical intervention during their lifetime and may be ‘medical-phobic’ 
(Evans et al. 2005). Home sleep studies have been shown to give a similar, and 
perhaps more representative, quality of sleep in comparison with inpatient hospital 
sleep studies (Kingshott & Douglas 2000). Limited sleep studies also offer 
significant cost savings over full PSG (Dingli et al. 2003; J. F. Masa et al. 2011). 
Channels were recorded in broad accordance with AASM guidelines for full PSG 
(Iber et al. 2007), as recommended by the AASM guidelines for portable monitoring 
(Collop et al. 2007), and are discussed in further detail below. The equipment was set 
up, downloaded and scored using RemLogic-E™ software Version 3.2 (Embla 
Systems LLC, Amsterdam, Netherlands). 
7.1.2.1 Nasal flow 
This was recorded using a disposable nasal pressure cannula (Embla Systems, 
Amsterdam, Netherlands) situated under and inside the nostrils, connected to an 
internal pressure sensor in the Embletta
®
 Gold™ device. As well as recording nasal 
airflow, snoring was derived from the pressure sensor. The cannula fits under the 
nose, loops behind the ears and tightens via a toggle under the chin. Participants were 
advised to use a small piece of adhesive tape (Mefix
®
, Mölnlycke Health Care Ltd., 
Dunstable, UK) over the tubing on each cheekbone to hold the cannula in place 
during the night. A number of participants in the study reported discomfort from the 
nasal cannula due to the length of the prongs entering the nostrils. As a result, they 
and subsequent participants were advised to trim the ends of the prongs to a 
comfortable length using sharp scissors. This may be related to the midface 
hypoplasia typical of the DS phenotype (see Chapter 1). 
Although the AASM guidelines (Iber et al. 2007) recommend the use of two separate 
measures of airflow - a nasal pressure cannula and a nasal-oral thermistor – we opted 
to use only the cannula in this study for the comfort of participants and their ease of 
use of the equipment. As the nasal pressure cannula provides a more accurate 
measure of airflow (Budhiraja et al. 2005), we felt that this would be of no detriment 
to the quality or reliability of the sleep study recording. AASM guidelines also allow 
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the use of the pressure cannula as an alternative measure in the absence of a 
scoreable thermistor signal.  
7.1.2.2 Respiratory effort 
Respiratory effort was recorded via single-use respiratory inductance 
plethysmography (RIP) effort bands (XactTrace
®
, Embla Systems LLC, Amsterdam, 
Netherlands) These provide an indirect, semi-quantitative measure of respiratory 
effort, measuring the change in electrical signal generated by stretching and 
relaxation of the copper wire running through the band in response to changing tidal 
volume. Bands were measured to the individual participant using standardised 
techniques (Embla Systems LLC 2011), and placed around the thorax at the level of 
the axilla, and abdomen at the level of the navel. As well as reducing infection risk, 
single-use belts often provide better signals than reusable belts due to reduced wear 
and tear and improved patient fit. 
7.1.2.3 Pulse oximetry 
Pulse oximetry was conducted using a soft, flexible, slip-on oximeter (Nonin Xpod
®
 
and Nonin reuseable soft cuff, Nonin Medical N.V., Amsterdam, Netherlands) for 
participant comfort and ease of application. This is a transmittance oximeter, 
deriving percentage arterial haemoglobin saturation (%SpO2) from the amount of red 
wavelength light transmitted from one side of the finger to the other; that is, the 
amount of light not absorbed by the haemoglobin. The Embletta
®
 Gold™ transforms 
the signal from the sensor to provide raw and averaged percentage oxygen saturation 
(SpO2), pulse rate and pulse plethysmography waveform (an indicator for peripheral 
blood flow that can be used to indicate heart rate and to assess the quality of the 
oximeter signal).  
Participants were instructed to close the hand into a fist before taping the oximeter 
cable to the back of the hand with adhesive tape. This prevents excessive movement 
of the sensor, which can cause signal artifact, whilst allowing the participant freedom 
of movement of their hand. Participants were also advised that they could thread the 
oximeter cable through the arm of their nightwear to minimise pulling of the cable 
whilst moving around during the night. 
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7.1.2.4 Body position 
The participant’s sleeping position was monitored via an internal position sensor 
built into the Embletta
®
 Gold™ device. This sensor collects gravity information to 
measure the patient's angle and elevation (whether standing or horizontal), then 
derives position changes from this data.  
 Participant education 7.1.3
Participants and their relatives/carers were instructed in the use of the home study 
equipment during their first visit (Visit 1), either in the Department of Sleep 
Medicine or at the participant’s home, immediately after informed consent was 
obtained. Usually, education was carried out on an individual basis, but, on occasion, 
group educations were conducted where two or more patients (usually friends who 
knew each other and had requested concurrent appointments) attended at the same 
time. Education sessions lasted a maximum of 30 minutes.  
The Embletta
®
 Gold™ was laid out and demonstrated to the participant and their 
relative/carer by a member of the research team who was fully trained and 
experienced in the use of the equipment; either a Registered Polysomnographic 
Technologist (RPSGT) or Registered Nurse (RN). The participant was encouraged to 
handle and try on the equipment, and familiarise themselves with it in their own 
time. A full-colour, easy-read instruction sheet was produced, featuring pictorial 
information including photos of an individual with DS assembling and wearing the 
Embletta
®
 Gold™. A laminated, A4-sized version of this instruction sheet was used 
during education and sent home with the participant to use whilst setting up the 
equipment at home that evening (see Appendix 2). A mobile phone number was 
provided to allow the family to contact an RPSGT or RN should they experience any 
problems or questions during set-up of the equipment on the night of the study. 
Participants were advised to use the equipment for two consecutive nights to allow 
for the first-night effect (Agnew et al. 1966; Toussaint et al. 1995; Scholle et al. 
2003), allowing the patient to acclimatise to the novel situation and maximise the 
chance of obtaining a good quality study. A morning questionnaire was issued and a 
liability form was signed by the patient, relative or carer as per normal departmental 
protocol. 
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The home study equipment was returned to the department upon completion of the 
study, either in person or by post. All postage costs were reimbursed to the 
participant by the investigators. 
 Scoring studies 7.1.4
All studies were manually validated and scored by one of two experienced RPSGTs 
(EAH and SW), using standard software. Automatic scoring in conjunction with 
manual validation has been well-documented as the gold-standard procedure for 
sleep scoring, as discussed in Chapter 2. Analysis start and stop times were set 
manually by the RPSGT scoring the study.  These were based on the subjective lights 
on and off times provided in the morning questionnaire, with the scorer using their 
judgement, based on clinical experience, to approximate sleep onset and offset from 
observation of the recorded signals.  
7.1.4.1 Automatic scoring 
Once analysis start/stop times were set, the study was automatically analysed using 
the inbuilt software algorithm. Default thresholds for automatic scoring were stated 
in the sleep study report and are detailed here. 
7.1.4.1.1 Automatic detection of events 
Events were not detected: during movement periods; within the 10 seconds after a 
movement period; during periods in the upright position. 
7.1.4.1.2 Pulse oximetry 
An oxygen desaturation event was detected when the oxygen saturation fell by at 
least 4%. The valid SpO2 range was from 50% to 100%, except during periods of 
artifact. All saturation values <50% were considered artifactual and not counted as 
part of a desaturation event.  The valid pulse range was 25-250bpm, except during 
periods of artifact. An artifact was flagged on the pulse trace when pulse values of 
<25bpm or >250bpm were found.  
7.1.4.1.3 Detection of breathing events 
An apnoea was detected when a 10-second portion of the flow signal dropped below 
10% of the reference amplitude. A hypopnea was detected when a 10-second portion 
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of the flow signal dropped below 70% of the reference amplitude and a desaturation 
event occurred ≤20 seconds after the start of the hypopnea. The reference amplitude 
was calculated as the mean of the peak amplitudes found in the 100 seconds 
preceding the event. All events of duration >120.0 seconds were excluded.  
7.1.4.1.4 Respiration effort stop detection 
Cessation of respiratory effort was marked when intersecting effort stops were found 
in both the thoracic and abdominal effort belts. A respiration effort stop was detected 
when the amplitude of a 5-second portion of the signal dropped below 10% of the 
reference amplitude. The reference amplitude was calculated as the mean of the 
amplitudes found in a period of 240 seconds preceding the signal drop. All events of 
duration >120.0 seconds were excluded.  
7.1.4.1.5 Snoring detection: 
The minimum number of snores needed to create a snoring period was 3. Snoring 
periods were merged into one if the interval between them was <10 seconds. Snoring 
periods were allowed to continue through movement periods. 
7.1.4.2 Manual validation 
Once the automatic analysis was complete, the study was manually validated by the 
RPSGT, deleting incorrectly-scored events, adding missed events and reclassifying 
events as required. Manual scoring was based broadly on the current international 
guidelines for full PSG (Iber et al. 2007). Although recommended (Collop et al. 
2007), these guidelines cannot be directly transferred for use with limited studies. 
The AASM guidelines’ definition of a hypopnoea requires the event to be associated 
with an oxygen desaturation of ≥3% or an arousal; since the Embletta
®
 Gold™, as 
with all limited cardiorespiratory sleep study equipment, does not incorporate a valid 
measure of arousal (i.e. EEG), this criterion cannot be accurately confirmed. 
Therefore, in this study, a hypopnoea was scored if it met the duration and amplitude 
criteria as set out in the AASM Manual (Iber et al. 2007), but regardless of whether 
or not there was a ≥3% oxygen desaturation; an event associated with a desaturation 
clearly meets the criteria, but in the absence of a desaturation, an arousal cannot be 
ruled out, and so was given the “benefit of the doubt”. We opted not to use pulse rate 
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rises, pulse transit time, peripheral arterial tone or other surrogate markers of arousal 
due to the paucity of evidence supporting the accuracy of these methods (Masa et al. 
2013).  
Manual scoring criteria are summarised herein. 
7.1.4.2.1 Detection of breathing events 
An apnoea was scored when the amplitude of the flow signal was reduced by ≥90%, 
based on the previous few stable breaths. If at least part of a breathing event met the 
criteria for an apnoea, the event was scored as such. Apnoeas were classified as 
obstructive if respiratory effort was maintained or augmented for the duration of the 
period of reduced flow. Apnoeas associated with a reduction of respiratory effort of 
≥90% on both the thoracic and abdominal bands for the duration of the flow 
reduction were classified as central. An apnoea was scored as mixed when the period 
of reduced flow was initially associated with a reduction of respiratory effort of 
≥90% on both the thoracic and abdominal bands, but effort was resumed prior to the 
end of the apnoea, i.e. if the apnoea started central then became obstructive. 
A hypopnea was scored when the amplitude of the flow signal was reduced by 
≥30%, based on the previous few stable breaths, regardless of whether a desaturation 
was associated with the event or not. Surrogate measures of arousal, e.g. pulse rate 
rises, were not considered. Hypopnoeas were not further classified as central or 
obstructive.  
Contrary to the automatic scoring criteria, events were scored during the upright 
position. It is not unusual for patients to sleep sitting upright in a chair or in other 
unusual upright postures. Indeed, there is some evidence that children with DS and 
SDB are more likely to sleep in unusual postures (Senthilvel and Krishna 2011), and 
this may also be the case in adults.  
Events were not scored within the 10 seconds after a clear body movement. 
7.1.4.2.2 Pulse oximetry 
Oxygen desaturations were not manually validated or reviewed. 
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7.1.4.3 Sleep study reporting 
Outcome parameters were generated and reported automatically by the software. 
Reported outcomes included: 
 Total Recording Time (TRT): Duration from analysis start time to analysis 
stop time.  
 Apnoeas/hypopnoeas per hour in bed (AH): Total number of apnoeas and 
hypopnoeas divided by the TRT in hours. 
 Flattening index: A measure of limitation of the airflow signal resulting from 
partial airway closure which can be an indicator of upper airways resistance, 
a sub-OSAHS form of sleep-disordered breathing. 
 Snoring time presented as a percentage of TRT. 
 Mean SpO2 measured across TRT. 
 SpO2 nadir: Lowest point of oxygen saturation across TRT. 
 Oxygen desaturation index (ODI): Total number of ≥4% oxygen desaturation 
events divided by the TRT in hours. 
 Mean heart rate measured across TRT. 
 Mean standard deviation of heart rate: Gives a measure of heart rate 
variability, which can be used as a proxy indicator of autonomic arousals in 
the absence of an electroencephalographic measure of arousal (Bonnet et al. 
2007). 
 Body position as a percentage of TRT. 
The index time was derived from the total analysed time minus the total of 
movement time and time in the upright position, i.e. 
Index time = TRT - (movement time + upright time). 
Once reported by the RPSGT, all studies were reviewed by a consultant physician 
experienced in sleep medicine (RLR or IM) and suitability for study inclusion 
confirmed. 
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Each participant was sent a results letter detailing the outcome of their sleep study in 
terms of their AH and ODI (Appendix 2), and all suitable participants were invited to 
proceed to the treatment phase of the study. 
 Reliability of sleep scoring 7.1.5
A randomly-selected subset of valid studies were scored by both RPSGTs to assess 
inter-rater variability (10% of studies scored by SW rescored by EAH). Intra-rater 
reliability was assessed by EAH blindly rescoring a 10% random subset of valid 
studies previously scored by herself after a period of ≥1 year had elapsed. Scoring 
concordance is shown in Error! Reference source not found.. Bivariate correlation 
analysis showed good concordance between scorers in terms of overall AH, 
obstructive apnoeas and hypopnoeas per hour in bed. No significant correlation in 
central and mixed apnoeas per hour in bed was observed, though this is likely due to 
the very small number of these events scored (mean <1.0 events per hour in bed by 
both scorers). 
 
Table 19: Scoring concordance for sleep study variables. Difference presented as median (IQR). 











Inter-rater reliability (n=6; 10% of total scored by SW) 
Apnoeas/Hypopnoeas 
per hour in bed 
18.8 (12.9-28.6) 24.8 (15.0-31.6) 3.7 (-0.06-5.3) 0.943 0.01 
Obstructive 9.6 (4.8-16.2) 7.3 (3.9-12.4) -2.7 (-4.1--0.2) 0.943 0.01 
Central 0.2 (0.1-0.4) 0.3 (0.0-0.4) 0.1 (-0.2-0.1) 0.470 0.35 
Mixed  0.1 (0.0-0.6) 0.1 (0.0-0.2) -0.1 (-0.4-0.1) 0.548 0.26 
Hypopnoea 9.5 (5.4-15.6) 17.5 (9.9-19.7) 4.8 (3.4-7.3) 0.943 0.01 
Intra-rater reliability (n=7; 10% of total scored by EAH) 
Apnoeas/Hypopnoeas 
per hour in bed 
18.0 (12.1-28.6) 19.9 (13.6-30.0) 1.5 (-3.6-1.9) 0.964 <0.0001 
Obstructive 3.8 (2.4-9.0) 5.9 (4.5-7.3) 1.1 (-0.9-2.1) 0.786 0.04 
Central 0.1 (0.0-0.6) 0.2 (0.1-0.6) 0.0 (-0.1-0.2) 0.692 0.09 
Mixed  0.0 (0.0-0.6) 0.0 (0.0-0.1) 0.0 (0.0-0.0) 0.197 0.67 
Hypopnoea 15.1 (6.8-24.6) 14.9 (9.5-20.4) -0.2 (-4.6-1.0) 0.964 <0.0001 
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7.2 Results 
Study participation is summarised in Figure 20. Of the 1067 valid questionnaire 
responders not currently receiving CPAP therapy, 277 (26%) did not wish to be 
contacted further. Of the 790 invitations sent, 427 responses were received (54%), 
260 of which declined to participate. Although a reason for declining was not sought, 
a number of responders annotated their reply slip with a reason; common reasons for 
declining participation included belief that the individual with DS would not tolerate 
the equipment or cope with the study (17%), the logistics of the study or general 
family circumstances making participation problematic (10%), other existing 
comorbidities or disabilities (7%) and a general dislike of hospitals/medical 
intervention (4%). Twelve individuals (5%) declined to participate because they did 
not perceive themselves to have a sleep problem. Six individuals reported that they 
were on CPAP or other sleep treatments and so were ineligible for further inclusion. 
One hundred and sixty seven individuals were willing to undergo a home sleep 
study. Of these, 151 (90%) completed informed consent and were formally recruited 
into the study. Of those who were not consented, 9 changed their mind and declined 
to participate, 2 could not be contacted to book an appointment and a further 2 had 
commenced CPAP through a local clinical service since returning a reply slip. Three 
individuals cancelled appointments and were not rebooked.  
One hundred and forty nine individuals underwent home sleep studies; two of the 
consented individuals were recruited on the basis of clinical polysomnography 
studies in the Department of Sleep Medicine, RIE, and did not undergo a home sleep 
study. Of the recorded studies, 15 studies (10%) did not yield valid results, with 12 
studies being unscoreable or not tolerated, and 3 studies having no data recorded or 
not been used, and were not repeated. Therefore, the final analysis is based on 134 
adults with DS with valid home sleep study data. 
The majority of participants (66%) lived in England, with 22% in Scotland, 9% in 
Wales and 3% in Northern Ireland. 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Objective assessment of prevalence  141 















Invitations sent = 790 
 
England = 519 (66% of total) 
Scotland = 189 (24%) 
Wales = 37 (5%) 
Northern Ireland = 45 (6%) 
Declined to participate = 260 
 
Invite undelivered = 7 
Deceased = 2 
 
Reason not stated = 171 
Would not tolerate/cooperate = 43 
Distance/logistics/ circumstances = 27 
Comorbidities/disabilities = 17 
No sleep problems = 12 
Dislikes hospitals/medical-phobic = 11 
CPAP/other sleep treatments = 6 
 
 
Non-responders = 363 
 
England = 260 
Scotland = 56 
Wales = 18 
Northern Ireland = 29 
Responses received = 427 (54%) 
 
England = 259 (61% of total) 
Scotland = 133 (31%) 
Wales = 19 (4%) 
Northern Ireland = 16 (4%) 
Questionnaire study analysis = 1067 
adults with Down syndrome, not 
receiving treatment with CPAP 
 
England = 701 (66% of total) 
Scotland = 267 (25%) 
Wales = 43 (4%) 
Northern Ireland = 59 (15%) 
No further contact = 277 (26%) 
 
England = 185  
Scotland = 76 
Wales = 5 
Northern Ireland = 11 
Participants consented = 151 (90%) 
 
England = 97 (64% of total) 
Scotland = 38 (25%) 
Wales = 12 (8%) 
Northern Ireland = 4 (3%) 
FINAL ANALYSIS = 134 adults with Down syndrome with valid sleep study data 
 
England = 88 (66% of total)     Scotland = 30 (22%)     Wales = 12 (9%)     Northern Ireland = 4 (3%) 
         
 
Sleep study completed = 149 (89%) 
 
England = 96 (64% of total) 
Scotland = 36 (24%) 
Wales = 13 (9%) 
Northern Ireland = 4 (3%) 
Not consented = 16 
 
Changed mind/declined = 9 
Uncontactable = 2 
Started CPAP locally = 2 




Invalid study = 15 
 
Could not tolerate/unscoreable = 12 
No data/did not use = 3 
 
+ve clinical PSG – no research study = 2 
 
Willing to participate = 167 (39%) 
 
England = 110 (66% of total) 
Scotland = 40 (24%) 
Wales = 13 (8%) 
Northern Ireland = 4 (2%) 
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 Anthropometric data 7.2.1
The subset of participants in the sleep study appears to be broadly representative of 
the questionnaire study cohort as a whole. Anthropometric characteristics of all sleep 
study participants, taken from their completed prevalence questionnaire, are 
summarised in Table 20. Participants were mainly young adults (mean age 26±8 
years). The mean BMI was 30.3±6.4kg/m
2
, with females significantly heavier than 
males (28.6±6.1 v. 32.5±6.2; p=0.001). Of the 90 individuals aged ≥20 years for 
whom the WHO international classification of BMI are valid (World Health 
Organization 2006), 76% were overweight or obese – see Figure 21. 
 Comorbidities and medication 7.2.2
Comorbidities and medication use were generally in line with the results of the 
questionnaire study (see Chapter 5), with 74% of participants using at least one 
medication, as shown in Table 20. As one would expect in this population, thyroid 
(38%) and heart disorders (39%) were prevalent. Respiratory problems were also 
noted, with 24% reporting hay fever and 15% asthma. This was reflected in the use 
of medications, with 41% using category H drugs (systemic hormonal preparations, 
which includes thyroxine) and 17% using category R (respiratory system) 
medications. Use of medications affecting sleep, including benzodiazepines, 
antidepressants, opiates, oxygen, melatonin and antihistamines were low, ranging 
between <1% and 8% (1-10 individuals). No significant gender differences in 
comorbidities and medication were noted, other than in use of category G 
medications (genito-urinary system and sex hormones), which were used more 
frequently by females (p<0.0001) due to the inclusion of contraceptives in this 
category (20% of female participants). Twenty-five percent of participants had 
previously undergone tonsil and/or adenoid surgery. 
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Figure 21: BMI classification of participants aged ≥20 years using the World Health 























Underweight (<18.5kg/m2) Normal weight (18.5-24.99kg/m2)
Pre-obesity (25.0-29.99kg/m2) Obesity class I (30.0-34.99kg/m2)








Underweight (<18.5kg/m2) Normal weight (18.5-24.99kg/m2)
Pre-obesity (25.0-29.99kg/m2) Obesity class I (30.0-34.99kg/m2)
Obesity class II (35.0-39.99kg/m2) Obesity class III (≥40.00kg/m2) 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Objective assessment of prevalence  144 
Table 20: Anthropometric characteristics of all sleep study participants. Chi-square test used 
for parametric categorical variables and t-test for continuous categorical variables. Values 
presented as mean±SD or n%.  
* Difference between males and females 
** 2 males did not complete a questionnaire 
*** WHO BMI category calculated for participants aged ≥20 years only 
**** Includes oxygen 
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p *
Age (years) 133 0.68
Body Mass Index (kg/m
2
) *** 114 0.001
Underweight (<18.5kg/m
2
) 0 0.0% 0 0.0% 0 0.0%
Normal weight (18.5-24.99kg/m
2
) 22 24.4% 19 35.8% 3 8.1%
Pre-obesity (25.0-29.99kg/m
2
) 26 28.9% 17 32.1% 9 24.3%
Obesity class I (30.0-34.99kg/m
2
) 18 20.0% 9 17.0% 9 24.3%
Obesity class II (35.0-39.99kg/m
2
) 14 15.6% 3 5.7% 11 29.7%
Obesity class III (≥40.00kg/m
2
) 10 11.1% 5 9.4% 5 13.5%
Collar size (cm) 86 0.03
Asthma 132 20 15.2% 16 21.1% 4 7.1% 0.03
Stroke 132 2 1.5% 0 0.0% 2 3.6% 0.18
Broken nose 132 1 0.8% 0 0.0% 1 1.8% 0.42
Diabetes 132 4 3.0% 2 2.6% 2 3.6% 1.00
Heart problems 132 51 38.6% 24 31.6% 27 48.2% 0.07
Hay fever 132 31 23.5% 18 23.7% 13 23.2% 1.00
Thyroid problems 132 50 37.9% 25 32.9% 25 44.6% 0.21
Epilepsy 132 3 2.3% 3 3.9% 0 0.0% 0.26
Liver problems 132 1 0.8% 1 1.3% 0 0.0% 1.00
Hypertension 132 1 0.8% 0 0.0% 1 1.8% 0.42
Nasal surgery 132 2 1.5% 1 1.3% 1 1.8% 1.00
Kidney problems 132 1 0.8% 1 1.3% 0 0.0% 1.00
Gluten intolerance 132 9 6.8% 3 3.9% 6 10.7% 0.17
Any adenoid and/or tonsil surgery 132 33 25.0% 18 23.7% 15 26.8% 0.69
Any medication 132 97 73.5% 51 67.1% 46 82.1% 0.07
A - Alimentary tract and metabolism 132 34 25.8% 18 23.7% 16 28.6% 0.55
B - Blood and blood forming organs 132 3 2.3% 1 1.3% 2 3.6% 0.57
C - Cardiovascular system 132 9 6.8% 3 3.9% 6 10.7% 0.17
D - Dermatologicals 132 15 11.4% 8 10.5% 7 12.5% 0.79
G - Genito-urinary system and sex hormones 132 15 11.4% 1 1.3% 14 25.0% <0.0001
H - Systemic hormonal preparations, excluding sex 
hormones and insulins
132 54 40.9% 28 36.8% 28 50.0% 0.29
J - Antiinfectives for systemic use 132 2 1.5% 1 1.3% 1 1.8% 1.00
L - Antineoplastic and immunomodulating agents 132 0 0.0% 0 0.0% 0 0.0% -
M - Musculo-skeletal system 132 8 6.1% 4 5.3% 4 7.1% 0.72
N - Nervous system 132 17 12.9% 10 13.2% 7 12.5% 1.00
P - Antiparasitic products, insecticides and repellents 132 0 0.0% 0 0.0% 0 0.0% -
R - Respiratory system 132 23 17.4% 15 19.7% 8 14.3% 0.49
S - Sensory organs 132 2 1.5% 1 1.3% 1 1.8% 1.00
V - Various **** 132 1 0.8% 0 0.0% 1 1.8% 0.42
Over-the-counter medications with no clear WHO 
ATC category
132 9 6.8% 3 3.9% 6 10.7% 0.17
Benzodiazepines 132 1 0.8% 1 1.3% 0 0.0% 1.00
Antidepressants 132 4 3.0% 1 1.3% 3 5.4% 0.31
Opiates 132 2 1.5% 0 0.0% 2 3.6% 0.18
Oxygen 132 1 0.8% 0 0.0% 1 1.8% 0.42
Melatonin 132 1 0.8% 1 1.3% 0 0.0% 1.00
Antiepileptics 132 4 3.0% 2 2.6% 2 3.6% 1.00
Contraceptives 132 11 8.3% - - 11 19.6% -













n = 78 (58%) **
Female
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 Sleep symptoms 7.2.3
Sleep and behaviour characteristics are summarised in Table 21, and appear to be a 
representative subset of the population surveyed. The mean pESS was 9±6, with 32% 
reporting a pESS of >10, indicative of EDS (in comparison to a mean pESS of 7±5 in 
the subjective prevalence cohort, 23% of whom reported EDS). However, daytime 
sleepiness was reported at least once per week by 85% of responders. Eighty-three 
percent of responders reported snoring at least 1 night per week, 59% frequently, 
with witnessed apnoeas ≥1 night/week reported by 40%, 20% frequently, although 
45% did not know whether they had breathing pauses during sleep or not. Nocturnal 
choking episodes ≥1 night/week were noted by 35%. Frequent night wakenings 
(81%) and unrefreshing sleep (85%) on ≥1 night/week were also prevalent. 
The mean estimated TST in 24hr was 9.0±1.4hr, with a trend towards females 
sleeping longer than males (p=0.002) observed, similar to the questionnaire cohort. 
There was no significant gender difference in estimated TST during the night 
(8.4±1.2; p=0.14) or during the day (0.0 (0.0-1.0); p=0.13). Thirty-eight percent of 
participants reported daytime napping, with a trend towards more napping in females 
(29% v. 49%; p=0.07). 
Using the same algorithms as the questionnaire study (Fuhrman et al. 2012), 56% of 
sleep study participants met the criteria for probable OSAHS on at least one of the 3 
algorithms, in contrast to 35% of the questionnaire study participants. Eight percent 
(10 participants) had an existing diagnosis of OSAHS. 
 
 Behavioural and emotional disturbances 7.2.4
Behaviour scores on the 3 subscales of the DBC-A (Table 21) were similar to those 
obtained overall in the questionnaire study, although the significant gender 
differences observed in the Disruptive behaviour subscale in the questionnaire study 
were not apparent in this subset. No significant gender differences were noted in 
terms of total scores, mean items scores or the breadth or intensity of problem 
behaviours.  
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Table 21: Self-reported sleep and behaviour characteristics of sleep study participants. Chi-
square test used for parametric categorical variables, t-test for continuous categorical variables 
and Mann-Whitney U test for non-parametric variables. Values presented as mean±SD, 
median(IQR) or n % unless otherwise stated. 
* Difference between males and females 
** 2 males did not complete a questionnaire 
 
p *
Disruptive behaviour subscale (scale range 0-34) 129 0.93
Mean item score (possible score 0-2) 129 0.95
Proportion of items checked (possible score 0-1) 129 0.84
Intensity index  (possible score 0-1) 119 0.62
Anxiety/Antisocial subscale (scale range -2-14) 129 0.29
Mean item score (possible score 0-2) 129 0.28
Proportion of items checked (possible score 0-1) 129 0.26
Intensity index  (possible score 0-1) 96 0.87
Depressive subscale (scale range 0-18) 129 0.18
Mean item score (possible score 0-2) 129 0.17
Proportion of items checked (possible score 0-1) 129 0.13
Intensity index  (possible score 0-1) 95 0.99
Pictorial Epworth Sleepiness Scale (pESS) 118 0.72
Pictorial Epworth Sleepiness Scale score >10 118 38 32.2% 22 32.8% 16 31.4% 1.00
Estimated total sleep time (TST) in 24 hours (hr) 68 0.002
Estimated TST during night (hr) 124 0.14
Estimated TST during daytime (hr) 103 0.13
Naps in daytime 103 39 37.9% 17 29.3% 22 48.9% 0.07
Snoring - ever (≥1 night/week) 107 82.9% 63 86.3% 44 78.6% -
Never 15 11.6% 7 9.6% 8 14.3%
Rarely/sometimes (1-2 night/week) 31 24.0% 16 21.9% 15 26.8%
Often/frequent (≥3 nights/week) 76 58.9% 47 64.4% 29 51.8%
Don't know 7 5.4% 3 4.1% 4 7.1% -
Witnessed apnoeas - ever (≥1 night/week) 52 40.0% 30 40.0% 22 40.0% -
Never 19 14.6% 15 20.0% 4 7.3%
Rarely/sometimes (1-2 night/week) 22 16.9% 11 14.7% 11 20.0%
Often/frequent (≥3 nights/week) 30 23.1% 19 25.3% 11 20.0%



















Sleep and behaviour characteristics
Male
n = 78 (58%) **
Female
n = 56 (42%)
0 (0-1)
3 (1-5)








0.22 (0.11-0.33) 0.11 (0.00-0.33)
0.00 (0.00-0.50) 0.00 (0.00-0.50)
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Nocturnal choking episodes - ever (≥1 night/week) 45 34.6% 25 33.3% 20 36.4% -
Never 63 48.5% 35 46.7% 28 50.9%
Rarely/sometimes (1-2 night/week) 37 28.5% 19 25.3% 18 32.7%
Often/frequent (≥3 nights/week) 8 6.2% 6 8.0% 2 3.6%
Don't know 22 16.9% 15 20.0% 7 12.7% -
Frequent night wakenings - ever (≥1 night/week) 106 80.9% 56 73.7% 50 90.9% -
Never 14 10.7% 12 15.8% 2 3.6%
Rarely/sometimes (1-2 night/week) 69 52.7% 35 46.1% 34 61.8%
Often/frequent (≥3 nights/week) 37 28.2% 21 27.6% 16 29.1%
Don't know 11 8.4% 8 10.5% 3 5.5% -
Unrefreshing sleep - ever (≥1 night/week) 110 84.0% 60 80.0% 50 89.3% -
Never 12 9.2% 10 13.3% 2 3.6%
Rarely/sometimes (1-2 night/week) 52 39.7% 24 32.0% 28 50.0%
Often/frequent (≥3 nights/week) 58 44.3% 36 48.0% 22 39.3%
Don't know 9 6.9% 5 6.7% 4 7.1% -
Daytime sleepiness - ever (≥1 night/week) 111 84.7% 63 84.0% 48 85.7% -
Never 19 14.5% 11 14.7% 8 14.3%
Rarely/sometimes (1-2 night/week) 59 45.0% 35 46.7% 24 42.9%
Often/frequent (≥3 nights/week) 52 39.7% 28 37.3% 24 42.9%
Don't know 1 0.8% 1 1.3% 0 0.0% -
Prior diagnosis of OSA 132 10 7.6% 7 9.2% 3 5.4% 0.52
Probable OSA using definition 1 129 70 54.3% 42 57.5% 28 50.0% 0.48
Probable OSA using definition 2 129 72 55.8% 44 60.3% 28 50.0% 0.29
Probable OSA using definition 3 129 70 54.3% 42 57.5% 28 50.0% 0.48
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 Objective sleep data 7.2.5
The home sleep study equipment was generally well-accepted, with scoreable results 
achieved on night 1 or 2 of the study in the majority of cases (Figure 22: Number of 
home sleep study nights required to obtain a valid diagnostic outcome.). Twelve 
individuals (9%) required a repeat study to obtain a scoreable result. The nasal 
airflow signal was not sufficient to provide a valid AH per hour in bed in 14 
participants, and so the ODI was used for diagnosis. Nineteen did not have a valid 
oximetry signal but had a valid AH. 
 
Figure 22: Number of home sleep study nights required to obtain a valid diagnostic outcome. 
 
 
Objective sleep study data are shown in Table 22. The total scored recording time 
averaged 488.4±115.1min (8.1±2.6hr), similar to the estimated TST at night reported 
subjectively via questionnaire (8.4±1.2hr), and did not differ significantly between 

























Number of sleep study nights 
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Table 22: Manually-scored objective sleep study characteristics of male and female participants. 
Chi-square test used for parametric categorical variables, t-test for continuous categorical 
variables and Mann-Whitney U test for non-parametric variables. Values presented as 
mean±SD, median(IQR) or n % unless otherwise stated.  
* Difference between males and females 
** 2 males did not complete a questionnaire 
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p *
Total recording time (min) 132 0.72







Flattening index 95 0.17
Mean SpO2 (%) 115 0.73
SpO2 nadir (%) 114 0.70
Average desaturation (%) 115 0.80
Oxygen desaturation index per hour in bed 114 0.01
Supine 114 0.02
Non-supine 114 0.80
Mean heart rate (BPM) 115 0.02
Mean standard devation of heart rate (BPM) 115 0.07
Supine % of total recording time 132 <0.0001
Left % of total recording time 132 0.31
Prone % of total recording time 132 0.002
Right % of total recording time 132 0.01
Upright % of total recording time 132 0.38
Transition index per hour in bed 132 0.02
AH ≥ 10 120 93 77.5% 58 84.1% 35 68.6% 0.05
AH ≥ 15 119 74 62.2% 48 69.6% 26 52.0% 0.58
ODI ≥ 10 114 47 41.2% 31 47.0% 16 33.3% 0.18
AH ≥ 15 + pESS >10 120 24 20.0% 16 22.9% 8 16.0% 0.49
AH ≥ 15 + unrefreshing sleep often/frequently 118 35 29.7% 25 36.2% 10 20.4% 0.70
AH ≥ 15 + daytime sleepiness often/frequently 128 30 23.4% 20 26.7% 10 18.9% 0.40
OSAHS on >1 definition 118 49 41.5% 34 48.6% 15 31.3% 0.09




10.1 (5.0-17.9) 12.1 (6.9-24.9)
93 ± 4


























11.2 (0.0-29.2) 4.7 (0.0-28.4)
0.1 (0.0-0.8) 0.0 (0.0-0.8) 0.1 (0.0-0.8)





n = 78 (58%) **
Female
n = 56 (42%)
Total 
included
0.0 (0.0-0.5) 0.0 (0.0-0.2)





















0.45 (0.0-1.2) 0.0 (0.0-0.3)
3.2 (0.6-15.4)
35.1 ± 29.8
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7.2.5.1 Breathing events 
The mean AH per hour in bed was 21.8(10.9-42.7), with a trend towards a higher AH 
noted in males (p=0.01). As would be expected, the supine AH (24.7(10.0-46.9)) was 
higher than the non-supine value (8.8(3.0-22.1)). The majority of scored events were 
hypopnoeas, and the majority of scored apnoeas were obstructive, rather than central 
or mixed. The flattening index, which can be an indicator of flow limitation, was 
10.1 (5.0-17.9) per hour. 
7.2.5.2 Pulse oximetry 
The mean ODI per hour was 6.6 (2.3-20.0), trending towards a higher ODI in males 
(p=0.01). Again, values were higher in the supine (7.6(1.6-24.1)) versus non-supine 
(2.2(0.5-8.0)) position. The mean baseline saturation was 94±3%, which is within 
normal limits, with an SpO2 nadir of 81±8% and mean desaturation of 5±1%. 
Despite the raised BMI of participants, obesity hypoventilation was not observed in 
any individual. 
7.2.5.3 Heart rate variability 
The mean heart rate was 63.4±10.6 BPM, within the normal range for adults. The 
mean standard deviation of the heart rate, was 6.6±3.1 BPM; this indicates a degree 
of heart rate variability, a proxy measure for autonomic arousal (Bonnet et al. 2007), 
suggesting a degree of sleep fragmentation. 
7.2.5.4 Body position 
The highest percentage of recording time was noted in the supine position. Males, on 
average, spent over half of the study supine (57.2±33.5%), with females supine for 
significantly less time (35.1±29.8%; p<0.0001). Females tended to spend more time 
prone than males, although this did not reach significance (p=0.002). Very little time 
was spent in the upright position (0.1(0.0-0.8)%). The transition index, which gives 
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 Diagnosis of OSAHS 7.2.6
In terms of diagnostic thresholds, 78% met the AH criteria for entry to the treatment 
study, with an AH≥10. An AH≥15 or an ODI ≥10/hr is considered diagnostic of 
OSA using the SIGN guidelines (Scottish Intercollegiate Guidelines Network 2003); 
62% met the SIGN criteria for AH and 41% the criteria for ODI. 
The probable OSAHS algorithms (Fuhrman et al. 2012) were adapted, in line with 
the SIGN guidelines, to allow direct comparison of the subjective diagnosis of 
probable OSAHS with the objective diagnosis of OSAHS by substituting snoring ≥3 
nights/week and witnessed apnoeas with AH≥15: 
4. AH≥15 plus pESS>10. 
5. AH≥15 plus unrefreshing sleep ≥3 nights per week. 
6. AH≥15 plus daytime sleepiness ≥3 nights per week. 
Using these modified algorithms, 42% of participants demonstrated OSAHS on ≥1 
definition (versus 56% of the same group who met the criteria for probable OSAHS).  
Subjective and objective measures of OSAHS were compared – see Table 23. 
Sensitivity of the probable OSAHS algorithms (ability of the algorithms to correctly 
identify individuals with objectively-diagnosed OSAHS) was 79.2%, with a 
specificity (ability of the algorithms to correctly identify individuals who do not have 
OSAHS) of 58.5%. The positive predictive value (PPV; the likelihood of an 
individual to have OSAHS in the event of meeting the criteria for probable OSAHS 
via the algorithms) was 58.5% and the negative predictive value (NPV; the 
likelihood of an individual to be OSAHS negative in the event of obtaining a 
negative result on the algorithms) was 79.2%. The likelihood ratio (how much more 
likely it is that an individual who is positive for probable OSAHS via the algorithms 
will have an objective diagnosis of OSAHS) was 1.9 (Lalkhen & McCluskey 2008). 
Characteristics of individuals with and without OSAHS are summarised in Table 24. 
No significant gender differences were noted in terms of age, gender, BMI, collar 
size or comorbidities or medications related to sleep between those with and without 
a diagnosis of OSAHS; those with a diagnosis of OSAHS via home sleep study were 
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more likely to have thyroid problems, though this did not reach statistical 
significance (p=0.01). 
Sleep and behaviour characteristics of those with and without a diagnosis of OSAHS 
are shown in Table 25. Self-reported symptoms including snoring, nocturnal choking 
episodes, unrefreshing sleep and daytime sleepiness were significantly higher in the 
OSAHS positive group (all p<0.0001, except nocturnal choking episodes p=0.001). 
Witnessed apnoeas did not differ significantly between those with and without 
OSAHS, although the number of individuals who did not know whether or not they 
had apnoeas was high in both groups (45% of OSAHS group and 46% of those 
without OSAHS). Ninety-four percent of those with OSAHS reported snoring, 
although 79% of those without OSAHS were also snorers.  
The mean pESS was significantly higher in those with OSAHS (11±6 v 7±5; 
p=0.001), with 55% of the OSAHS positive group exhibiting EDS on the pESS, 
versus 18% of those without OSAHS (p<0.0001), although 71% of those with 
OSAHS and 24% of the OSAHS negative group reported daytime sleepiness ≥3 
nights per week. Seventy-nine percent of the OSAHS group were correctly identified 
using the probable OSAHS algorithms, while 42% of those not exhibiting OSAHS 
via objective testing were suggestive of probable OSAHS using the algorithms 
(p<0.0001).  
 
Table 23: Comparison of subjective and objective measures of OSAHS prevalence. Comparison 
data unavailable for 21 participants. No significant difference was noted between genders 
(p=0.22). 
  
Objective OSAHS any 
  
Yes No Total 
Probable 
OSAHS any 
Yes 38 27 65 
No 10 38 48 
Total 48 65 113 
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Table 24: Anthropometric characteristics of sleep study participants by presence or absence of 
OSAHS via objective sleep study. Chi-square test used for parametric categorical variables and 
t-test for continuous categorical variables. Values presented as mean±SD or n%. 





Age (years) 117 0.28
Gender (males : females) 118 0.09
Body Mass Index (kg/m
2
) 101 0.84
Collar size (cm) 76 0.41
Asthma 116 7 14.3% 9 13.4% 1.00
Hay fever 116 7 14.3% 15 22.4% 0.34
Thyroid problems 116 24 49.0% 16 23.9% 0.01
Epilepsy 116 3 6.1% 0 0.0% 0.07
Any adenoid and/or tonsil surgery 116 17 34.7% 11 16.4% 0.03
Any medication 116 40 81.6% 44 65.7% 0.06
Benzodiazepines 116 1 2.0% 0 0.0% 0.42
Antidepressants 116 2 4.1% 2 3.0% 1.00
Opiates 116 2 4.1% 0 0.0% 0.18
Oxygen 116 0 0.0% 1 1.5% 1.00
Melatonin 116 1 2.0% 0 0.0% 0.42
Antiepileptics 116 2 4.1% 2 3.0% 1.00
Contraceptives 116 3 6.1% 6 9.0% 0.73










n = 49 (37%) *
30.2 ± 7.0
26 ± 9 25 ± 7
34 : 15 36 : 33
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Table 25: Self-reported sleep and behaviour characteristics of sleep study participants by 
presence or absence of OSAHS. Chi-square test used for parametric categorical variables, t-test 
for continuous categorical variables and Mann-Whitney U test for non-parametric variables. 
Values presented as mean±SD, median(IQR) or n%.  




Disruptive behaviour subscale (scale range 0-34) 114 0.01
Mean item score (possible score 0-2) 114 0.01
Proportion of items checked (possible score 0-1) 114 0.03
Intensity index  (possible score 0-1) 104 0.001
Anxiety/Antisocial subscale (scale range -2-14) 114 0.91
Mean item score (possible score 0-2) 114 0.004
Proportion of items checked (possible score 0-1) 114 0.01
Intensity index  (possible score 0-1) 84 0.33
Depressive subscale (scale range 0-18) 114 0.07
Mean item score (possible score 0-2) 114 0.07
Proportion of items checked (possible score 0-1) 114 0.12
Intensity index  (possible score 0-1) 83 0.08
Pictorial Epworth Sleepiness Scale (pESS) 107 0.001
Pictorial Epworth Sleepiness Scale score >10 107 24 54.5% 11 17.5% <0.0001
Snoring - ever (≥1 night/week) 45 93.8% 51 78.5% -
Never 1 2.1% 11 16.9%
Rarely/sometimes (1-2 night/week) 7 14.6% 20 30.8%
Often/frequent (≥3 nights/week) 38 79.2% 31 47.7%
Don't know 2 4.2% 3 4.6% -
Witnessed apnoeas - ever (≥1 night/week) 20 40.8% 24 36.9% -
Never 7 14.3% 11 16.9%
Rarely/sometimes (1-2 night/week) 4 8.2% 15 23.1%
Often/frequent (≥3 nights/week) 16 32.7% 9 13.8%
Don't know 22 44.9% 30 46.2% -
114
0.22 (0.11-0.33) 0.11 (0.00-0.11)
0.27 (0.00-0.50) 0.00 (0.00-0.50)




Sleep and behaviour characteristics
OSAHS positive
n = 49 (37%) *
OSAHS negative
n = 69 (52%) *
0 (0-1)
2 (0-5)
Developmental Behaviour Checklist for Adults (DBC-A):















0.22 (0.11-0.44) 0.11 (0.00-0.22)
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Nocturnal choking episodes - ever (≥1 night/week) 21 42.9% 19 29.2% -
Never 17 34.7% 40 61.5%
Rarely/sometimes (1-2 night/week) 14 28.6% 19 29.2%
Often/frequent (≥3 nights/week) 7 14.3% 0 0.0%
Don't know 11 22.4% 6 9.2% -
Frequent night wakenings - ever (≥1 night/week) 38 79.2% 55 82.1% -
Never 7 14.6% 6 9.0%
Rarely/sometimes (1-2 night/week) 21 43.8% 40 59.7%
Often/frequent (≥3 nights/week) 17 35.4% 15 22.4%
Don't know 3 6.3% 6 9.0% -
Unrefreshing sleep - ever (≥1 night/week) 45 91.8% 52 78.8% -
Never 1 2.0% 11 16.7%
Rarely/sometimes (1-2 night/week) 10 20.4% 39 59.1%
Often/frequent (≥3 nights/week) 35 71.4% 13 19.7%
Don't know 3 6.1% 3 4.5% -
Daytime sleepiness - ever (≥1 night/week) 47 95.9% 49 74.2% -
Never 2 4.1% 17 25.8%
Rarely/sometimes (1-2 night/week) 17 34.7% 33 50.0%
Often/frequent (≥3 nights/week) 30 61.2% 16 24.2%
Don't know 2 4.1% 3 4.5% -
Prior diagnosis of OSA 116 6 12.2% 1 1.5% 0.04
Probable OSA using definition 1 113 36 75.0% 27 41.5% 0.001
Probable OSA using definition 2 113 38 79.2% 27 41.5% <0.0001
Probable OSA using definition 3 113 36 75.0% 27 41.5% 0.001
Probable OSA on ≥1 definition 113 38 79.2% 27 41.5% <0.0001
114
115
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 OSAHS severity 7.2.7
Differences in characteristics related to the objective severity of OSAHS are 
displayed in Table 26, Table 27, Table 28 and Table 29. 
7.2.7.1 Anthropometric characteristics 
No significant differences were noted in anthropometric measures or comorbidities 
or medications related to sleep using an AH cut-off of AH≥10 per hour in bed, the 
entry threshold for the treatment study, or an AH cut-off of AH≥25 per hour in bed, 
which is used clinically within the Department of Sleep Medicine, RIE, to diagnose 
OSAHS via a home sleep study. However, a trend was noted towards those with an 
AH≥25 per hour in bed being older (p=0.01), and to more males than females having 
an AH≥25 per hour in bed (p=0.03). Using an ODI cut-off of ODI≥10 as per the 
SIGN guidelines (Scottish Intercollegiate Guidelines Network 2003), no significant 
differences were noted, although there was a strong trend towards BMI being higher 
in with an ODI above the threshold (p=0.002). 
7.2.7.2 Sleep symptoms 
The prevalence of self-reported snoring was significantly higher in those with an 
AH≥10 per hour in bed (p<0.0001), with 64% reporting frequent snoring, and 
approached significance with thresholds of AH≥25 per hour in bed (74%; p=0.002) 
and ODI≥ 10 (74%; p=0.002) – see Table 27 . No significant differences were 
observed with any of the thresholds in terms of other symptoms including witnessed 
apnoeas, nocturnal choking, frequent night wakenings, unrefreshing sleep or daytime 
sleepiness. 
Neither the total pESS score nor the proportion of participants with EDS differed 
significantly with an AH≥10, AH≥25 or ODI≥10, although there was trend towards 
higher pESS scores with an AH≥25 (p=0.04).  
7.2.7.3 Behavioural and emotional disturbances 
DBC-A subscale total scores, MIS, PIC and II did not differ significantly with an AH 
cut-off of AH≥10, AH≥25 or ODI≥10 (Table 27).  
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Table 26: Anthropometric characteristics of sleep study participants by severity of OSAHS, 
using AH cut-offs of ≥10/hr (CPAP trial entry point) and ≥25/hr (departmental clinical 
diagnostic threshold). Chi-square test used for parametric categorical variables and t-test for 
continuous categorical variables. Values presented as mean±SD or n%. 
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Table 27: Self-reported sleep and behaviour characteristics of sleep study participants with 
severity of OSAHS. Chi-square test used for parametric categorical variables, t-test for 
continuous categorical variables and Mann-Whitney U test for non-parametric variables. 
Values presented as mean±SD, median(IQR) or n% unless otherwise stated. 
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Table 28: Anthropometric characteristics of sleep study participants by ODI. Chi-square test 
used for parametric categorical variables and t-test for continuous categorical variables. Values 
presented as mean±SD or n %. 






Age (years) 113 0.05
Gender (males : females) 114 0.18
Body Mass Index (kg/m
2
) ** 100 0.002
Collar size (cm) 74 0.05
Asthma 113 8 12.1% 10 21.3% 0.20
Hay fever 113 14 21.2% 13 27.7% 0.50
Thyroid problems 113 17 25.8% 21 44.7% 0.04
Epilepsy 113 0 0.0% 3 6.4% 0.07
Any adenoid and/or tonsil surgery 113 15 22.7% 16 34.0% 0.21
Any medication 113 42 63.6% 39 83.0% 0.03
Benzodiazepines 113 0 0.0% 1 2.1% 0.42
Antidepressants 113 3 4.5% 0 0.0% 0.27
Opiates 113 0 0.0% 2 4.3% 0.17
Oxygen 113 1 1.5% 0 0.0% 1.00
Melatonin 113 1 1.5% 0 0.0% 1.00
Antiepileptics 113 1 1.5% 3 6.4% 0.31
Contraceptives 113 1 1.5% 6 12.8% 0.02





n = 67 (50%) *
35 : 32 31 : 16
28.4 ± 5.3





n = 47 (35%) *
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Table 29: Self-reported sleep and behaviour characteristics of sleep study participants by ODI. 
Chi-square test used for parametric categorical variables, t-test for continuous categorical 
variables and Mann-Whitney U test for non-parametric variables. Values presented as 
mean±SD, median(IQR) or n %.  






Disruptive behaviour subscale (scale range 0-34) 111 0.21
Mean item score (possible score 0-2) 111 0.20
Proportion of items checked (possible score 0-1) 111 0.24
Intensity index  (possible score 0-1) 101 0.26
Anxiety/Antisocial subscale (scale range -2-14) 111 0.93
Mean item score (possible score 0-2) 111 0.18
Proportion of items checked (possible score 0-1) 111 0.30
Intensity index  (possible score 0-1) 81 0.15
Depressive subscale (scale range 0-18) 111 0.90
Mean item score (possible score 0-2) 111 0.86
Proportion of items checked (possible score 0-1) 111 0.93
Intensity index  (possible score 0-1) 80 0.91
Pictorial Epworth Sleepiness Scale (pESS) 100 0.22
Pictorial Epworth Sleepiness Scale score >10 100 13 22.0% 14 34.1% 0.25
Snoring - ever (≥1 night/week) 49 76.6% 42 91.3% -
Never 11 17.2% 2 4.3%
Rarely/sometimes (1-2 night/week) 20 31.3% 8 17.4%
Often/frequent (≥3 nights/week) 29 45.3% 34 73.9%
Don't know 4 6.3% 2 4.3% -
Witnessed apnoeas - ever (≥1 night/week) 22 33.8% 22 46.8% -
Never 11 16.9% 5 10.6%
Rarely/sometimes (1-2 night/week) 11 16.9% 8 17.0%
Often/frequent (≥3 nights/week) 11 16.9% 14 29.8%
Don't know 32 49.2% 20 42.6% -
0.11 (0.00-0.28) 0.22 (0.11-0.33)
0.00 (0.00-0.42) 0.10 (0.00-0.67)






Sleep and behaviour characteristics
ODI <10
n = 67 (50%) *
ODI ≥10
n = 47 (35%) *
0 (0-1)
2 (1-4)
Developmental Behaviour Checklist for Adults (DBC-A):















0.11 (0.00-0.39) 0.22 (0.11-0.44)
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Nocturnal choking episodes - ever (≥1 night/week) 24 36.4% 15 32.6% -
Never 35 53.0% 19 41.3%
Rarely/sometimes (1-2 night/week) 22 33.3% 10 21.7%
Often/frequent (≥3 nights/week) 2 3.0% 5 10.9%
Don't know 7 10.6% 12 26.1% -
Frequent night wakenings - ever (≥1 night/week) 53 81.5% 36 76.6% -
Never 6 9.2% 8 17.0%
Rarely/sometimes (1-2 night/week) 35 53.8% 22 46.8%
Often/frequent (≥3 nights/week) 18 27.7% 14 29.8%
Don't know 6 9.2% 3 6.4% -
Unrefreshing sleep - ever (≥1 night/week) 51 78.5% 41 87.2% -
Never 7 10.8% 4 8.5%
Rarely/sometimes (1-2 night/week) 26 40.0% 18 38.3%
Often/frequent (≥3 nights/week) 25 38.5% 23 48.9%
Don't know 7 10.8% 2 4.3% -
Daytime sleepiness - ever (≥1 night/week) 52 78.8% 42 89.4% -
Never 14 21.2% 4 8.5%
Rarely/sometimes (1-2 night/week) 29 43.9% 24 51.1%
Often/frequent (≥3 nights/week) 23 34.8% 18 38.3%
Don't know 0 0.0% 1 2.1% -
Prior diagnosis of OSA 113 2 3.0% 6 12.8% 0.07
Probable OSA using definition 1 111 27 42.2% 33 70.2% 0.004
Probable OSA using definition 2 111 28 43.8% 34 72.3% 0.004
Probable OSA using definition 3 111 27 42.2% 33 70.2% 0.004
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 Relationship between sleepiness, objective sleep 7.2.8
measures and behaviour 
Bivariate correlation analysis was used to explore the relationships between 
sleepiness, objective sleep measures and behaviour. Generalized linear modelling 
was used to further explore the determinants of behaviour, sleepiness and home sleep 
study outcomes – see Table 30. 
Associations between subjective sleepiness, as measured by pESS score, and 
increased total scores on the DBC Disruptive (ρ=0.382, p<0.0001) and Depressive 
(ρ=0.404, p<0.0001) subscales were noted, with weak but significant associations 
between pESS and Anxiety/Antisocial MIS (ρ= 0.255, p=0.05) and PIC (ρ=0.258, 
p=0.005) scores also evident. An increase in pESS was significantly associated with 
higher DBC-A Disruptive (β=0.31, p=0.03) and Depressive (β=0.12, p=0.03), but not 
Anxiety/Antisocial (p=0.18), subscale scores, controlling for age, gender and BMI. 
Higher pESS was also associated with higher BMI (ρ=0.277, p=0.005) and collar 
size (ρ=0.238, p=0.039), and lower mean oxygen saturation (ρ=-0.198, 0.047). 
Transition index was related to higher intensity of problem behaviours (II) on the 
Anxiety/Antisocial (ρ=0.222, p=0.031) and Depressive DBC subscales (ρ=0.325, 
p=0.001). 
BMI was associated with increased Anxiety/Antisocial behaviour (β=0.07, p=0.04), 
pESS (β=0.19, p=0.02) and ODI (β=0.81, p=0.01) scores, as well as a lower mean 
saturation (ρ=-370, p<0.0001), lower SpO2 nadir (ρ=-0.335, p=0.001) and higher 
mean desaturation (ρ==0.316, p=0.001).  
Male gender was linked with a higher AH (β=16.34, p=0.01) and ODI (β=8.02, 
p=0.02) on the home sleep study. However, AH and ODI do not predict pESS or 
behaviour scores, and no other significant gender effects were noted. 
Age did not demonstrate a significant effect on behaviour, sleepiness, AH or ODI in 
this population, although correlations with age and lower mean oxygen saturation 
(ρ=-0.385, p<0.0001) and larger mean desaturations (ρ=0.212, p=0.024) were noted. 
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Table 30: Determinants of subjective sleepiness, objective sleep measures and behaviour 
assessed by generalised linear modelling for continuous variables, controlling for age, gender, 













Age -0.03 -0.25 0.19 0.81
Gender (male) 0.25 -2.82 3.31 0.88
BMI 0.06 -0.19 0.32 0.62
pESS (self-rated) 0.31 0.04 0.58 0.03
AH/hr in bed -0.02 -0.08 0.04 0.57
ODI 0.03 -0.09 0.15 0.62
Age 0.01 -0.05 0.07 0.76
Gender (male) 0.35 -0.46 1.17 0.40
BMI 0.07 0.01 0.14 0.04
pESS (self-rated) 0.05 -0.02 0.12 0.18
AH/hr in bed 0.00 -0.02 0.01 0.62
ODI -0.01 -0.04 0.02 0.57
Age 0.00 -0.09 0.09 0.98
Gender (male) -0.66 1.89 0.565 0.29
BMI 0.05 0.05 0.153 0.34
pESS (self-rated) 0.12 0.02 0.233 0.03
AH/hr in bed -0.01 -0.04 0.01 0.29
ODI 0.03 -0.02 0.08 0.21
Age 0.00 -0.13 0.13 0.98
Gender (male) 1.08 -0.89 3.04 0.28
BMI 0.19 0.03 0.35 0.02
DBC Disruptive subscale total score 0.20 0.00 0.41 0.048
DBC Anxiety/Antisocial  subscale total score -0.11 -0.76 0.53 0.73
DBC Depressive subscale total score 0.35 -0.03 0.73 0.07
Age 0.93 -0.05 1.90 0.06
Gender (male) 16.34 3.68 28.99 0.01
BMI 0.67 -0.37 1.74 0.22
pESS (self-rated) 0.39 -0.84 1.61 0.54
DBC Disruptive subscale total score 0.34 -0.91 1.59 0.59
DBC Anxiety/Antisocial  subscale total score -1.98 -6.01 2.05 0.34
DBC Depressive subscale total score -0.79 -3.30 1.73 0.54
Age 0.41 -0.04 0.86 0.07
Gender (male) 8.02 1.14 14.91 0.02
BMI 0.81 0.24 1.38 0.01
pESS (self-rated) 0.37 -0.32 1.05 0.30
DBC Disruptive subscale total score 0.20 -0.50 0.89 0.58
DBC Anxiety/Antisocial  subscale total score -1.66 -4.07 0.76 0.18
DBC Depressive subscale total score 0.69 -0.89 2.27 0.39
pESS (self-rated) 101
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7.3 Discussion 
 Acceptability of diagnostic test 7.3.1
Overall, the Embletta
®
 Gold™ home sleep study equipment appears to be well 
accepted and effective in testing for OSAHS in the adult DS population. The 
majority of participants used the kit successfully, with only 10% of participants 
unable to obtain a study of sufficient quality to make a meaningful diagnosis. Most 
individuals managed to obtain a valid study after 1 or 2 nights, suggesting that a 
standard 2-night study as used in our trial is sufficient for the majority of DS adults. 
Only 6% required more than 2 nights to obtain a diagnosis. Although a “first-night 
effect” is well documented in the literature (Agnew et al. 1966; Toussaint et al. 1995; 
Scholle et al. 2003), this approach is not often adopted clinically due to financial and 
waiting time concerns, and there is also some evidence that multiple nights of 
recording are not required for the diagnosis of OSAHS in the majority of cases (Li et 
al. 2004; Ahmadi et al. 2009). Ambulatory testing at home may represent a 
significant cost saving over in-patient polysomnography, as demonstrated in studies 
in the general population (Dingli et al. 2003; J. F. Masa et al. 2011). A number of 
individuals (4% of those stating a reason) declined to participate in the sleep study 
due to being ‘medical-phobic’, having had numerous hospital procedures during their 
life, therefore home sleep studies may be more acceptable and appropriate in this 
group who may become anxious at the thought of attending hospital (Evans et al. 
2005).  
The families of 17% of responders who stated a reason declined to have a home sleep 
study due to the belief that the adult with DS for whom they care would be unable to 
tolerate the equipment or cope with the study; it is impossible to say whether this 
would have been the case or not, with the individual themselves having not been 
given the opportunity to try. Newer, smaller ambulatory sleep study devices are now 
available; a recent study in children with DS successfully used such equipment (Hill 
et al, personal communication re. UKCRN ID 14250), and future studies in adults 
with DS may recruit larger numbers of participants using similar, less intrusive 
equipment. Parental support and beliefs are known to have an effect on outcomes for 
the individual with ID (Cunningham 1996; Hassall et al. 2005), and so may be a 
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factor in the paucity of individuals with DS presenting at clinic; this is an area for 
further investigation. 
 Prevalence of OSAHS 7.3.2
In this study, 42% of individuals demonstrated a diagnosis of OSAHS via home 
polygraphy, much higher than the 2-4% prevalence reported in the general 
population (Young et al. 1993). This is lower than reported in previous studies in 
adults with DS using polysomnography, which have estimated prevalence at 83% 
(Resta et al. 2003) and 88% (Trois et al. 2009). However, both of these studies 
included a small number of individuals (n=6 and n=16 respectively), recruited from 
residential care home settings. As a community-based study of 134 individuals from 
across all four nations of the UK, our results may be more generalisable to the DS 
population as a whole. Baseline characteristics of participants undergoing home sleep 
study were broadly similar to those of the questionnaire study cohort as a whole, 
suggesting that this is a representative subset.  However, the higher mean pESS score 
(9±6 v. 7±5) and higher percentage of probable OSAHS assessed by algorithm (56% 
v. 35%) in the sleep study group may indicate an element of selection bias. 
Objective prevalence (42%) was similar to the subjective prevalence (35%) 
estimated via the questionnaire study. Comparison of these outcomes showed that the 
algorithms previously published by Furhmann et al (Fuhrman et al. 2012) have a 
good sensitivity and negative predictive value (79%), but a poor specificity and 
positive predictive value (58%). The algorithms are good at correctly identifying 
those with OSAHS, but perform less well in correctly identifying those without 
disease, and a high rate of false positives is evident – although 56% of our cohort had 
evidence of probable OSAHS using the algorithms, only 42% achieved a positive 
diagnosis via objective polygraphy. However, given the low rate of false negatives 
and a likelihood ratio of 1.9, our results suggest that screening for probability of 
OSAHS via questionnaire may be useful, particularly to allow a tentative diagnosis 
in individuals who may be intolerant of objective testing or in areas where access to 
sleep studies is limited. Prediction of OSAHS using subjective methods has been 
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shown to offer time and cost savings in individuals with high probability of OSAHS 
in the general population (Anttalainen et al. 2011). 
7.3.2.1 Anthropometric data, comorbidities and medication 
No significant differences were noted in terms of age, BMI, collar size, medication 
use or comorbidities between those with an objective diagnosis of OSAHS and those 
without.  
In the general population, a gender effect is evident, with a male predominance of 
2:1 noted (Young et al. 1993; Redline et al. 1994; Jordan & McEvoy 2003). 
Interestingly, no significant gender difference was noted in our group, despite a 
higher mean BMI in females. This suggests that other features related to DS may be 
more important than gender in the aetiology of OSAHS in this population. As 
discussed in Chapter 1, a raised BMI in females versus males with ID has been 
reported in the literature (Melville et al. 2005; Boyle et al. 2010). 
It is possible that the absence of significant differences in outcomes between the 
OSAHS positive and OSAHS negative groups may be due to the use of home 
polygraphy rather than PSG. Studies have noted a dilution of the AHI when scoring 
home sleep studies versus polysomnography (Escourrou et al. 2015) due to 
limitations of the current international scoring rules, which require a measure of EEG 
arousal as part of the scoring criteria (Iber et al. 2007). It is important to bear in mind 
that the AH per hour in bed and the true AHI are not the same, and that accepted 
diagnostic thresholds, including the SIGN guidelines (Scottish Intercollegiate 
Guidelines Network 2003), are based on AHI on polysomnography. Our 
interpretation of the scoring rules, by scoring a reduction in airflow whether or not it 
is associated with an oxygen desaturation, with the assumption that there may have 
been an arousal, aimed to minimise the dilution effect. However, future studies 
should attempt to use PSG to more accurately quantify the severity of OSA in adults 
with DS; again, newer equipment which allows a limited PSG to be run at home with 
a minimum of extra sensors, may make this achievable. It may be that a higher AH 
threshold on home polygraphy is required, although using a cut-off of AH≥25 per 
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hour in bed, as used clinically within the Department of Sleep Medicine, and an 
ODI≥10 did not reveal any significant differences between groups.  
It may be that, in adults with DS, multiple factors over and above age, gender and 
BMI influence the severity of OSAHS. These may include anatomical and 
physiological factors, such as anatomical variations in hard and soft tissue in the 
head and neck (Shott & Donnelly 2004; Shott 2006). Twice as many of those 
participants with an objective diagnosis of OSAHS had previously undergone 
tonsil/adenoid surgery (35%) compared with those who did not exhibit OSAHS on 
their sleep study (16%), though this did not reach significance using our stringent 
criteria (p=0.03). This suggests that adenotonsillectomy in childhood may not 
provide lasting resolution of OSAHS in this group, although, as discussed in Chapter 
5, selection bias due to previous diagnosis and surgical treatment of OSAHS cannot 
be ruled out. Nevertheless, a prospective study of the long-term efficacy of 
adenotonsillar surgery in individuals with DS would be of interest. Although a 
number of studies have examined the effects of adenotonsillectomy in children with 
and without DS (Chervin et al. 2006; Mitchell 2007; Rogers et al. 2009; Shete et al. 
2010; Bhattacharjee et al. 2010; Rosen et al. 2011; Thottam et al. 2015), none of 
these have assessed long-term benefit. Indeed, the recent CHAT study, which 
assessed neurocognitive performance before and after adenotonsillectomy in 
typically-developing children (Marcus et al. 2013) followed up participants for only 
7 months postoperatively.  
7.3.2.2 Sleepiness, behavioural and emotional disturbances 
Although behaviour scores did not differ significantly between those with and 
without a diagnosis of OSAHS using our strict criteria, there was a trend towards 
more disruptive behaviour in the OSAHS group, which may have been limited by the 
relatively small numbers in each group. Higher pESS scores were significantly 
associated with higher scores in the Disruptive and Depressive domains of the    
DBC-A. Sleep fragmentation was weakly associated with increased intensity of 
Anxiety/Antisocial behaviour. Although not reaching significance, these results 
support previous reports of behavioural disturbances related to OSAHS and other 
sleep disturbances in individuals with DS (Brylewski & Wiggs 1999; Capone et al. 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Objective assessment of prevalence  171 
2006; Dykens 2007). Behavioural problems in individuals with ID, including DS, 
have been associated with living in a residential care setting (Jones et al. 2008), and 
it has been suggested that challenging behaviour is a factor in individuals being 
moved from family to residential care (Oakes 2012). Behaviour changes can also be 
viewed as a marker of the early stages of dementia in adults with DS (Ball et al. 
2006). Given these potentially major implications, it is important that other reasons 
for behavioural disturbance, such as OSAHS, are investigated. It is likely that 
treatment of OSAHS may improve behaviour in this group, and this is explored 
further in Chapter 8. 
 
7.4 Conclusion 
This first large survey of objective prevalence of OSAHS in adults with DS suggests 
that 42% of this population may have the disorder. Subjective assessment of probable 
risk of OSAHS using questionnaire data is useful in this group. A trial of the effects 
of treatment on OSAHS in adults with DS was warranted on the basis of these 
findings, and this is the focus of Chapter 8 of this thesis. 
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Chapter 8: Treatment study 
This chapter describes the treatment phase of the study: a randomised, controlled trial 




 Treatment study invitation 8.1.1
All participants meeting inclusion criteria after successful completion of a home 
sleep study were invited to participate in the treatment phase of the study.  
Once their sleep study had been scored by an RPSGT and reviewed by a sleep 
physician, as per Chapter 7, all participants were sent written confirmation of their 
home study results. The results letter (see Appendix 2) included details of their AH 
and ODI, as well as their eligibility for further participation. In those participants 
eligible for the treatment study, the results letter was followed up by a phone call 
from the investigator to discuss the results as required and to schedule an 
appointment for the baseline visit.  
 Inclusion criteria  8.1.2
The inclusion criteria for the treatment phase of the study were as follows: 
 A clinical diagnosis of DS.  
 Age ≥16 years.  
 A clinical diagnosis of OSAHS, defined as AH ≥ 10 events per hour on 
multichannel sleep study and symptoms of excessive daytime sleepiness or pESS 
≥9.  
 Ability to give informed consent and comply with protocol (participant or 
welfare guardian/attorney, as appropriate).  
The age of legal capacity in Scotland is 16 years (Scottish Government 1991). 
Although the legal age of adulthood is 18 across the rest of the UK, consenting 
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participants aged ≥16 years were enrolled in the study, regardless of their country of 
residence. 
The clinical diagnosis of DS including results of karyotyping were confirmed 
verbally with the participant’s relative/carer. 
Liberal OSAHS diagnostic criteria were set for this study. It is possible that adults 
with DS who already have a degree of cognitive impairment may be more sensitive 
to the effects of mild OSAHS or SDB, and so we were keen to include these 
participants in the study to assess their response to CPAP treatment. As discussed in 
Chapter 2, the standard threshold for OSA diagnosis of OSA is an AHI of ≥5 events 
per hour of sleep on PSG, with an AHI of 5-14 rated as mild, 15-30 as moderate and 
>30 as severe OSA (Scottish Intercollegiate Guidelines Network 2003; Epstein et al. 
2009). Clinically, treatment with CPAP is usually indicated in symptomatic patients 
with an AHI ≥15. The literature generally states that there is a dilution of AHI when 
using limited cardio-respiratory studies, related to two main factors: the absence of a 
valid measure of sleep/wake resulting in calculation of the number of events per hour 
using hours in bed rather than hours of sleep; and the absence of a valid measure of 
EEG arousal, resulting in systematic underscoring when using the recognised 
standard scoring criteria (Collop et al. 2007; Epstein et al. 2009; Hedner et al. 2011). 
However, in our clinical experience, our in-house interpretation of the AASM2007 
scoring criteria for use when scoring limited sleep studies may also result in over-
scoring of breathing events due to the inclusion of events without associated oxygen 
desaturation which may not have an associated arousal. Clinically, to compensate for 
the possible disparity between AH and AHI, we use a higher diagnostic threshold of 
≥25 events per hour of sleep on a limited study, with patients in the “grey area” 
below this threshold typically going on to have a full PSG study. 
Although a pESS ≥10 is generally considered abnormally sleepy in the general adult 
population, this subjective rating scale can be underscored or misinterpreted, and can 
often be underestimated due to situation-specific issues resulting in omission of 
particular questions; for example, if an individual does not drive, they may omit or 
under-score the driving-related questions, reducing their overall score. Therefore, in 
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this study, a conservative pESS of ≥9 was used. In  the event of an pESS <9, other 
symptoms of excessive daytime sleepiness were also acceptable, for example 
unrefreshing sleep or daytime sleepiness reported to occur at least once per week on 
the prevalence questionnaire. See Chapter 5 for a discussion of issues with the use of 
the pESS in this population 
As discussed in Chapter 4, ethical approval was initially only given for inclusion of 
adults with capacity to give consent for themselves. However, from March 2013, 
AWI were also eligible to participate, with consent given on their behalf by their 
nearest relative or welfare guardian. 
Those not fulfilling the inclusion criteria were withdrawn from the study, and were 
integrated into the normal clinical pathways of the Department of Sleep Medicine or 
referred to their local sleep centre as appropriate. 
 Exclusion criteria 8.1.3
The exclusion criteria for the treatment phase of the study were as follows: 
 Previous exposure to CPAP therapy.  
 Arterial oxygen saturation <90% on room air.  
 Participants with chronic heart failure or recent myocardial infarction.  
 Participants with known moderate or severe dementia.  
 Participants with severe behavioural problems that would preclude sleep studies 
or CPAP treatment.  
 Inability to comply with the protocol. 
CPAP-naïve participants were enrolled in the study; individuals currently using 
CPAP or who had previously been successfully established on CPAP for at least 2 
weeks were excluded. Individuals who had tried CPAP but who were not established 
remained eligible.  
Awake arterial oxygen saturation on room air was assessed using the oximetry trace 
of the home sleep study. Medical history was discussed verbally with the participant 
and their relative/carer prior to study entry. 
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Although the study procedures were designed to be accessible to participants with as 
broad a range of abilities as possible, any individuals whose disabilities or 
behavioural problems would preclude the collection of useful data were excluded 
from participation. To allow inclusion of as many participants as possible, travel 
expenses were paid for all study-related hospital visits. Home visits were offered to 
any willing participants whose mobility or transport availability meant they were 
unable to attend appointments at the Royal Infirmary of Edinburgh. 
Initially, FEV1 <60% was included as an exclusion criterion. However, significant 
problems were encountered in conducting spirometry testing with adults with DS. 
Many participants had not had lung function tests prior to enrolment, and conducting 
spirometry at baseline proved difficult. This was discussed with Dr Andy Robson, 
Senior Clinical Scientist at the Respiratory Function Department, Royal Infirmary of 
Edinburgh. Dr Robson advised that people with learning disabilities often had 
problems complying with spirometry test instructions, and that no specific protocol 
or advice to improve this was available. On discussion with the Principal 
Investigator, Dr Renata Riha, Consultant in Sleep and Respiratory Medicine, it was 
felt that this exclusion criterion could be omitted without any detriment to 
participants. 
 Blinding 8.1.4
This was a single-blind study. All study-specific procedures at visits 2, 5, 6 and 7 
were completed by a blinded investigator. The randomisation procedure and all 
subsequent treatment-related procedures, including visits 3 and 4a, were completed 
by a non-blinded investigator. Since only participants in the lifestyle group required 
visit 4b, this visit was conducted by a second blinded investigator to maintain the 
blinding status of the first blinded investigator. As far as possible, the same second 
blinded investigator conducted visit 4 to minimise inter-rater variability. 
 Recording and storage of study data 8.1.5
All study data and study-related documents were stored within case report files 
(CRFs). Three CRFs were used per participant: a blinded CRF, containing the home 
sleep study report, anthropometric assessments, cognitive function tests results and 
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completed questionnaires from all visits except visit 3, 3a, 4, 4a and 4b and copies of 
study-related correspondence; an unblinded CRF, containing treatment-related 
information from all visits including CPAP download reports, the monthly diaries 
and any other treatment-related correspondence; and a second unblinded CRF, 
containing the cognitive test results and questionnaires from visits 4 and 4a. All 
CRFs were stored securely in lockable filing cabinets within the Department of Sleep 
Medicine, which is a restricted-access area controlled by proximity card. 
Hospital casenotes were recalled for any participant who was already registered as an 
NHS Lothian patient. Copies of study-related documents and correspondence were 
filed and patient interactions were documented in the casenotes as required. 
 Study visit schedule 8.1.6
The study visit schedule is shown in Figure 23. All study visit dates were agreed at 
the baseline visit where possible. All visits were scheduled based upon the date of the 
baseline visit, i.e. 1 month from baseline, 3 months from baseline etc. Visits were 
booked as close to the expected date as possible; however, a tolerance of one week 
either side of the expected date was allowed for visits up to 3 months, and 2 weeks 
either side for visits after 3 months to accommodate staff and participant availability 
Visits which were cancelled for any reason were rescheduled within the same 
tolerance limits as far as possible.  
Participants were asked to attend all appointments with a relative/carer who knew 
them well, and to attend with the same relative/carer on every occasion, as far as 
possible, to minimise inter-rater variability in questionnaire completion. In the event 
of a different carer attending, the relative/carer questionnaire for that visit was sent to 
the usual carer for completion and return by post. 
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Figure 23: Flow diagram of CPAP evaluation phase of study: trial entry, randomisation, 
treatment arms and follow-up schedule. 
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Trial Entry – visit 1 
 Adult patients ≥ 16 years who fulfil inclusion criteria 
 Informed consent (participant or relative/welfare guardian/attorney) 
 Diagnosis of  OSAHS (AHI on home study of ≥ 10 events/hr  + sleepiness) 
 
 
Baseline Measurements – visit 2 
 Weight, height, neck circumference, facial examination 
 Cognitive function tests: ACTB 
 Health questionnaires: RAND-36, EQ5D, ESS 
 Carer questionnaires: modified DBC-A, modified CBI, GHQ-12 






































All patients on CPAP integrated into standard patient pathways  
in Dept. of Sleep Medicine  
  CPAP + Lifestyle advice continue 
        Lifestyle advice 
Follow-up: 1 week (Face-to-face) – visit 3 (and 4a) 
Troubleshoot potential adherence issues 
Offer optional visits 
Follow-up: 1 month (Face-to-face) – visit 4 (and 4b) 
Measures as at baseline  
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Follow-up: 12 months (Department visit): measures as at baseline – visit 7 
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 Baseline visit (Visit 2) 8.1.7
Participants fulfilling the inclusion criteria attended a baseline visit, either in hospital 
or at home. Baseline measurements and procedures are detailed below. This visit 
took approximately 1.5hr to complete, although up to 3 hours was allocated to allow 
for variations in participants’ level of ability. 
8.1.7.1 Anthropometric data 
Height, weight, neck circumference and craniofacial features (presence of 
macroglossia, gothic palate, adenoid facies, malocclusion and tonsillar enlargement) 
were assessed using standardised techniques. 
8.1.7.1.1 Body mass index 
The participant’s height (m) and weight (kg) were measured, fully clothed but 
without shoes. Body mass index (BMI) was calculated in kg/m
2
 using these 
measurements. Although gender-specific percentile growth charts for children with 
DS are available (McGowan et al. 2012), BMI norms for adults with DS are not; 
BMI was classified using the standard World Health Organisation International 
Classification of adult underweight, overweight and obesity according to BMI 
(World Health Organization 2006): 
 <18.50kg/m2 = underweight 
 18.50-24.99kg/m2 = normal 
 25.00-29.99kg/m2 = overweight 
 30.00-34.99kg/m2 = obese class I 
 35.00-39.99kg/m2 = obese class II 
 ≥40kg/m2 = obese class III. 
WHO BMI categories are applicable to individuals aged ≥19 years only.  
8.1.7.1.2 Neck circumference 
The participant’s neck circumference (cm) was measured using a soft, flexible 
measuring tape, with the participant in the standing position. Neck circumference 
corrected for height has been shown to be a useful predictor of OSA, more so than 
general obesity(Davies & Stradling 1990; Davies et al. 1992).  
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8.1.7.1.3 Macroglossia 
Individuals with DS frequently show evidence of relative, rather than true, 
macroglossia; that is, the tongue appears large relative to the size of the oral cavity 
(Guimaraes, Donnelly et al. 2008). Participants were asked to open their mouth, and 
a subjective assessment of tongue size was made by the investigator, using the 
clinical features described by Vogel et al (Vogel et al. 1986) . 
8.1.7.1.4 Gothic palate 
A high, vaulted or “gothic” palate has been reported in adults with DS (Panchón-
Ruiz et al. 2000; Dellavia et al. 2007). Subjective assessment of the presence of a 
high, arched palate was made by the investigator. 
8.1.7.1.5 Adenoidal facies 
The characteristic appearance of a pinched nose, nasal congestion and mouth 
breathing during wakefulness is known as adenoidal facies (Quick & Gundlach 
1978). Often seen in conjunction with a gothic palate, adenoidal facies can be an 
indicator of nasal airway obstruction. Again, subjective assessment of the presence 
adenoidal facies was made by the investigator. 
8.1.7.1.6 Malocclusion 
A subjective assessment of each participant’s tooth alignment was made by asking 
the participant to open their mouth and then bite together. Occlusion was rated as 
normal, slight overbite (class I malocclusion), retrognathia (class II malocclusion) or 
prognathia (class III malocclusion); see Figure 24. 
8.1.7.1.7 Mallampati score 
A subjective assessment of Mallampati score (Mallampati et al. 1985) was made by 
the investigator. This scale, which rates crowding of the oropharynx based on 
visibility of the tonsillar pillars, soft palate and uvula (see Figure 25), was originally 
developed as a method of predicting patients at risk of difficult intubation under 
anaesthetic. However, it has since been shown to be of clinical value in assessment 
of SDB, with Mallampati score significantly associated with both presence and 
severity of OSA in individuals with a high clinical suspicion of OSA (Nuckton et al. 
2006). 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Treatment study  180 
Figure 24: Assessment of dental occlusion: (A) Normal occlusion; (B) Class I malocclusion; (C) 
Class II malocclusion; (D) Class III malocclusion. From: Dorland's Medical Dictionary for 




Figure 25: Mallampati score, rating crowding of the oropharynx based on visibility of the 
tonsillar pillars, soft palate and uvula. Author Jmarchn, January 29, 2011. Permission is 
granted to copy, distribute and/or modify this document under the terms of the GNU Free 
Documentation License, Version 1.2 or any later version published by the Free Software 
Foundation. 
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8.1.7.1.8 Friedman score 
The Friedman score (Friedman et al. 2002) was originally developed as a predictor of 
successful uvuolpalatopharyngoplasty (UPPP) in patients with SDB. This staging 
system uses assessment of palate position and tonsillar size, combined with BMI, to 
give a score of I to III (see Figure 26). 
 
Figure 26: Friedman scale. Originally developed to predict surgical success, this rating system 
combines palate position, tonsillar size and body mass index to give a rating of oropharyngeal 
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8.1.7.2 Cognitive function tests 
Cognitive function was assessed using tests from the Arizona Cognitive Test Battery 
(ACTB) - a set of computer-based tests developed specifically to assess cognitive 
function and dysfunction in adults and children with DS (Edgin et al. 2010). Data 
suggests that this collection of measures is well suited for outcome studies in this 
patient group, with few participants unable to complete the tasks and low levels of 
floor effects (where tests are too difficult to perform and so do not provide a 
meaningful measure). Importantly, the tests have been validated for use in both 
laboratory and home settings, with no significant differences in outcomes. 
Following discussion of the design of this study with Professor Lynn Nadel of the 
Down Syndrome Research Group at the University of Arizona, whose team 
developed and validated the ACTB, the following subset of ACTB tests was used: 
 Kaufman Brief Intelligence Test 2nd edition (KBIT-2) – to assess 
background performance level. 
 Scales of Independent Behaviour Revised (SIB-R) – parent/carer rating of 
problem behaviours and their severity. 
 CANTAB paired associates learning (PAL) – measuring hippocampal 
function. 
 CANTAB simple reaction time (SRT) – measuring cerebellar function. 
 Modified DOTS test (Frogs & Cats) – measuring prefrontal function. 
 
These measures were chosen to be as concise as possible whilst still including a 
measure of the function of the brain region which are known to be most affected in 
individuals with DS and in OSAHS, and so are potentially most likely to benefit 
from improvement in sleep architecture and oxygenation (see Chapters 1-3). The 
complete battery took approximately 45min to complete. Testing was conducted at 
the same time (early to mid-afternoon) on every visit for all participants to minimise 
circadian effects on performance (Schmidt et al. 2012). 
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8.1.7.2.1 KBIT-2 
The Kaufmann Brief Intelligence Test Version 2, or KBIT-2 (Pearson Clinical 
Assessment, San Antonio, TX, USA), is a validated instrument, suitable for 
individuals aged 4-90 years, providing a quick and reliable measure of verbal and 
non-verbal intelligence. The test is administered using a full-colour flipchart, and 
comprises 3 parts: Verbal Knowledge, Matrices and Riddles. Each section is scored 
individually. Scores on the Verbal Knowledge and Riddles sections are combined to 
give a Verbal score, which tests crystallised ability. The Matrices test gives a 
Nonverbal score, measuring fluid reasoning. The Verbal and Nonverbal scores are 
then combined to give an overall score, the IQ Composite. Normative data, based on 
the US population, is provided for both the Verbal and Nonverbal domains, as well 
as the IQ Composite. The test has been specifically validated in adults and children 
with intellectual disability, and has been shown to be perform effectively in this 
group despite low mean IQ scores (Kaufman & Kaufman 2004). The KBIT-2 
correlates well with a number of other standard measures of cognitive ability and IQ, 
including the Wechsler Abbreviated Scale of Intelligence (WASI) and Wechsler 
Adult Intelligence Scale – 3
rd
 Edition (WAIS-III) (Kaufman & Kaufman 2004).  
The Verbal Knowledge subtest is comprised of 60 multiple-choice items measuring 
vocabulary and general knowledge about the world, covering a number of areas 
including nature, geography, science and the arts. The examiner asks the question 
verbally and the individual points to the correct picture from a selection of 6 pictures 
shown. Two types of item are presented in this subtest: questions assessing receptive 
vocabulary (e.g. “Point to money”, “point to elderly”) and questions examining 
general information (“Point to the one that goes with thunder”, “Point to a famous 
building in India”). 
The Matrices subtest has 46 multiple-choice items, assessing the participant’s 
reasoning and problem-solving ability. These include meaningful stimuli such as 
everyday objects and people, as well as abstract signs and symbols. The early items 
ask which picture goes best with a stimulus picture, e.g. a car goes with a truck, a 
fishbowl goes with a fish. Later items can be meaningful or abstract, and ask which 
picture best completes an analogy, e.g. a boat goes with the sea, just as a car goes 
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with a road; a square with a circle inside goes with an empty square, just as a triangle 
with a circle inside goes with a triangle. The final matrices require the participant to 
select the missing symbol from a matrix of 4 or 9 symbols. 
The Riddles subtest has 48 items assessing verbal comprehension, reasoning and 
vocabulary. The examiner asks a question, and the participant has to either point to 
the picture that shows the best answer or verbally provide a single-word answer. 
From item 9 onwards, no picture stimuli are provided. Early questions contain 2 
clues (e.g. “Point to something you can ride in that floats”, “Point to something that 
squeaks and has a skinny tail”), with later questions providing 3 (e.g. “What has a 
checkout desk, places to read and rows of books?”, “What melts, burns and is made 
of wax?”). 
The KBIT-2 is particularly useful for testing persons with ID. Questions are 
administered using only spoken word and pictures, allowing it to be used with 
individuals who cannot read. Answers in the Verbal Knowledge and Matrices tests, 
and in the early part of the Riddles test, are indicated by pointing, allowing testing of 
persons without speech. The test allows teaching during administration, so the 
examiner can rephrase a question or use sign and gesture to help individuals 
understand the instructions more clearly, ensuring valid testing of persons with ID.  
The KBIT-2 is designed to be administered starting from the individual’s age range, 
dropping back a start point if the individual gets any of the first 3 questions at their 
start point wrong. The process of dropping back a start point continues until the 
individual correctly answers the first 3 questions of a point or start point 1 is reached. 
However, for ease of administration and to avoid unnecessary frustration for adults 
with DS with significant ID, all subtests were administered from question 1 in this 
study. Questions were presented in stepwise order, with each subtest discontinued 
upon 4 consecutive incorrect answers being given at any point after the individual’s 
age-designated start point. Depending on the participant’s level of ability, the test 
took 20-40 minutes to administer. 
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The KBIT-2 test was scored manually using the standard instructions, giving raw 
scores for the verbal (maximum possible score =108) and non-verbal (maximum 
possible score =46) domains (Kaufman & Kaufman 2004). 
8.1.7.2.2 SIB-R 
The Scales of Independent Behaviour - Revised, or SIB-R (Riverside Publishing 
Company, Rolling Meadows, IL, USA), is a standardised tool for assessment of 
skills required for everyday independent living, administered to the participant’s 
relative/carer and validated in individuals aged 3 month to 90 years. The full scale 
comprises 259 items measuring broad independence. These items are divided into 14 
subscales, covering a diverse range of areas including gross- and fine-motor skills, 
language expression and comprehension, use and understanding of money, toileting, 
domestic skills, work skills and timekeeping. The subscales are then grouped into 4 
adaptive behaviour clusters: Motor Skills, Social Interaction and Communication 
Skills, Personal Living Skills and Community Living Skills. 
Different forms of the test can be used, including the Full Scale, Short Form and 
Early Development Form, and these can be administered either by structured 
interview or by checklist administration, where the relative/carer marks the answers 
themselves in the response booklet. All forms of the test are administered alongside 
the Problem Behavior Scale, which gives an overview of 8 types of problem 
behaviour (Hurtful to Self, Unusual or Repetitive Habits, Withdrawal or Inattentive 
Behaviour, Socially Offensive Behavior, Uncooperative Behavior, Hurtful to Others, 
Destructive to Property, Disruptive Behavior) which can then be grouped into 3 
Maladaptive Behavior groups (Internalized, Asocial and Externalized). The 
relative/carer is asked to state whether the individual exhibits each type of behaviour 
and, if so, describe the behaviour and, using Likert-type scales, rate its frequency (1 
= less than once a month to 5 = 1 or more times an hour) and severity (0 = not 
serious to 4 = extremely serious).  
In this study, the Short Form was used via checklist administration, along with the 
Problem Behavior Scale, providing a brief evaluation of participants and taking 
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around 20 minutes to complete. Time was taken to instruct the relative/carer in the 
correct use of the SIB-R questionnaire at the first visit. 
The SIB-R Short Form is uses 40 items from across the 14 subscales of the Full 
Scale. For each item, the relative/carer is asked to rate the participant’s ability (“Does 
(or could do) the task  completely, without help or supervision”) on a Likert-type 
scale: 0 = Never or rarely, even if asked; 1 = Does, but not well or about ¼ of the 
time, may need to be asked; 2 = Does fairly well or about ¾ of the time, may need to 
be asked; 3 = Does very well, always or almost always, without being asked. Item 
scores are summed to give a total raw score from a possible total of 120 (Bruininks et 
al. 2006). 
8.1.7.2.3 CANTAB PAL 
The Cambridge Neuropsychological Test Automated Battery (CANTAB; Cambridge 
Cognition Ltd., Cambridge, UK) is a suite of highly validated cognitive function tests 
(>1600 peer reviewed papers; www.camcog.com), covering a range of 
neuropsychological functions associated with different brain regions. All tests are 
visual, using abstract shapes and symbols, allowing the tests to be used and 
compared regardless of language, culture or literacy level. Tests are interactive and 
presented via a touch screen. 
The Paired Associates Learning task (CANTAB PAL) is a test of hippocampal 
function, spatial associative memory (Swainson et al. 2001), which was selected for 
inclusion in the ACTB on the basis of previous studies which showed impairment in 
this area in individuals with DS (Pennington 2009; Visu-Petra et al. 2007). In this 
test, 6 white boxes are displayed in a circle on the screen. Each box “opens up” one 
at a time to show its contents, then closes again, with one of the boxes containing an 
abstract figure. Once all the boxes have displayed their contents, the figure appears in 
the centre of the screen and the participant must touch the box containing the figure. 
The test increases in complexity with each correct answer, from one, to two, then 
three figures to remember, then six or eight boxes containing a figure. The test ends 
once the eight-box stage is completed successfully, or after ten incorrect attempts. 
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The test is scored automatically by the CANTAB software, and a standard report 
produced. The outcome measures used were the number of attempts required to 
obtain a correct answer (mean errors to success – range 0-9) and the number of trials 
completed correctly at the first attempt (first trial memory score – range 0-26) . 
 
Figure 27: CANTAB Paired Associates Learning. The content of each box is displayed in turn 
(left); the participant must then touch the box in which the figure shown in the centre of the 
screen was located (right). From Cantab Research Suite 6 Test Administration Guide Version 
6.0.0, Cambridge Cognition Ltd., 2014. Used with permission. 
                  
 
Figure 28: CANTAB Simple Reaction Time – the participant must press a button on a press-pad 
as quickly as they can when the white square is displayed. From Cantab Research Suite 6 Test 
Administration Guide Version 6.0.0, Cambridge Cognition Ltd., 2014. Used with permission. 
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8.1.7.2.4 CANTAB SRT 
The CANTAB Simple Reaction Time test (CANTAB SRT) is a measure of 
cerebellar function, specifically motor response time and attention (Allen 1997). A 
white square is presented on the screen, and the participant must respond by pressing 
a button on a press pad as quickly as possible. The delay between stimuli 
presentation varies throughout the test. Twenty-four practice trials are presented, 
prior to two blocks of 50 test trials. The outcome measure for this test is the mean 
latency of correct responses in milliseconds. 
8.1.7.2.5 Modified Dots task – Frogs and Cats 
The Dots task (Davidson et al. 2006) is a measure of prefrontal function, specifically 
working memory and inhibitory control, which is suitable for individuals aged ≥4 
years.  
A modified version of the Dots task was provided by the Down Syndrome Research 
Group, Department of Psychology, University of Arizona, running on the 
Presentation platform (Neurobehavioral Systems Inc., Berkeley, CA, USA). Entitled 
Frogs and Cats, this task has two training phases and one testing phase. The first 
learning phase involves the display of a picture of a cat on the left or right side of a 
touch screen, which the participant must respond to by pressing a button on screen 
beneath the picture “because cats like to curl up and sleep and stay still” (congruent 
phase). Next, a picture of a frog is displayed on the left or right of the screen, to 
which the participant must respond by pressing a button on the opposite side of the 
screen, “because frogs like to hop over to the other side” (incongruent phase). The 
test phase involves the display of frogs and cats in a random order, with the 
participant responding using the congruent or incongruent rule as appropriate.  
This test was scored on behalf of the investigators by Goffredina Spanὸ, Department 
of Psychology, University of Arizona. The outcome measures for this test are the 
percentage of correct responses for the congruent, incongruent and testing phases. 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Treatment study  189 
8.1.7.3 Health & sleepiness questionnaires 
A series of questionnaires assessing the participant’s subjective sleepiness and 
general health and wellbeing were completed at baseline, 1 month, 3 months, 6 
months and 12 months: 
 EQ-5D 
 RAND-36 
 Epworth Sleepiness Scale (ESS) 
 Questions regarding healthcare contact, caffeine intake and medication use 
The questionnaires were printed using a minimum 14-point font for accessibility to 
participants who may have visual impairment. However, the wording of the standard 
instruments (EQ-5D, RAND-36, pESS) could not be simplified without 
compromising the validity of the measures; therefore, many participants required 
their relative/carer’s assistance with completion of these questionnaires. Easy-read 
language was used wherever possible elsewhere in the questionnaire, including the 
healthcare use and caffeine/medication use sections. 
8.1.7.3.1 EQ-5D 
The EQ-5D questionnaire  is a standardised measure of health status and economics 
(The EuroQol Group 1990). The 2-page questionnaire is designed to be self-
completed, and is written in simple language for ease of use. It can be quickly scored 
to give two standardised outcome measures (The EuroQol Group 2010). The first 
page of the questionnaire consists of five multiple-choice questions, answered via 
tick-box. The individual is asked to rate their level of ability in five domains on a 
scale of 1 to 3, representing no problems (1), moderate problems (2) or severe 
problems (3) in each area: mobility; self-care; usual activities; pain/discomfort; and 
anxiety/depression. This allows 243 different health states to be defined via a five-
digit descriptive rating of the five domains, from 11111, representing no problems in 
any domain, to 33333, severe problems in all domains. It is important to note that 
these scores are descriptive only and do not have any arithmetic properties. The 
second page asks the participant to rate how good or bad they feel their health is on a 
visual analogue scale from 0 (worst imaginable health state) to 100 (best imaginable 
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health state). This gives a percentage score which can be used as a quantitative 
measure of the individual’s health at a given point in time. 
8.1.7.3.2 RAND-36 
The RAND-36 questionnaire is a widely-used, standardised measure of health-
related quality of life (Hays et al. 1993; Hays & Morales 2001). Thirty-six multiple-
choice items assess physical, mental and social functioning over eight domains: 
physical functioning; role limitation related to health problems; role limitation 
related to emotional problems; social functioning; emotional wellbeing; 
energy/fatigue; pain; and general health perceptions. Each item has between 2 and 6 
possible answers, answered by tick-box, with each answer allocated a value between 
0 and 100. Questions are grouped together into domains, and the values for each 
question are added together to give a percentage score for each domain. An overall 
total percentage is also calculated. Repeated measures give an indication of change in 
status in each domain over time.  
8.1.7.3.3 pESS 
A review of the properties and utility of the pESS is included in Chapter 5. 
8.1.7.3.4 Healthcare usage 
Information on frequency of use of healthcare services over the preceding month, 
including GP, nurse and hospital visits and planned and unplanned hospital 
admissions, was collected via a simple checklist. 
8.1.7.3.5 Caffeine and medication use 
Participants were asked to report their average daily intake of tea, coffee and 
caffeinated soft drinks over the preceding month, by the number of drinks. Current 
prescribed and unprescribed medications were listed in a free-text box, which were 
coded by the investigators using the ATC-DDD classification (see Chapter 5). 
8.1.7.3.6 Relative/carer questionnaires 
At baseline, 1 month, 3 months, 6 months and 12 months, relative/carers were asked 
to complete questionnaires including: 
 Developmental Behaviour Checklist for Adults (DBC-A) 
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 Modified Zarit Burden Inventory (ZBI)  
 General Health Questionnaire (GHQ-12)  
 Epworth Sleepiness Scale (ESS) - giving their rating of the participant’s 
sleepiness 
 
These questionnaires were completed by the same carer/relative at all visits as far as 
possible to allow direct comparison of scores and outcomes and minimise inter-rater 
variability. In the event of a different carer/relative attending, the questionnaire was 
sent to the usual carer to complete and return, by either post of email. 
8.1.7.3.7 DBC-A 
A review of the properties and utility of the DBC-A is provided in Chapter 5. 
8.1.7.3.8 Modified ZBI 
The impact of caring for the individual with DS on their relative/carer was assessed 
using the short version of the Zarit Burden Interview (ZBI; Bédard et al. 2001). This 
12-item questionnaire is a modified version of the original ZBI, which was 
developed to assess the level of burden experienced by caregivers of individuals with 
Alzheimer’s disease (Zarit et al. 1985). The short version has been shown to give 
comparable results to the full version (Bédard et al. 2001), and was selected for use 
in this study to reduce the time constraint on the participant’s relative/carer. The 
individual is asked to rate 12 statements about their experience of caring on a Likert-
type scale of 0-4, where 0=never, 1=rarely, 2=sometimes, 3=quite frequently and 
4=nearly always. The scores for all 12 questions are totalled together to give a score 
in the range 0-48 (Bédard et al. 2001). 
8.1.7.3.9 GHQ-12 
the General Health Questionnaire (GHQ) is a 60-item, self-rated questionnaire, 
originally designed to detect psychiatric illness in a community setting (Goldberg 
1972). For simplicity and expediency of questionnaire completion, the shorter 12-
item version (GHQ-12) was used (Goldberg & Williams 1988); reliability and 
validity of both versions are comparable. Twelve questions relating to mental health 
and wellbeing of the individual (in this case, the relative or carer of the adult with 
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DS) are presented with 4 possible answers. These can be scored in a number of ways; 
in this study, we opted to use the Likert scoring method, in which answers are coded 
0-4 and the 12 answers summed to give a score in the range 0-36, with higher scores 
indicating a higher level of psychiatric burden (Goldberg & Williams 1988).  
8.1.7.3.10 pESS 
The pESS was used, as per the patient questionnaire. However, on this occasion, it 
was used as a proxy measure, with the relative/carer rating the participant’s 
sleepiness. The use of the ESS/pESS as a proxy measure is discussed in Chapter 5. 
8.1.7.4 GP information 
A standard letter (see Appendix 3) was sent to each participant’s general practitioner 
to inform them of the individual’s participation in the study. Copies of the participant 
and carer information sheets were included, along with a copy of the signed consent 
form. Letters were sent to any other health professionals actively involved with the 
participant’s care at the time of the study, such as hospital specialists, nurse 
practitioners or care workers. 
8.1.7.5 Discussion of sleep study results 
Time was taken to discuss the results of the participant’s home sleep study with the 
participant and their relative/carer. In particular, the significance of the AH and ODI 
were highlighted, along with any suggested relationship to position or probable sleep 
stage. This provided an opportunity for the family to ask questions regarding the 
participant’s diagnosis, improving their understanding of the need for treatment and 
the possible benefits prior to randomisation.  
8.1.7.6 Randomisation 
After completion of all anthropometric measures, cognitive function tests and 
questionnaires, participants were randomly allocated to either the treatment group or 
lifestyle group.  
Randomisation was by balanced block design (Altman & Bland 1999). Blocks were 
created by an investigator not chiefly involved in either testing or treatment, and 
individual allocations placed in sealed, numbered envelopes.  
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Randomisation envelopes were opened sequentially at the time of randomisation by 
an unblinded investigator. Upon randomisation, patients were allocated individual, 
sequential identification numbers, from DSR01-DSR28 (with DSR an acronym for 
Down syndrome randomised). These numbers were used for identification of 
participants throughout the study and allowed anonymised storage of data. The 
randomisation envelope and allocation slip was filed in the unblinded CRF. 
The unblinded investigator explained the allocation to the participant and their 
relative/carer, and issued a participant folder (see Appendix 3). This included: a 
“People You Will Meet” sheet with photos of the study team and contact details; 
copies of the participant and carer information sheets; a copy of the signed consent 
form; a lifestyle advice information sheet; 12 diary questionnaires to be completed 
and returned to the unblinded investigator in a pre-paid envelope on a monthly basis, 
commencing from one month after the baseline visit; and a list of all study 
appointment dates. Participants and relative/carers were advised to use the unblinded 
investigator as the primary point of contact with all study-related queries from this 
point forward so as to maintain the other investigators’ blinding to treatment status. 
 Follow-up: 1 week (Visit 3) 8.1.8
Participants on both limbs of the study were followed up by telephone consultation 
with an unblinded investigator at 1 week. Any CPAP adherence issues were dealt 
with and further troubleshooting appointments, in person or by phone, were offered 
if required. 
 Follow-up: 1 month (Visit 4) 8.1.9
Participants in both limbs of the study attended for follow-up at 1 month from 
baseline. Cognitive function tests and questionnaires were completed as at baseline.  
At the end of this visit, participants in the lifestyle limb were offered CPAP. Those 
accepting were initiated on CPAP via the same procedure as those commencing 
CPAP at baseline (see Figure 23 above and Section 8.1.14 below).  
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 Follow-up: 1 month + 1 week (Visit 4a and 4b) 8.1.10
Participants randomised to the lifestyle group who commenced CPAP at the end of 1 
month were followed up in the same manner as those randomised to the CPAP group 
A phone follow-up was completed after one week (visit 4a, procedure as visit 3 
above) and one month (visit 4b, procedure as visit 4 above). This model allowed 
assessment of treatment effects to be made within the lifestyle group (i.e. before 
commencing CPAP versus after one month on CPAP), as well as between groups 
after one month (i.e. CPAP group versus lifestyle group). 
All test procedures at visits 4 and 4b were carried out by a second blinded 
investigator to prevent unblinding of the main blinded investigator whilst minimising 
inter-rater variability. 
 Follow-up: 3, 6 and 12 months (Visits 5, 6 and 7) 8.1.11
All participants attended for follow-up at 3, 6 and 12 months from baseline. 
Cognitive function tests and questionnaires were completed as at baseline by blinded 
investigator. 
 Monthly diary 8.1.12
Participants and relative/carers were asked to complete a monthly diary questionnaire 
throughout the 12 month period (see Appendix 3). This recorded GP and hospital 
visits, caffeine intake, medication and CPAP side effects. Participants completed the 
ESS and EQ-5D. Relative/carers completed the pESS (as a proxy measure, rating the 
participant’s sleepiness) and modified DBC-A, as well as providing qualitative 
feedback on their relative’s progress. Diary questionnaires were returned by pre-paid 
envelope to the unblinded investigator and filed in the unblinded CRF. 
 Lifestyle advice 8.1.13
Participants in both arms of the study received a lifestyle advice package, written 
using easy-read format and pictorial information (see Appendix 3). The information 
package was discussed with participants and relative/carers by the unblinded 
investigator after randomisation at the end of the baseline visit. Each family was 
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advised to read through the information at home in their own time and to contact the 
unblinded investigator with any questions. 
Information contained in the package was based on standard sleep hygiene advice 
issued to clinical patients attending the Department of Sleep Medicine. Guidance was 
given regarding the sleeping environment, including controlling light and 
temperature and avoiding electronic devices such as televisions, computers and 
mobile phones which may disrupt circadian rhythm. Participants were advised to 
avoid exercise, caffeine, tobacco and nicotine close to bedtime. The importance of 
daylight exposure, strengthening circadian rhythm, was highlighted, and participants 
were recommended to initiate a good bedtime routine. Specific advice regarding the 
non-therapeutic management of snoring and daytime sleepiness was provided. 
 Initiation and monitoring of CPAP 8.1.14
The literature shows that adherence to CPAP and subsequent therapeutic outcomes 
can be improved by intensive CPAP education and support (Hoy et al. 1999; 
Engleman & Wild 2003). CPAP therapy was initiated and monitored by an unblinded 
investigator with eight years’ experience in administering CPAP therapy, in line with 
international recommendations (Morgenthaler et al. 2008). 
 CPAP device 8.1.15
All participants receiving CPAP were issued with an auto-titrating CPAP device (S8 
AutoSet Spirit II™; ResMed (UK) Ltd., Abingdon, UK) with standard 2m hose and 
removable secure digital (SD) data card for recording of usage data (ResMed Ltd 
2008) – see Figure 29. Autosetting CPAP machines by ResMed and other 
manufacturers are used widely worldwide and have been well validated (Farré et al. 
2002; Senn et al. 2003; Cross et al. 2006; Sériès et al. 2008; McArdle et al. 2010; 
Vennelle et al. 2010). 
CPAP units were set up and data downloaded and reported via a PC running 
specialised software (ResScan™ version 03.11.009, ResMed (UK) Ltd., Abingdon, 
UK).  
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All CPAP devices were initially set to variable pressure mode, with pressure ranges 
set to the default minimum of 4cmH2O and maximum of 20 cmH2O. However, the 
unblinded investigator could, optionally, curtail or fix pressures as required at any 
point in the study, depending on the participant’s individual requirements and the 
unblinded investigator’s clinical experience and judgement. Median, 95
th
 centile and 
maximum pressure (all cmH2O) were reported. 
The CPAP units offer an expiratory pressure relief feature (EPR), which senses 
expiration and reduces the delivered CPAP pressure by 1, 2 or 3cmH2O (ResMed Ltd 
2008); this is a comfort feature which may be of particular benefit to individuals 
requiring very high CPAP pressures, who may experience difficulty breathing out 
against the pressure, resulting in an increased frequency of awakening at higher 
pressures. The EPR function was initially switched off and locked, but was altered by 
the investigator as required during troubleshooting.  
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The ramp or settling time was set to a default of 30min; this is the duration of the 
interval between the airflow switching on and treatment commencing, during which 
time the machine runs continually at minimum pressure. It is a comfort feature, 
allowing users a period in which they can settle and fall asleep before pressure 
variation begins. Ramp time was locked so participants could not alter it themselves. 
However, the unblinded investigator could adjust the ramp time as required during 
troubleshooting. 
The SmartStart™ facility, which allows the machine to run and record data only 
when it senses that the mask is in contact with the patient’s face - thereby avoiding 
falsely elevated compliance - was switched on in all cases and could not be altered 
by the participant. 
8.1.15.2 Leak 
Mask leak was recorded and reported in l/sec, with a leak of <4.0l/sec considered 
acceptable; a certain amount of intentional leak is expected due to the mask 
exhalation port which allows exhaled air to be expelled, preventing a build-up of 
carbon dioxide within the mask. Increased mask leak has been linked to poor CPAP 
adherence (Valentin et al. 2011). 
8.1.15.3 Breathing events 
Breathing events, classified as hypopnoea, obstructive apnoea, central apnoea or 
unknown apnoea, were detected and recorded, and used to create an AHI based on 
the hours of CPAP use per night. Events were classified as “unknown” in the event 
of high mask leak, during which the open or closed status of the airway cannot be 
assessed accurately by the CPAP machine. An AHI of <5 is considered normal, as 
per SIGN guidelines (Scottish Intercollegiate Guidelines Network 2003). 
8.1.15.4 Compliance/adherence 
CPAP compliance (mean number of hours per night) was recorded using the inbuilt 
machine timeclock, which records periods for which the machine is on and being 
used, and provide the standard method for monitoring CPAP compliance (H. M. 
Engleman et al. 1994).  
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A range of usage variables were reported: 
 Total number of calendar days on which CPAP was used (days). 
 Total number of calendar days on which CPAP was used for ≥4hr - generally 
considered the therapeutic minimum (Weaver & Grunstein 2008) (days). 
 Total number of calendar days on which CPAP was used for <4hr (days).  
 Total number of calendar days on which CPAP was not used (days). 
 Percentage of days on which CPAP was used for ≥4hr (%). 
 Median daily usage (hr/day). 
 Total hours used (hr). 
 Mean daily usage (hr/day), calculated on total days in reporting period (i.e. 
days used + days not used). 
Summary graphs of usage, pressure and leak were produced, providing a visual 
representation of these variables over the reporting period. 
8.1.15.5 Humidification 
Heated humidification was not issued at commencement of therapy as standard, but 
was available as an adjunct and was prescribed, as required, by the unblinded 
investigator using her clinical judgement using an integrated heated humidifier 
(HumidAire 3i™ or H4i™, ResMed (UK) Ltd., Abingdon, UK). Symptoms which 
indicate the addition of humidification include dryness of the nose/mouth, nasal 
congestion or sneezing (Martins de Araújo 2000; Koutsourelakis et al. 2010; 
Worsnop et al. 2010). 
8.1.15.6 CPAP interfaces and hose 
A range of styles, sizes and brands of mask were available, and participants had the 
opportunity to try a number of different masks during their education session to 
ensure best fit and comfort. Available masks are shown in Table 31. A standard 2m 
CPAP hose, provided as part of the CPAP machine, was used. 
8.1.15.7 CPAP initiation 
CPAP therapy was commenced at the end of visit 2 for participants randomised to 
the CPAP group and at the end of visit 4 for participants in the lifestyle group. CPAP 
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initiation was generally carried out on an individual basis but, similarly to home 
study education, group education was occasionally employed where groups of 
friends participating in the study attended together by choice. The education and 
mask fitting session was conducted in line with the usual clinical procedure followed 
within the Department.  
All participants and their relative/carers were shown an in-house instructional film as 
used in the Department for education of clinical patients. This discusses clinical 
features and consequences of obstructive sleep apnoea and describes CPAP 
treatment. Visual CPAP education has been shown to aid CPAP compliance in the 
general population (Basoglu et al. 2011), and, although the film was produced for the 
general, mainstream clinical population and, as such, does not use simplified 
language, the visual nature of the medium lends itself to people with DS, who tend to 
be visual learners (Hodapp & Dykens 2009). Since the film was produced in-house, 
it features staff and locations involved in the research study; this may help 
participants to directly relate the information on screen to their own situation, 
providing familiarity, which may in turn encourage better outcomes relating to CPAP 
therapy (Heller et al. 2006). 
Following the video, each participant was fitted with a suitable CPAP mask from the 
range available by the unblinded investigator, an experienced CPAP nurse. The 
patient interface has been shown to be an important factor determining CPAP use 
(Parthasarathy 2008). Time was taken to desensitise the participant, allowing them to 
handle the mask themselves and explore it in their own time, including holding and 
fitting it to the face themselves, with and without the CPAP machine running. The 
participant and relative/carer were shown how to correctly fit and adjust the mask. 
Desensitisation protocols have been shown to be beneficial, improving compliance 
and adherence in a number of populations, including the general adult population 
(Engleman & Wild 2003). 
 
 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Treatment study  200 
Table 31: Range of CPAP interfaces available to study participants. Each participant had a 
suitable mask fitted from this range by an experienced CPAP nurse to ensure optimum fit and 
comfort. 





















Figure 30: Study participant wearing ResMed Quattro™ FX full face mask. 
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Once the participant was fitted with a suitable mask and was comfortable enough to 
use it with the air pressure switched on, they were encouraged to lie down with the 
mask and machine on for a short period. During this time, the relative/carer could 
remain in the bedroom with the participant, and lights could be left on or switched 
off at the participant’s preference. This allowed a short period of acclimatisation to 
the sensation of pressure flow, as well as offering the investigator an opportunity to 
assess and rectify unintentional mask leak, changing to a different style of mask if 
required. Upon leaving the room, the investigator monitored the participant remotely 
via infra-red video, and the participant or relative/carer could call the investigator for 
assistance using a patient buzzer system. 
During the course of the study, the unblinded investigator attended training courses 
run by Down’s Syndrome Scotland aimed at understanding and managing the 
behaviour of children and young people with Down's syndrome and improving 
compliance with medical treatments using behavioural techniques (Improving the 
Health and Well Being of Children and Adults with Learning Disabilities, 26 April 
2013, Medica CPD; Positive Behaviour Support, 23 May 2013, Down’s Syndrome 
Scotland). Skills gained by the unblinded investigator were incorporated into the 
CPAP initiation and support process to optimise treatment success. 
8.1.15.8 CPAP follow-up and troubleshooting 
Participants’ adherence and response to CPAP therapy was monitored by the 
unblinded investigator, with steps taken to optimise these throughout. Participants 
and their relatives/carers were encouraged to report any problems by phone or email 
at any point during the study. All participant contact (face-to-face, phone or email), 
including time spent on each interaction, was documented in the unblinded CRF. 
CPAP machines were downloaded at each visit. The unblinded investigator reviewed 
usage, compliance, leak and AHI over the study period and action was taken to 
optimise these outcomes at every stage. The optimal desired thresholds were: 
average usage ≥4hr/night; AHI <5; leak <0.4l/sec (Scottish Intercollegiate Guidelines 
Network 2003; Weaver & Grunstein 2008; Morgenthaler et al. 2008). Adverse events 
were recorded and rectified where possible. Mask fit was assessed subjectively by 
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the unblinded investigator, with the fit of the current mask optimised or a new mask 
issued. Humidification was prescribed as required (Engleman & Wild 2003). 
 Study completion 8.1.16
At the end of the 12 month follow-up visit, participants were encouraged to continue 
on CPAP therapy. Participants from within the catchment area of the Department of 
Sleep Medicine were integrated into the local clinical pathway and issued with a 
clinical CPAP unit. Participants from outwith the local area were referred to their 
nearest NHS sleep service. Formal referral letters were sent by a consultant from the 
Department of Sleep Medicine, with copies sent to the participant and their GP. All 
participants wishing to continue on CPAP at the end of the study retained the 
research CPAP machine. Machines were retrieved from participants wishing to cease 
CPAP. A card thanking the participant and their family for their participation in the 
study was sent by the investigators. 
 Statistical analysis 8.1.17
As previously stated in the Acknowledgements, statistical analysis was overseen by 
an experienced Trial Statistician, Dr Linda J. Williams, Centre for Population Health 
Sciences, The University of Edinburgh. Analysis was conducted by the Investigator 
under the guidance of the Trial Statistician.  
Standard statistical analyses were conducted using SPSS Statistics version 19 (IBM). 
All analyses were two-tailed, with significance set at p=0.001 to allow for the effects 
of multiple testing, where the number of significant findings by chance increases 
with the number of comparisons run. A value of p=0.001 was considered a cautious, 
but sensible, threshold for significance, being less conservative than other methods of 
correcting for multiple testing, such as the Bonferroni correction (Feise 2002). All 
variables were checked for normality. Discrete variables were evaluated using the 
Chi-square test, and the Student’s t-test was used to evaluate normally-distributed 
continuous variables. The Mann-Whitney-U test was used for non-normally 
distributed data. Results are presented as mean ± standard deviation for normal 
variables, as median(IQR) for non-normally distributed variables or as number and 
percentage. 
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 Pearson’s rank correlations were used to explore associations between continuous 
variables, with results shown as Pearson’s r and p-value.   
Discrete variables were evaluated using the Chi-square test and continuous variables 
using the Student’s T-test. Pearson’s and Spearman’s rank correlations were used to 
explore the correlations between parametric and non-parametric variables 
respectively. The Mann-Whitney-U test was used for non-parametric variables. 
Regression analysis was undertaken to explore significant associations between 
variables, using binary logistic regression for categorical variables and generalized 
linear modelling for continuous variables. Results are presented as mean ± standard 
deviation for parametric variables or as a median with interquartile range (IQR 25-
75%) for non-parametric data as appropriate, or as number and percentage. 
Up to the 1 month visit, the study was analysed as a randomised, controlled trial of 
CPAP therapy versus conservative lifestyle measures. 
At the end of the 1 month visit, individuals in the lifestyle group commenced CPAP. 
Thereafter, all study participants were pooled into a single group, and the study 
analysed as a prospective cohort study. 
8.2 Results 
Trial entry and completion information is summarised in Figure 31. Of the 134 
participants with a valid home sleep study result, described in Chapter 7, 32 (24%) 
were ineligible for the treatment phase of the trial. Of these, 27 had a negative sleep 
study (AH<10), 3 had positive sleep studies but were asymptomatic, one had 
previously trialled CPAP therapy and one was unable to comply with the protocol. 
Seven individuals had an inconclusive sleep study which was not repeated, although, 
in clinical practice, a polysomnographic sleep study would be indicated. 
Ninety-seven eligible adults with DS were invited to participate in the treatment 
study, of which 69 did not participate. The majority (n=67) were unable to participate 
due to a lack of funding available to complete the study caused by the delay in 
ethical approval. One participant declined to join the treatment phase of the trial and 
one did not respond when contacted to book an appointment. 
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Twenty-eight individuals (19 male; 9 female) were enrolled in the study and were 
randomised. Twenty-four adults with DS and OSAHS completed the full 12 month 
study, with 19 continuing with CPAP and 5 discontinuing treatment at the end of the 
study. One individual withdrew immediately prior to the 12 month visit due to an 
unexpected close family bereavement. Although withdrawn from the study, 
participant and relative/carer questionnaires were completed and the participant’s 
CPAP machine was downloaded, although the 12 month visit was not conducted. In 
the event of participant withdrawal, the CPAP machine was retrieved and 
downloaded, allowing compliance data to be obtained up to the withdrawal date. 
Of the 28 participants enrolled, 24 were judged to have capacity to consent for 
themselves. The remaining four participants were deemed to lack capacity to 
consent, and so consent was given on their behalf by their parent/carer. In all cases, 
the individual’s parent/carer was present during the consenting process, and the 
decision as to whether an individual could consent for themself was made by the 
investigator, with additional guidance from the parent/carer. No significant 
differences were noted between individuals with and without capacity to consent in 
terms of anthropometric characteristics, sleepiness, behaviour, cognitive function, 
general health or pre-CPAP AHI (data not shown), other than a significantly higher 
mean PAL errors to success noted in AWI at baseline (9±4 v. 4±2; p=0.001) and 5 
months (8±5 v. 4±3; p<0.0001).  
 
 Baseline characteristics 8.2.1
Anthropometric characteristics of the enrolled participants at baseline are 
summarised in Table 32. No significant gender differences were evident. 
The majority of participants (71%) reported a trisomy 21 karyotype and 7% reported 
mosaic DS, although 21% reported that their karyotype was unknown or had never 
been tested. Participants displayed moderate (64%) to severe (36%) levels of ID. 
Eighty-nine percent of individuals lived at home with a parent or parents, with the 
remaining 11% living in supported accommodation. 
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The mean age of participants was 28±9 years. Around a quarter of participants (26%) 
were of normal BMI, with the remainder in the overweight or obese category. The 
mean BMI was 31.5±7.9kg/m
2




8.2.1.1 Sleep characteristics 
Subjective and objective sleep characteristics for all participants at study entry are 
detailed in Table 33Table 33: Subjective and objective sleep characteristics and 
subjective behaviour characteristics of participants enrolled in treatment study. Chi-
square test used for parametric categorical variables, t-test for continuous categorical 
variables and Mann-Whitney U test for non-parametric variables. Values presented 
as mean±SD, median(IQR) or n% unless otherwise stated.. No significant gender 
differences were evident. The mean self-rated pESS was 11±6, with 41% exhibiting 
EDS (pESS>10). The mean pESS as reported by a relative or carer was 11±5, with 
55% rated at having EDS. 
The mean AH per hour in bed was 28.6(14.8-47.9), worse in the supine position 
(31.9(17.1-90.7)). The mean ODI was 7.3(1.8-21.9), again worse when supine 
(8.8(1.8-27.1)). A mean SpO2 of 93.8±3.5% was noted, falling to a nadir of 
81.0±8.9%. A degree of flow limitation was evident, with a flattening index of 
12.6(5.6-19.7). The mean heart rate was 60.1±8.1BPM, with a mean heart rate 
standard deviation of 6.3±1.9BPM, consistent with a degree of sleep fragmentation. 
On average, participants spent the majority of their sleep study (66(24-75)%) in the 
supine position, with a mean transition index of 2.0(1.0-4.1) position changes per 
hour in bed. 
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Figure 31: CONSORT diagram summarising enrolment in and completion of the treatment 













Eligible to participate = 97 
including 2 with +ve clinical PSG only 
 
England = 58      
Scotland = 25 
Wales = 10 
Northern Ireland = 4 
Did not participate = 69 
 
No further funding = 67 
Declined = 1 
Did not respond = 1 
 
 
Ineligible for treatment study = 32 
 
AH <10 = 27 
Asymptomatic = 3 
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Table 32: Anthropometric characteristics of participants enrolled in treatment study at baseline 
visit. Chi-square test used for parametric categorical variables and t-test for continuous 
categorical variables. Values presented as mean±SD or n%. 
  
p *
Age (years) 28 0.15
Body Mass Index (kg/m
2
) ** 27 0.009
Underweight (<18.5kg/m
2
) 0 0.0% 0 0.0% 0 0.0%
Normal weight (18.5-24.99kg/m
2
) 7 25.9% 7 36.8% 0 0.0%
Pre-obesity (25.0-29.99kg/m
2
) 6 22.2% 4 21.1% 2 25.0%
Obesity class I (30.0-34.99kg/m
2
) 7 25.9% 5 26.3% 2 25.0%
Obesity class II (35.0-39.99kg/m
2
) 2 7.4% 1 5.3% 1 12.5%
Obesity class III (≥40.00kg/m
2
) 5 18.5% 2 10.5% 3 37.5%
Collar size (cm) 0.61
Trisomy 21 20 71.4% 15 78.9% 5 55.6%
Translocation 0 0.0% 0 0.0% 0 0.0%
Mosaic 2 7.1% 1 5.3% 1 11.1%
Unknown/not tested 6 21.4% 3 15.8% 3 33.3%
Mild 0 0.0% 0 0.0% 0 0.0%
Moderate 18 64.3% 11 57.9% 7 77.8%
Severe 10 35.7% 8 42.1% 2 22.2%
Profound 0 0.0% 0 0.0% 0 0.0%
At home with parents 25 89.3% 18 94.7% 7 77.8%
Supported accommodation 3 10.7% 1 5.3% 2 22.2%
A 5 17.9% 3 15.8% 2 22.2%
B 8 28.6% 5 26.3% 3 33.3%
C 0 0.0% 0 0.0% 0 0.0%
D 15 53.6% 11 57.9% 4 44.4%
Macroglossia 28 9 32.1% 5 26.3% 4 44.4% 0.41
Gothic palate 28 26 92.9% 19 100.0% 7 77.8% 0.10
Adenoid facies 28 6 21.4% 3 15.8% 3 33.3% 0.35
Class I 1 3.6% 1 5.3% 0 0.0%
Class II 6 21.4% 5 26.3% 1 11.1%
Class III 14 50.0% 10 52.6% 4 44.4%
Class IV 7 25.0% 3 15.8% 4 44.4%
Stage I 0 0.0% 0 0.0% 0 0.0%
Stage II 17 70.8% 11 64.7% 6 85.7%
Stage III 7 29.2% 6 35.3% 1 14.3%
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Table 33: Subjective and objective sleep characteristics and subjective behaviour characteristics 
of participants enrolled in treatment study. Chi-square test used for parametric categorical 
variables, t-test for continuous categorical variables and Mann-Whitney U test for non-
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8.2.1.2 Behavioural and emotional disturbances 
As summarised in Table 33, no significant gender differences were noted in terms of 
raw total scores, MIS, PIC or II on the DBC-A subscales at baseline. 
 Randomisation 8.2.2
Fourteen participants were randomly allocated to each group. As summarised in 
Tables 34, 35, 36 and 37. The groups were equivalent at baseline in terms of 
anthropometric characteristics, subjective and objective sleep characteristics, 
behavioural and emotional disturbances, cognitive function, general health status, 
medication use and carer burden at baseline, with no significant differences 
observed. 
Although 86% of participants in each group used ≥1 medication, use of medications 
which may impact on sleep was very low, with one participant in the lifestyle group 
using an antiepileptic medication and one individual in the CPAP group taking 
antihistamines. As with the subjective and objective prevalence studies, category H 
drugs (systemic hormonal preparations excluding insulin) and category R 
(respiratory system) drugs were the most commonly used; 57% of the lifestyle group 
and 50% of the CPAP group used category H drugs (p=1.00), with category R 
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Table 34: Anthropometric characteristics of participants enrolled in treatment study at baseline 
visit by randomisation group. Chi-square test used for parametric categorical variables and t-
test for continuous categorical variables. Values presented as mean±SD or n %. 
*Not yet commenced on CPAP 
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p
Gender (males : females) 28 0.10
Age (years) 28 0.54
Body Mass Index (kg/m
2
) 27 0.29
Collar size (cm) 28 0.93
Trisomy 21 10 71.4% 10 71.4%
Translocation 0 0.0% 0 0.0%
Mosaic 2 14.3% 0 0.0%
Unknown/not tested 2 14.3% 4 28.6%
Mild 0 0.0% 0 0.0%
Moderate 10 71.4% 8 57.1%
Severe 4 28.6% 6 42.9%
Profound 0 0.0% 0 0.0%
At home with parents 12 85.7% 13 92.9%
Supported accommodation 2 14.3% 1 7.1%
A 2 14.3% 3 21.4%
B 4 28.6% 4 28.6%
C 0 0.0% 0 0.0%
D 8 57.1% 7 50.0%
Macroglossia 28 4 28.6% 5 35.7% 1.00
Gothic palate 28 13 92.9% 13 92.9% 1.00
Adenoid facies 28 3 21.4% 3 21.4% 1.00
Class I 1 7.1% 0 0.0%
Class II 1 7.1% 5 35.7%
Class III 7 50.0% 7 50.0%
Class IV 5 35.7% 2 14.3%
Stage I 0 0.0% 0 0.0%
Stage II 6 50.0% 11 91.7%
Stage III 6 50.0% 1 8.3%











12 : 2 7 : 7
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Table 35: Subjective and objective sleep characteristics and subjective behaviour characteristics 
of participants enrolled in treatment study by randomisation group. Chi-square test used for 
parametric categorical variables, t-test for continuous categorical variables and Mann-Whitney 
U test for non-parametric variables. Values presented as mean±SD, median(IQR) or n% unless 
otherwise stated. 
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Table 36: Cognitive function status of participants enrolled in treatment study by 
randomisation group at baseline visit. Chi-square test used for parametric categorical variables, 
t-test for continuous categorical variables and Mann-Whitney U test for non-parametric 
variables. Values presented as mean±SD, median(IQR) or n% unless otherwise stated. 




Raw score verbal 28 0.83
Raw score non-verbal 28 0.30
Raw score 27 0.50
Mean correct cats - -
Mean correct frogs - -
Mean correct combined - -
Mean errors to success 27 0.62
First trial memory score 28 0.52




606.8 ± 346.2 557.3 ± 311.8
CANTAL Simple Reaction Time (SRT):
Kaufmann Brief Intelligence Test (KBIT-2):
Total 
included
30.6 ± 17.6 31.9 ±  13.3
12.3 ± 6.3 14.4 ± 4.2
CANTAB Paired Associates Learning (PAL):
Modified DOTS task:
4.5 ± 3.5 5.1 ± 2.9
11.4 ± 7.4 9.9 ± 4.3
84.2 ± 14.6 80.1 ± 11.1
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Table 37: General health and carer burden status of participants enrolled in treatment study by 
randomisation group at baseline visit. Chi-square test used for parametric categorical variables, 
t-test for continuous categorical variables and Mann-Whitney U test for non-parametric 
variables. Values presented as mean±SD, median(IQR) or n % unless otherwise stated. 
* Not yet commenced CPAP therapy 





Usual activities 28 0.80
Pain/discomfort 28 0.84
Anxiety/depression 28 0.70
Health state (visual analogue scale; %) 27 0.08
Total percent 28 0.13
Physical functioning 27 0.26
Role limitations due to physical health 28 0.19
Role limitations due to emotional problems 28 0.73
Energy/fatigue 28 0.13
Emotional well-being 5 0.20
Social functioning 27 0.38
Pain 28 0.27
General health 28 0.76
Total score 27 0.84
Total score 27 0.51






0.0 (0.0-1.3) 0.0 (0.0-1.3)
0.0 (0.0-2.0) 0.0 (0.0-1.3)
1.0 (0.0-1.0) 0.0 (0.0-2.0)
0.0 (0.0-1.0) 0.0 (0.0-1.0)
50.0 (49.4-90.0) 50.0 (40.6-80.0)
80.8 (63.2-85.0) 63.1 (40.1-81.7)
90.0 (45.0-96.3) 65.0 (30.0-97.5)
100.00 (100.0-100.0) 100.0 (18.8-100.0)
100.0 (71.9-100.0) 87.5 (68.8-100.0)
100.0 (100.0-100.0) 100 (83.3-100.0)
62.5 (48.8-65.0) 47.5 (32.5-55.0)




0.0 (0.0-1.3) 0.0 (0.0-2.0)
RAND SF-36:
80 (65-90) 93 (75-100)
10.8 ± 7.0 9.0 ± 6.7
General Health Questionnaire 12-item version (GHQ12):
Modified carer burden inventory (CBI):
10.7 ± 2.5 10.5 ± 3.9
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Any medication 28 12 85.7% 12 85.7% 1.00
A - Alimentary tract and metabolism 28 5 35.7% 3 21.4% 0.68
B - Blood and blood forming organs 28 0 0.0% 1 7.1% 1.00
C - Cardiovascular system 28 1 7.1% 0 0.0% 1.00
D - Dermatologicals 28 1 7.1% 2 14.3% 1.00
G - Genito-urinary system and sex hormones 28 0 0.0% 1 7.1% 1.00
H - Systemic hormonal preparations, excluding sex hormones and insulins 28 8 57.1% 7 50.0% 1.00
J - Antiinfectives for systemic use 28 0 0.0% 1 7.1% 1.00
L - Antineoplastic and immunomodulating agents 28 0 0.0% 0 0.0% -
M - Musculo-skeletal system 28 1 7.1% 1 7.1% 1.00
N - Nervous system 28 2 14.3% 0 0.0% 0.48
P - Antiparasitic products, insecticides and repellents 28 0 0.0% 0 0.0% -
R - Respiratory system 28 3 21.4% 5 35.7% 0.68
S - Sensory organs 28 0 0.0% 0 0.0% -
V - Various ** 28 0 0.0% 0 0.0% -
Over-the-counter medications with no clear WHO ATC category 28 0 0.0% 0 0.0% -
Benzodiazepines 28 0 0.0% 0 0.0% -
Antidepressants 28 0 0.0% 0 0.0% -
Opiates 28 0 0.0% 0 0.0% -
Oxygen 28 0 0.0% 0 0.0% -
Melatonin 28 0 0.0% 0 0.0% -
Antiepileptics 28 1 7.1% 0 0.0% 1.00
Contraceptives 28 0 0.0% 1 7.1% 1.00
Antihistamines 28 1 7.1% 1 7.1% 1.00
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 1 month follow-up 8.2.3
At this point, the study was analysed as a randomised, controlled trial of CPAP 
therapy versus conservative lifestyle measures.  
When the randomised groups were compared at 1 month from baseline (Table 38), 
no significant differences were observed, despite the use of CPAP by one group. The 
CPAP group averaged 36±9 days from CPAP initiation at the time of the 1 month 
follow-up visit. CPAP had been used on 69.4(22.6-84.8)% of days since initiation, 
with 35.7(0.0-52.6)% of used days averaging ≥4hr usage, considered the 
conventional therapeutic minimum in the general population (Weaver & Grunstein 
2008). Total usage averaged 62.4(13.0-110.3)hr, with a median usage of 3.0(1.6-
4.7)hr/night. The mean 95
th
 centile pressure was 8.9±2.8cmH2O, with a mean leak 
within normal limits (0.3(0.2-0.4)l/sec). The machine-derived AHI was 10.4(1.5-
12.4) events/hr, with an AHI <5 per/hr considered the upper limit of normal. 
Pressure, leak and AHI data were unavailable for 1 participant due to a machine 
error. No significant differences were noted between those who consented for 
themselves and those who did not (data not shown). 
 Prospective treatment study 8.2.4
The lifestyle group did not differ significantly in outcomes between their baseline 
and 1 month visits (Table 39), both pre-CPAP, indicating that an additional pre-
treatment visit did not have a significant effect in this group. Therefore, the lifestyle 
group baseline measures were pooled with the CPAP group baseline measures for 
use in the whole group prospective treatment study analysis. 
Measured sleep, behaviour, cognitive function and general health outcomes for the 
whole group on CPAP across the 12 month study period are summarised in Table 40 
(raw values at baseline, 3 months and 12 months) and  Table 41 (change (Δ) values at 
1, 3, 6 and 12 months). Again, no significant differences were noted between those 
who consented for themselves and those who did not (data not shown). 
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Table 38: Characteristics of lifestyle and CPAP groups at 1 month. Chi-square test used for 
parametric categorical variables, t-test for continuous categorical variables and Mann-Whitney 
U test for non-parametric variables. Values presented as mean±SD, median(IQR) or n % unless 
otherwise stated. 
* Not on CPAP 
** No CPAP data for 1 participant due to machine error 
 
Body Mass Index (kg/m
2
) 25 0.14
Collar size (cm) 26 0.53
Disruptive behaviour subscale (scale range 0-34) 26 0.84
Mean item score (possible score 0-2) 26 0.39
Proportion of items checked (possible score 0-1) 26 0.39
Intensity index  (possible score 0-1) 25 0.81
Anxiety/Antisocial subscale (scale range -2-14) 26 0.34
Mean item score (possible score 0-2) 26 0.34
Proportion of items checked (possible score 0-1) 26 0.29
Intensity index  (possible score 0-1) 18 0.63
Depressive subscale (scale range 0-18) 26 0.55
Mean item score (possible score 0-2) 26 0.55
Proportion of items checked (possible score 0-1) 26 0.51
Intensity index  (possible score 0-1) 20 0.71
Self-rated 26 0.70
Pictorial Epworth Sleepiness Scale score >10 26 4 30.8% 6 46.2% 0.69
Carer-rated 22 0.99
Pictorial Epworth Sleepiness Scale score >10 22 5 45.5% 6 54.5% 1.00
Raw score verbal 25 0.94
Raw score non-verbal 26 0.96
Raw score 26 0.83
Mean correct cats 25 0.04
Mean correct frogs 25 0.67
Mean correct combined 25 0.40
Mean errors to success 26 0.80
First trial memory score 26 0.73
Mean correct latency (ms) 26 0.82
2.0 (1.3-6.8) 3.0 (1.5-4.3)
13.2 ± 6.1 12.4 ± 6.3
CANTAL Simple Reaction Time (SRT):
0.40 ± 0.13 0.42 ± 0.11
0.40 ± 0.12 0.43 ± 0.06
CANTAB Paired Associates Learning (PAL):
0.38 ± 0.13 0.49 ± 0.13
576.1 ± 197.7 554.0 ± 280.4
Scales of Independent Behaviour - Revised (SIB-R) Adaptive Behavior Short Form:
83.3 ± 15.4 82.2 ± 11.4
Modified DOTS task:
Arizona Cognitive Test Battery (ACTB):
Kaufmann Brief Intelligence Test (KBIT-2):
36.4 ± 18.1 35.9 ± 11.4
14.0 (12.5-17.5) 16.0 (11.58-17.0)
Pictorial Epworth Sleepiness Scale (pESS):
9 ± 5 10 ± 6
11 ± 4 11 ± 6
0.11 (0.11-0.22) 0.11 (0.11-0.28)
0.11 (0.11-0.22) 0.11 (0.00-0.28)
0.00 (0.00-0.00) 0.00 (0.00-0.00)
0.00 (-0.06-0.11) 0.00 (-0.11-0.11)
0.00 (0.00-0.38) 0.00 (0.00-0.00)
1 (1-2) 1 (0-3)
0.00 (0.00-0.00) 0.00 (0.00-0.00)
0.0 (-1-1.0) 0 (-1-1)
0.00 (-0.06-0.11) 0.00 (-0.11-0.11)
0.24 (0.15-0.41) 0.18 (0.06-0.32)
0.24 (0.15-0.38) 0.18 (0.06-0.32)
29.4 ± 7.0 34.1 ± 8.5
41.1 ± 3.4 42.4 ± 6.8








4 (3-7) 3 (1-6)
p 
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Usual activities 26 0.88
Pain/discomfort 26 0.39
Anxiety/depression 26 0.84
Health state (visual analogue scale; %) 26 0.69
Total (%) 26 0.29
Physical functioning (%) 25 0.27
Role limitations due to physical health (%) 24 0.94
Role limitations due to emotional problems (%) 26 0.58
Energy/fatigue (%) 26 0.17
Emotional well-being (%) 5 0.20
Social functioning (%) 26 0.31
Pain (%) 26 0.92
General health (%) 26 0.84
Total score 24 0.32
Total score 25 0.24
Total days since CPAP initiation 13 -
Days used (%) 13 -
Days used ≥4hr (%) 13 -
Total usage (hr) 13 -
Mean usage (hr) 13 -
Median usage (hr) 13 -
95th centile pressure (cmH20) 12 ** -
95th centile leak (L/min) 13 ** -







Continuous positive airway pressure (CPAP) :
- 36 ± 9
- 1.9 (0.2-4.0)
- 3.0 (1.6-4.7)
- 8.9 ± 2.8
62.4 (13.0-110.3)-
12.8 ± 7.7 8.9 ± 8.4
Carer-related measures:
General Health Questionnaire 12-item version (GHQ12):
11.2 ± 3.5 9.6 ± 4.4
Modified carer burden inventory (CBI):
87.5 (62.5-100.0) 100.0 (100.0-100.0)
50.0 (50.0-77.5) 50.0 (47.5-90.0)
80.0 (72.5-95.0) 85.0 (60.0-97.5)
100.0 (100.0-100.0) 100.0 (100.0-100.0)
65.0 (47.5-75.0) 50.0 (27.5-67.5)
80.1 (76.2-80.1) 72.0 (64.0-72.0)
75.6 (60.0-87.6) 69.2 (49.7-83.3)
92.5 (51.3-100.0) 75.0 (33.8-97.5)
100.0 (37.5-100.0) 100.0 (100.0-100.0)
0.0 (0.0-0.5) 0.0 (0.0-0.0)
90.0 (77.5-98.5) 95.0-57.5-97.0)
RAND SF-36:
0.0 (0.0-1.0) 0.0 (0.0-1.5)
0.0 (0.0-1.0) 1.0 (0.0-1.0)
0.0 (0.0-0.5) 0.0 (0.0-2.0)
General health measures:
EQ-5D:
0.0 (0.0-1.0) 0.0 (0.0-1.5)
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Table 39: Characteristics of participants in the lifestyle group at baseline and 1 month (not on 
CPAP). Chi-square test used for parametric categorical variables, t-test for continuous 
categorical variables and Mann-Whitney U test for non-parametric variables. Values presented 
as mean±SD, median(IQR) or n % unless otherwise stated. 
 
p 
Body Mass Index (kg/m
2
) 27 0.83
Collar size (cm) 27 0.82
Disruptive behaviour subscale (scale range 0-34) 27 0.55
Mean item score (possible score 0-2) 27 0.55
Proportion of items checked (possible score 0-1) 27 0.52
Intensity index  (possible score 0-1) 27 0.98
Anxiety/Antisocial subscale (scale range -2-14) 27 1.00
Mean item score (possible score 0-2) 27 1.00
Proportion of items checked (possible score 0-1) 27 0.72
Intensity index  (possible score 0-1) 17 1.00
Depressive subscale (scale range 0-18) 27 0.58
Mean item score (possible score 0-2) 27 0.58
Proportion of items checked (possible score 0-1) 27 0.58
Intensity index  (possible score 0-1) 23 1.00
Self-rated 26 0.59
Pictorial Epworth Sleepiness Scale score >10 26 5 38.5% 4 30.8% 1.00
Carer-rated 21 0.82
Pictorial Epworth Sleepiness Scale score >10 21 5 50.0% 5 45.5% 1.00
Raw score verbal 26 0.42
Raw score non-verbal 27 0.13
Raw score 27 0.88
Mean correct cats 12 -
Mean correct frogs 12 -
Mean correct combined 12 -
Mean errors to success 26 0.34
First trial memory score 27 0.48









Pictorial Epworth Sleepiness Scale (pESS):
0.00 (0.00-0.00) 0.00 (0.00-0.00)
0.11 (0.11-0.22)
0.11 (0.11-0.22)0.17 (0.11-0.44)
0.06 (-0.11-0.11) 0.00 (0.00-0.11)
2 (1-4)
0.06 (-0.03-0.14) 0.00 (-0.06-0.11)
0.00 (0.00-0.25) 0.00 (0.00-0.38)
1 (1-2)
30.0 ± 7.4 29.4 ± 7.0
0.38 ± 0.13
- 0.40 ± 0.13
- 0.40 ± 0.12
0 (-1-1)










Arizona Cognitive Test Battery (ACTB):
3.0 (1.9-6.4) 2.0 (1.3-6.8)
11.4 ± 7.4 13.2 ± 6.1
84.2 ± 14.6
-
41.4 ± 4.2 41.0 ± 3.4
10 ± 5 9 ± 5
10 ± 4 11 ± 4
Kaufmann Brief Intelligence Test (KBIT-2):
30.6 ± 17.6 36.4 ± 18.1
12.3 ± 6.3 21.9 ± 20.3
83.3 ± 15.4
Scales of Independent Behaviour - Revised (SIB-R) Adaptive Behavior Short Form:
530.0 (338.3-772.6) 624.6 (358.9-703.9)
CANTAL Simple Reaction Time (SRT):
CANTAB Paired Associates Learning (PAL):
Modified DOTS task:
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Usual activities 27 0.91
Pain/discomfort 27 0.16
Anxiety/depression 27 0.58
Health state (visual analogue scale; %) 27 0.14
Total (%) 27 0.91
Physical functioning (%) 27 0.56
Role limitations due to physical health (%) 27 0.49
Role limitations due to emotional problems (%) 27 0.79
Energy/fatigue (%) 27 0.62
Emotional well-being (%) 4 0.67
Social functioning (%) 27 0.49
Pain (%) 27 0.58
General health (%) 27 0.98
Total score 27 0.66
Total score 27 0.49
50.0 (50.0-77.5)
EQ-5D:
0.0 (0.0-1.3) 0.0 (0.0-1.0)
RAND SF-36:
10.8 ± 7.0 12.8  ± 8
General Health Questionnaire 12-item version (GHQ12):
Modified carer burden inventory (CBI):
10.7 ± 2.5 11.2 ± 3.5
Carer-related measures:
100.0 (100.0-100.0)




100.0 (100.0-100.0) 100.0 (100.0-100.0)
100.0 (100.0-100.0) 100.0 (100.0-100.0)
62.5 (48.8-65.0) 65.0 (47.5-75.0)
84.1 (76.2-84.1) 80.1 (76.2-80.1)
0.0 (0.0-1.3) 0.0 (0.0-1.0)
0.0 (0.0-2.0) 0.0 (0.0-1.0)
1.0 (0.0-1.0) 0.0 (0.0-0.5)
0.0 (0.0-1.0) 0.0 (0.0-0.5)
80.8 (63.2-85.0) 75.6 (60.0-87.6)
90.0 (45.0-96.3) 92.5 (51.3-100.0)
80.0 (65.0-90.0) 90.0 (77.5-98.5)
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Table 40: Measured outcomes in all participants at baseline, 3 month and 12 month visits. 
Paired samples t-test used for parametric variables and Wilcoxon ranked pairs test for non-
parametric variables. Values presented as mean±SD or median(IQR). 
* Comparison of baseline & 3 month visits 
** Comparison of baseline & 12 month visits 
*** Comparison of 3 month & 12 month visits 
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Table 41: Whole group sleep, behaviour and CPAP usage data across months 1-12 of the study. 
It should be noted that the lifestyle group commenced CPAP at the end of the 1 month visit, and 
so lifestyle group 1 month data was collected at an additional 1 month + 1 month visit and 
pooled with the CPAP group 1 month visit data. Significance of change assessed using paired 
sample t-tests versus change of 0 (i.e. no change).  
* Includes CPAP data from machine download of patient at withdrawal.  
** No data due to machine error. 
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8.2.4.1 CPAP usage 
At 1 month post-CPAP initiation (mean total days since initiation 39±4 days), CPAP 
compliance across the whole group (n=27) was low, with a mean usage of 1.7(0.2-
4.5)hr/night and median usage of 2.8(1.1-6.7)hr/night. CPAP was used on 55±35% 
of days, and the mean proportion of used days where CPAP was used for ≥4hr was 
35.7(0.0-84.0)%. The mean total hours used was 64.6(8.2-143.3)hr. The mean 95
th
 
centile pressure was 8.2±3.0cmH2O and the 95
th
 centile leak was within normal 
limits at 0.3(0.2-0.5)L/min. The mean machine-derived AHI was 9.7(1.2-11.8)/hr in 
bed (an AHI <5 is considered normal (Scottish Intercollegiate Guidelines Network 
2003)). 
No significant changes were noted with respect to compliance, pressure, leak or AHI 
at 3 month, 6 months or 12 months post-CPAP initiation (see Table 41). Mean 
compliance at 12 months (352±17 days from CPAP initiation) remained low: mean 
usage 1.5(0.3-4.6)hr/night; median usage 2.3(01.0-6.4)hr/night; days used 
53.7±33.7%; used days ≥4hr 34.3(4.1-83.3)% (all n=25). The mean 95
th
 centile 
pressure was 8.6±2.2cmH2O, and the 95
th
 centile leak was 0.3±0.2L/min. The mean 
AHI was 6.7(2.9-8.7)/hr in bed.  
Correlation and regression analysis did not reveal any significant associations 
between age, gender, BMI, AH, ODI, behaviour or sleepiness at baseline with CPAP 
compliance at 12 months (data not shown). 
All participants were fitted with full face masks: 14 commenced CPAP using a 
ResMed Mirage Quattro™ mask (extra small or small), 13 using a ResMed 
Quattro™ FX mask (extra small or small) and 1 using a Respironics Amara mask 
(petite). Eight participants required a change of mask during the trial; the majority 
switched from the ResMed Mirage Quattro™ to ResMed Quattro™ FX (n=5), with 3 
switching from FX to Mirage and one individual switching from FX to Mirage and 
back to FX by the end of the study. No significant differences in usage, compliance, 
pressure, leak or AHI were noted between the mask types at 12 months (data not 
shown). 
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8.2.4.1.1 Adverse events 
CPAP was generally well-tolerated, with only minor adverse events reported. 
At 1 month, one participant reported skin irritation from the mask and another 
anxiety or fear related to the CPAP equipment. One participant was withdrawn from 
the study due to inability to tolerate CPAP. 
At 3 months, a further participant had withdrawn from the study due to inability to 
tolerate CPAP and 9 individuals (35%) reported adverse events. These included 
anxiety/fear of CPAP (12%), inability to tolerate CPAP (8%), mask leak (8%), 
wakening due to CPAP (4%) and nasal congestion (4%). 
Twenty-eight percent of participants reported adverse events at 6 months, including 
dry mouth (8%), respiratory infection (8%), skin irritation, anxiety/fear of CPAP and 
inability to tolerate CPAP (all 4%). 
By 12 months, 24 participants remained in the study, with 2 participants withdrawn 
due to close family bereavement and moving into residential care respectively. Six 
participants (25%) reported adverse events: anxiety/fear of CPAP (8%); inability to 
tolerate CPAP (8%); skin irritation (4%); wakening due to CPAP (4%). Of the 24 
individuals remaining in the study, 25% reported that they were not using CPAP at 
the time of the 12 months visit. Half of these reported not using CPAP due to a 
dislike of CPAP, one was afraid of CPAP, one felt their symptoms had improved and 
so no longer wished to use CPAP and one parent was unwilling to continue CPAP. 
Nineteen individuals (79% of those completing the study) elected to continue using 
CPAP at the end of the study period. Of the 5 individuals who returned their 
machines, two were unable to tolerate CPAP, 2 did not like CPAP and one refused to 
use the treatment. 
8.2.4.1.2 Humidification 
Humidification was commenced as required based on reported symptoms, such as 
nasal congestion or dryness, and the unblinded investigator’s clinical judgement. 
Two individuals (7%) used humidification at 1 month, 4 (15%) at 3 months, 7 (28%) 
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at 6 months and 7 (29%) at 12 months. No significant differences were evident in 
CPAP outcomes between those using humidification and those without (data not 
shown). 
8.2.4.2 Anthropometric characteristics 
BMI and collar size did not vary significantly across the study, as evidenced in Table 
40. 
8.2.4.3 Subjective sleepiness 
As shown in Table 40 and Table 41, mean self-rated pESS scores improved 
significantly across the 12 month study period, falling from 11±6 at baseline to 7±6 
at 3 months (p<0.0001) 6±5 at 12 months (p=0.001). The mean self-rated pESS from 
baseline was not significantly reduced at 1 month post-CPAP initiation, but the mean 
Δ in pESS showed a significant reduction in subjective sleepiness at 3 months (-
4.4±5.4; p<0.0001), which was sustained at 6 (-4.8±5.6; p<0.0001) and 12 months 
(p=0.001). There was an overall downward trend in proxy-rated pESS scores with 1 
month (p=0.29), 3 months (p=0.02), 6 months (p=0.02) and 12 months (p=0.03) on 
CPAP, although this did not reach significance. 
8.2.4.4 Behavioural and emotional disturbances 
As shown in Table 40, a significant decrease in DBC-A Disruptive subscale raw 
scores was observed at 12 months in comparison to baseline, indicating an overall 
improvement in Disruptive behaviour (1(0-3) v. 4 (2-8); p<0.0001). Disruptive MIS 
and PIC scores were also significantly reduces (both p<0.0001), indicating a 
reduction in both the severity of behavioural/emotional disturbance and the breadth 
of problem behaviours. Similar reductions were also noted in Depressive behaviour 
raw, MIS and PIC scores (all p=0.001). No significant change was evident in 
Anxiety/Antisocial behaviour scores, though scores remained very low throughout 
the study. 
Change (Δ) in behaviour scores is summarised in Table 41. A downward trend in 
scores on the Anxiety/Antisocial and Depressive subscale raw scores was observed 
across the 12 month study period, but did not reach the conservative significance 
Prevalence and treatment of OSAHS in adults with Down syndrome 
Treatment study  232 
threshold for this trial. Raw scores in the Disruptive behaviour domain also exhibited 
a steady reduction from baseline, reaching significance at 3 months (p=0.001) and 12 
months (p<0.0001). 
8.2.4.5 Cognitive function 
ACTB scores at baseline, 3 months and 12 months are shown in Table 40. The 
change in scores across the study is summarised in Table 41. 
8.2.4.5.1 KBIT-2 
Raw scores in the verbal domain of the KBIT-2 showed a significant improvement 
12 months (p=0.001), with a trend towards improvement at 3 months (p=0.002). The 
mean baseline verbal score was 31±15, of a possible total of 108, rising to 37±19 at 
the 12 month visit. Non-verbal subscale scores were increased at 3 and 12 months 
but did not reach significance (p=0.05, p=0.01 respectively). The mean baseline 
score in this subscale was 13±5 of a possible 4, rising to 20±17 at 12 months. 
When Δ values were compared to baseline, a sustained increase in verbal scores was 
noted, reaching significance at 12 months (p=0.001). Increases in non-verbal scores 
were observed across the study, but, again, did not reach significance. 
8.2.4.5.2 SIB-R 
The mean raw score on the SIB-R at baseline was 82.6±12.9 from a possible total of 
120, and did not change significantly with CPAP use. An average, typically-
developing adult aged 30 years achieves a score of 117/120 (Bruininks et al. 2006). 
8.2.4.5.3 Modified Dots task 
Data for the modified Dots task was overwritten due to operator error, and so no 
baseline data were available. However, the University of Arizona were able to 
recover data for the majority of patients for visits 4 and 7 only. No significant 
differences were noted between groups at visit 4, or between visit 4 and 7. 
8.2.4.5.4 CANTAB PAL 
No significant differences in the mean number of errors to success or first trial 
memory score on the CANTAB PAL test were noted (4.9±3.2 and 10.6±6.0 at 
baseline respectively). 
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8.2.4.5.5 CANTAB SRT 
No significant improvement or decrement in reaction time scores was evident, with a 
mean correct latency of 582.1±324.3ms recorded at baseline.  
8.2.4.6 General health measures 
8.2.4.6.1 EQ-5D 
The overall mean health state of participants as rated by the EQ-5D visual analogue 
scale was 81±19% at baseline, and this did not differ significantly across the study, 
despite CPAP use. Reported problems with mobility, self-care, carrying out usual 
activities, pain/discomfort and anxiety/depression were all low at baseline (Table 
40), and did not vary significantly across the 12 months of the study. 
8.2.4.6.2 RAND SF-36 
RAND SF-36 scores at baseline, 3 months and 12 months are summarised in Table 
40. The total percentage score was 68±21% at baseline, and was increased at 3 
months and 12 months, though this did not reach significance (p=0.01 and p=0.02 
respectively). Physical functioning increased significantly from baseline (68±31%) to 
3 months (73±30%; p<0.0001). A further increase at 12 months was noted 
(78±27%), but this did not reach significance (p=0.03). General health increased 
from 74±23% at baseline to 84±21% at 12 months, but, again, this change was not 
significant in this small cohort (p=0.02 at 3 months, p=0.05 at 12 months). 
No significant changes were evident in physical or emotional role limitation, 
energy/fatigue, emotional wellbeing, social functioning or pain as measured by the 
RAND SF-36. Notably, energy/fatigue scores were low in this population at baseline, 
with a mean score of 50±21%. This rose to 59±20% after 12 months on CPAP, but 
this was not significant (p=0.14). 
The low number of participants with RAND SF-36 emotional wellbeing scores 
should be noted (n=5 at baseline and 3 months, and n= 4 at 12 months). The printed 
questionnaire issued to participants in the early stages of the study omitted a question 
used in calculation of this score in error (question 28: “Have you felt downhearted 
and blue?”), resulting in missing data for the majority of participants and rendering 
outcomes for this domain invalid. 
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8.2.4.7 Carer burden 
8.2.4.7.1 Modified ZBI 
Scores on the modified ZBI remained stable across the 12 month study period, 
averaging 10±7 of a possible 48 at baseline, with no significant change was noted. 
Higher scores indicate an increased burden of caring. 
8.2.4.7.2 GHQ-12 
At baseline, carers’ mean baseline rating of their own general health was 11±3 out of 
a possible score of 36, with higher scores indicating a greater level of health 
impairment. This did not vary significantly during the 12 months of the study. 
 
8.3 Discussion  
This is the first randomised, controlled trial of CPAP therapy in adults with DS. 
Despite being underpowered due to small participant numbers, real and significant 
improvements in sleepiness, behaviour and daytime cognitive function were 
demonstrated, even with only modest use of CPAP. 
To date, no other studies have formally evaluated the use of CPAP in adults with DS. 
Trois et al reported informally on the treatment of the individuals who had abnormal 
sleep studies as an aside to their prevalence study (Trois et al. 2009). Nine of the 14 
adults with DS referred for CPAP treatment were followed up by the researchers, one 
sought treatment elsewhere and the follow-up status of the remaining 4 participants 
was not known. This study suggests that CPAP was acceptable to the majority of 
adults with DS, with over half of the individuals followed up using therapy for 6-
8hr/night; the families of these adults with DS reported subjective improvements in 
sleepiness and daytime function. Two individuals did not accept CPAP, one quit due 
to side effects and one used CPAP for only <2hr/night. However, no formal 
assessment of sleepiness, daytime function, cognition or behaviour was undertaken 
in this very small group of adults with DS and OSAHS, and no standard 
methodology for CPAP initiation and support was described. The only other 
literature relating to the use of CPAP in individuals with DS focusses on children, 
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which cannot be generalised to the adult population, given the differences in OSAHS 
risk factors between these two groups. 
There is a wealth of evidence that CPAP improves cognitive function and behaviour 
in the general population, as reviewed in Chapter 2, but much less is known in the 
DS population. A study of the effects of CPAP on neurobehavioural outcomes in 
52children with OSAHS included a subset of 10 individuals with developmental 
delays, 6 of whom had DS (Marcus et al. 2012). Significant improvements in ESS, 
behaviour and quality of life were reported, despite the very small number of 
individuals in this group, and a similar finding was noted in the current study in 
adults with DS. 
The AH requirement for entry to the treatment phase of this study was AH≥10 per 
hour in bed, lower than the generally-accepted diagnostic threshold (Scottish 
Intercollegiate Guidelines Network 2003). Studies in the general population have 
assessed the efficacy of treating mild OSAHS with CPAP, with two  placebo-
controlled studies of symptomatic individuals with an AHI in the mild range (5.0-
14.9 events per hour) demonstrating  improvements in sleepiness, mood and daytime 
function, even with low CPAP compliance (Engleman et al. 1997; Engleman et al. 
1999). As discussed in Chapter 3, adults with DS may be more sensitive to the 
cognitive effects of untreated OSAHS given the existing cognitively impairment seen 
in this group, and so may stand to benefit even when diagnosed with only mild 
OSAHS (Beebe & Gozal 2002; Fernandez & Edgin 2013). 
Although no significant differences were noted in the ACTB tests with CPAP use, 
this study has further validated the use of the ACTB in adults with DS. We have 
demonstrated that individuals with DS and moderate to severe ID can perform the 
tests in both home and hospital settings, confirming previous findings (Edgin et al. 
2010).  
There are a number of limitations to this study. Funding issues forced early closure 
of recruitment, which resulted in underpowering of the study, with only 28 of a 
projected 68 participants enrolled. It is of note that a further 67 individuals were 
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eligible to participate, but could not be enrolled due to lack of funding related to the 
delay in receiving ethical approval for the study as discussed in Chapter 4. However, 
this is still, to date, the largest study of CPAP in adults with DS reported worldwide. 
Moreover, despite the small number of participants and our conservative threshold 
for significance, statistically significant improvements in sleepiness, behaviour and 
cognitive function have been demonstrated. These positive results, alongside trends 
towards significant improvement in other domains, suggest that a larger trial may be 
of merit. Future studies may benefit from employing a multicentre design, allowing 
easier recruitment of the required numbers across the whole of the UK.  
No significant differences in outcomes were evident after the one month randomised 
phase of the study. One month was selected as this length of time has been sufficient 
to show a significant change in the general population (Engleman et al. 1997; 
Engleman et al. 1999; McArdle et al. 2001; Robinson 2006; McArdle et al. 2010), 
and was felt to be the maximum time for which CPAP treatment could ethically be 
delayed. It may be that a longer randomised phase may have been optimal – other 
studies in the general population have used periods ranging from 6 weeks to 12 
months (Engleman et al. 1993; McFadyen et al. 2001; Antic et al. 2011; Sivam et al. 
2012; McMillan et al. 2014) – though perhaps unacceptable to the ethics committee. 
Since all participants in this phase of the study had either moderate or severe ID, 
results may not be generalisable to the DS population as a whole. No significant 
differences were observed between those with capacity to give consent and AWI, 
though numbers were small. Future studies should, if possible, include adults with 
mild and profound ID, in large enough numbers to allow comparison across the 
spectrum of ability seen in individuals with DS. This may, however, prove difficult 
given the ethical issues faced when conducting research in AWI, as discussed in 
Chapter 4.  
Problems with mask fit and comfort were encountered during this study, with many 
of the commercially-available CPAP interfaces proving to be too large for 
participants, even in the smallest sizes. All participants were fitted with full face 
masks due to obligate mouth breathing, related to relative macroglossia and 
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adenoidal facies. A recent study in the general population suggested that use of a 
full-face mask impacts negatively on compliance (Borel et al. 2013). Masks designed 
specifically for individuals with DS, taking into account the midface hypoplasia 
which is common in DS, may be required, and recent advances in 3D printing 
technology (Ventola 2014), may allow personalised masks modelled on each 
individual’s face to become an option in the near future. Further research in this area 
is required.  
It is usual clinical practice within the department to introduce heated humidification 
only as required in the event of side effects to CPAP such as nasal congestion or 
dryness, and so a similar approach was taken in this study. With hindsight, given the 
known issues of increased mucus secretion and frequent respiratory tract infections 
in individuals with DS (see Chapter 1), it may have been appropriate to start all 
participants on CPAP with humidification from day 1. There is conflicting evidence 
as to whether humidification improves CPAP compliance, with some studies 
showing a significant improvement (Massie et al. 1999; Neill et al. 2003) and others 
not (Worsnop et al. 2010). Although some participants did report side effects and 
were later issued with humidification, it is possible that this contributed to the poor 
compliance noted. A study of fixed versus auto-titrating CPAP in the general 
population noted a significant order effect, with neither type of device improving 
compliance but participants preferring whichever they used first (Vennelle et al. 
2010); it is possible that a similar effect might be apparent with humidification, and 
so it may have been beneficial to commence humidification to all participants at the 
time of CPAP initiation.  
The majority of participants in our study lived at home with their parent/carer, and 
so, again, results may not be generalisable to the adults DS population as a whole. 
Given that residential status can impact on a number of outcomes in people with DS 
as discussed elsewhere in this thesis, future research should include individuals 
living in supported accommodation and residential care settings, in sufficient 
numbers to allow comparison and to control for differences between these groups. 
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Given the small sample size, it was not viable to undertake the planned health 
economic analysis. However, we have, for the first time, demonstrated the utility of 
the EQ-5D instrument in adults with DS, and a larger trial to assess the health 
economic benefits of CPAP in this population is required. Health economic benefits 
of CPAP use have been demonstrated in older adults in the general population, 
despite modest compliance (McMillan et al. 2014). 
Changes were noted in pESS, KBIT-2 and DBC-A scores despite a low median 
usage across the group, and it would be of interest to see whether these effects are 
amplified and if other measures show improvement in a dose-dependent manner. 
Although steps were taken in this study to encourage CPAP usage, future studies 
may wish to employ additional strategies to increase compliance. Cognitive 
behavioural interventions, self-management, peer support and intensive education 
and follow-up have all been shown to improve CPAP compliance in the general 
population (Hoy et al. 1999; Engleman & Wild 2003; Stepnowsky et al. 2007; 
Damjanovic et al. 2009; Parthasarathy et al. 2013; Wozniak et al. 2014), and 
incentivisation via token economy has been shown to increase adherence to physical 
activity programmes in individuals with DS (Bennett et al. 1989), offering many 
avenues to explore in future studies. 
Reasons for continuing or quitting CPAP therapy were diverse, and included both 
patient and parental concerns. It is impossible to assess all the possible factors 
influencing CPAP compliance, but future studies should consider areas such as 
parental support and perception of CPAP and social factors surrounding CPAP use; 
socioeconomic status has been noted to impact on compliance in the general 
population (Platt et al. 2009), and a number of studies in the general population have 
investigated predictors of CPAP compliance, including psychological profiles, 
behaviour styles, perceptions of CPAP and health beliefs, as well as spouse or family 
member involvement ( Wild et al. 2004; Aloia et al. 2005; Olsen et al. 2008; Baron et 
al. 2011; Baron et al. 2012; Balachandran et al. 2013).  However, this study has 
demonstrated that the majority of adults with DS can tolerate CPAP, with over half 
of those entering the study continuing after 12 months, and its use as a standard 
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treatment for OSAHS in this group should not be ruled out purely on the basis of a 
diagnosis of DS.  
8.4 Conclusion 
Despite small participant numbers, this first randomised, controlled trial of CPAP 
therapy in adults with DS demonstrated that CPAP use leads to sustained, significant 
improvements in subjective sleepiness, behavioural and emotional outcomes and 
cognitive function in a group of individuals exhibiting moderate/severe intellectual 
disability. It is possible that some of the cognitive impairment seen in adults with DS 
may be related to untreated OSAHS, and that treatment can lessen, if not reverse, 
some of this impairment. CPAP appears to be effective and well-tolerated in this 
population, and, given the potential benefits in terms of improved daytime function 
and quality of life, a further, larger-scale randomised, controlled trial in this 
population is warranted.
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9.1.1 What is the prevalence of OSAHS in adults with DS in 
Scotland (and the UK)? 
Prior to this study, the prevalence of OSAHS in DS was unclear and had not been 
reported adequately in any country. In this series of studies, we have, for the first 
time, documented the prevalence of OSAHS in a large population of adults with DS 
by both subjective and objective means. 
Using a subjective, easy-read questionnaire, we contacted over 5000 adults with DS 
across all four nations of the UK, covering a wide geographic area and 
socioeconomic range. Using previously validated algorithms and based on a cohort 
of 1067 valid responders, the prevalence of OSAHS in adults aged ≥16 years with 
DS living in the UK is 35%, with no gender difference evident. This is significantly 
higher than the 2% of women and 4% of men reported to have OSAHS in the general 
population (Young et al. 1993). Even in comparison to the recently updated 
Wisconsin Sleep Cohort data, which estimates that 10-17% of men and 3-10% of 
women now have OSAHS (Peppard et al. 2013), this represents a significantly 
elevated risk of OSAHS in the adult DS population. However, the majority of 
participants in our study (69%) were aged 20-40 years; the Wisconsin data surveyed 
individuals aged 30-70 years, and so these prevalence data may not be comparable. 
Our prevalence of 35% is modest compared to the studies of Trois et al and Resta et 
al, who estimated an OSAHS prevalence of >80% in adults with DS in Italy and the 
USA. Although these studies used objective measures of OSAHS, the very small 
sample size in these studies (n=16 and n=6 respectively) must be taken into 
consideration (Resta et al. 2003; Trois et al. 2009).  
The prevalence we have reported in adults is also lower than the 55% reported in 
children with DS in Spain (de Miguel-Díez et al. 2003). This may reflect differing 
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risk factors for and aetiology of OSAHS in children and adults with DS. In the 
general population, OSAHS affects around 6% of children and is related mostly to 
hypertrophy of the adenoids and tonsils in relation to size of the airways, particularly 
between the age of 2-8 years (Marcus et al. 2012; Tan et al. 2013), while, in adults, 
the problem is related more to gender, advancing age and obesity. It is likely that this 
is similar in children with DS, though compounded by hypotonia, which is worse in 
children with DS and becomes less pronounced in adults, and obesity, which is more 
prevalent in those with DS than in the general population. Although obesity is less of 
a risk factor for OSAHS in typically-developing, pre-pubescent, children than it is in 
adults, this may not be the case in children with DS. 
The majority of responders in or study were young adults, and, given the increasing 
prevalence of OSAHS with age in the general population, it is possible that OSAHS 
prevalence may be even higher in older adults with DS. Declining cognitive function 
may be a factor in the paucity of older people responding to the questionnaire in this 
study. Older adults are more likely to be living in residential care, which may also 
have affected the response rate in this subpopulation. Future studies should seek to 
recruit more individuals with DS in the older age group to further explore the 
relationship between age and OSAHS in this population. 
Responders were predominantly overweight or obese. Females had a higher mean 
BMI, as reported in previous studies (Melville et al. 2005; Melville et al. 2007), and 
also had a higher prevalence of thyroid dysfunction. A link between these has been 
noted in women, but not men, in the general population (Milionis & Milionis 2013). 
Poorly controlled hypothyroidism and the use of oral contraceptives, both associated 
with weight gain, may explain the difference in BMI between genders, though other 
factors may be involved and further investigation is required. Residential status is 
known to affect BMI. This may account for some of the difference in BMI between 
men and women, but this information was not collected as part of the questionnaire 
study. 
Coincidentally, the opportunity arose to undertake a comparative study of prevalence 
of OSAHS in adults with DS in Scotland and Japan. This is the first international 
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study to compare self-reported symptoms of OSAHS in adults with DS. Subjective 
prevalence of OSAHS in 267 adults with DS in Scotland was 20%, and in 522 adults 
with DS in Japan was 14%. The overall prevalence of OSAHS in adults with DS was 
16% across both countries. Given that ethnic differences in OSAHS prevalence exist 
in the general population, it is interesting to note that this was not evident in two 
ethnically distinct populations of adults with DS. This suggests that the characteristic 
craniofacial features of DS override differing ethnicity in terms of the risk of 
OSAHS. A limitation of the UK prevalence study is that specific information on 
ethnicity was not collected although Scotland has a largely homogeneous (96%) 
Caucasian population (Scottish Government 2014).   
Women with DS had a higher mean BMI than men in Scotland, though this 
difference was not seen in Japan. The use of contraceptives in women with DS is rare 
in Japan, and may play a role in this observation. Overall, both men and women had 
significantly lower mean BMI in Japan than in Scotland. Raised BMI was a risk 
factor for sleepiness in Scotland but not Japan, even when using Asian-specific BMI 
thresholds. The reasons for this are unknown, but may be cultural, diet-related or due 
to differing distribution of body fat between Asian and Western populations (Wang 
et al. 1994; Ogce et al. 2008).  
The reason for the differences observed between the subjective prevalence of 
OSAHS in the UK, Scottish and Japanese populations are unclear. Although the 
Scottish and Japanese prevalences did not differ significantly at 20% and 14% 
respectively (16% overall), this is much lower than the 35% seen in the UK as a 
whole. This may partly reflect methodological differences. In the UK study, 
symptoms were classified as occurring never, rarely/sometimes (1-2 nights per week) 
or often/frequently (≥3 nights per week), whereas, in the Japan/Scotland comparison 
study, the classification was never, sometimes (1-4 nights per week) or frequently (5-
7 nights per week). The effects of residential status on these observations cannot be 
ascertained, as information on this was not collected.  
The subjective nature of both the UK and Japan prevalence studies represents a clear 
limitation. However, we also collected objective prevalence data for OSA in a subset 
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of the questionnaire study participants using home polygraphy. Of a sample of 134 
adults with DS, 56% met the criteria for probable OSAHS using the same 
algorithmic method of assessment employed in the questionnaire study. Forty-two 
percent of the subjects were diagnosed with OSAHS on using objective testing. 
OSAHS was defined as an AH≥15 per hour in bed plus symptoms (pESS>10, 
unrefreshing sleep ≥3 nights per week or daytime sleepiness ≥3 nights per week). 
This demonstrated that the algorithms utilised (Fuhrman et al. 2012) had good 
sensitivity (79%), but relatively poor specificity (59%). In line with the subjective 
prevalence study results, no gender difference in OSAHS prevalence was evident. 
Symptoms alone were not indicative of the severity of OSAHS, as defined by AH per 
hour in bed or ODI, reflecting similar observations in the general population.   
The limitations of home polygraphy, including the absence of data on sleep 
architecture and dilution of the AHI, must be borne in mind. Nevertheless, the 
validity and cost-effectiveness of home polygraphy versus inpatient PSG has been 
demonstrated by previous studies (Dingli et al. 2003; Juan F. Masa et al. 2011), and 
current guidelines recommend this as the first-line diagnostic test for adults with a 
high clinical suspicion of OSAHS (Scottish Intercollegiate Guidelines Network 
2003). We have demonstrated the tolerability and reliability of home polygraphy in a 
large group of adults with DS; it is of note that home polygraphy was tolerated by the 
majority of participants and a scoreable study was obtained in 90% of cases, 94% of 
these after only 1 or 2 nights of recording. Future studies may use smaller, more 
modern polygraphy equipment or ambulatory PSG with digital video to collect 
further information on sleep staging and quantification of sleep fragmentation via 
EEG arousal scoring. 
In both the subjective and objective prevalence studies, probable or actual OSAHS 
was associated with worse behaviour scores in the Disruptive, Anxiety/Antisocial 
and Depressive subscales of the DBC-A, though these did not reach significance in 
the objective prevalence study with its smaller sample size and our strict threshold 
for significance. Behaviour scores were generally low, which is perhaps unsurprising 
given that individuals with DS exhibit a lower prevalence of maladaptive behaviours 
than those with ID of other aetiologies (Chapman & Hesketh 2000; Blacher & 
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McIntyre 2006). It may be that the DBC-A and/or the subscales selected are less 
sensitive in individuals with DS than others with ID. The absence of normative data 
for the version of the DBC-A used in this study makes this difficult to assess. 
However, differences in behaviour have been demonstrated and should be explored 
further in future studies with the same or alternative instruments.  
9.1.2 Does CPAP use in DS adults with OSAHS improve 
sleepiness and quality of life more effectively than 
lifestyle measures alone? 
This is the first RCT of CPAP therapy in adults with DS, and provides the first 
empirical evidence of improvement in sleepiness, behaviour and cognitive function 
in adults with DS and OSAHS.   
No significant difference was noted between the CPAP and lifestyle groups after 1 
month. This may be due to a number of factors, including the small number of 
participants (27 in total), low CPAP compliance (median usage 3.0(1.6-4.7) 
hr/night), and short duration to follow-up (1 month). Very low levels of impairment 
on subjective measures of behaviour, quality of life and general health may have left 
little room for improvement. Although RCTs of CPAP efficacy in the general 
population have shown an effect after 1 month (McFadyen et al. 2001; McArdle et 
al. 2001; Senn et al. 2003; Robinson 2006), a longer period may be required in 
individuals with DS. A larger sample size of sufficient power is also required. 
However, despite these limitations, when the whole group was assessed after 12 
months, significant and sustained improvements in Disruptive and Depressive 
behaviour scores, self-rated subjective sleepiness and verbal intelligence measured 
by the KBIT-2 were noted. Strong trends towards improvement in carer-rated 
sleepiness, Anxiety/Antisocial behaviour scores and KBIT-2 non-verbal intelligence 
scores were noted, but did not reach significance at the p<0.001 level. Interestingly, 
no change was noted in the ACTB measures of prefrontal, cerebellar or hippocampal 
function. This may, again, be related to the small number of participants in the study 
or, perhaps, the sensitivity of the tests selected from the battery. However, we have 
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further validated the acceptability and utility of the ACTB, and further examination 
in a larger trial is warranted. 
9.1.3 What are the potential barriers to implementing CPAP 
effectively in DS adults with OSAHS? 
CPAP compliance in our population was generally low. Over the first month on 
CPAP, participants used the machine on only 55±35% of nights, with a median usage 
of 2.8(1.1-6.7) hr/night. After 12 months, this had not changed significantly, with use 
on 54±34% of nights and a median usage of 2.3(1.0-6.4) hr/night. The reasons for 
this are unclear; despite some problems finding a suitable mask initially, the mean 
mask leak remained well within acceptable limits throughout the study. Very few 
side effects were reported, and these were in line with the general population: skin 
irritation; nasal congestion; dry mouth; respiratory infection; mask leak; wakening 
due to CPAP; and anxiety or fear of CPAP. Humidification was started only when 
required; given that individuals with DS often have increased mucus secretion and 
recurrent respiratory infections, there may be an indication to commence 
humidification in all adults with DS, although, in this study, the use of 
humidification did not result in any significant difference in outcomes. 
Of the 28 participants enrolled in the study, 4 had withdrawn by 12 months. Of the 
24 remaining at 12 months, 5 opted not to continue with CPAP. Of the 9 participants 
who quit CPAP, 7 did so because they could not tolerate CPAP, disliked CPAP or 
refused to use the machine. One withdrew due to a close family bereavement and 
another due to moving to residential care, and CPAP was withdrawn at the request of 
the parent. Of the 24 individuals completing the full 12 months of the trial, a quarter 
were not using CPAP at 12 months; half of these disliked CPAP, one no longer 
wished to use CPAP as their symptoms had improved and one parent was unwilling 
to continue with CPAP. 
CPAP compliance and acceptance is variable in the general population, and this 
study in adults with DS has shown similar outcomes. Despite frequent follow-up and 
support, a proportion used CPAP infrequently or quit altogether. Further studies 
should assess the efficacy of techniques to improve CPAP compliance in this group, 
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such as specific behavioural interventions or, reward systems adapted to the level of 
ID. (Bennett et al. 1989; Engleman & Wild 2003). It may be that individuals with DS 
need more time, more intense support, more accessible information and more tailored 
interventions to improve compliance and acceptance of treatment. DS-specific CPAP 
interfaces would be beneficial. Our results suggest that the beliefs and perceptions of 
the parent/carer may also be important, and this is another area for investigation. 
However, it is of note that over two thirds of individuals continued on CPAP at the 
end of the study, suggesting that CPAP is generally acceptable in this group and that 
benefits are perceived by the patients and/or their relatives/carers. 
 
9.2 Future work and considerations 
Although this series of studies addresses a number of gaps in the current evidence 
base relating to adults with DS and OSAHS, there is scope for further work. 
With only 28 participants, the treatment phase of the study is underpowered. This 
was due to funding issues resulting from the one-year delay in recruitment due to 
difficulties gaining ethical approval to include adults with DS of all levels of ID in 
the study, as discussed in Section 4.5. The initial decision of the ethics committee to 
grant permission only to include adults with DS who had capacity to consent for 
themselves not only introduced a barrier to carrying out the study, but potentially 
limited the usefulness of the results, which would only be generalisable to the small 
population of high functioning adults with DS and not the majority of the population 
who present with moderate to severe ID. While this barrier was eventually overcome 
and permission was granted to include AWI, the commencement of the study was 
delayed and the catchment area of the trial had to be extended in an attempt to recruit 
the minimum number of participants required. This delay to the start of the study, 
coupled with the additional time and expense of visiting participants over a much 
larger geographical area, meant that the study was not complete by the end of the 
funding period and a further 67 individuals who were eligible to participate in the 
study could not be enrolled. Many of these individuals went on to start CPAP 
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outwith the study through their local clinical service, and, while it is appropriate that 
they receive treatment, it is somewhat frustrating to be unable to include their data 
and experience of CPAP use within this study. 
However, despite being underpowered, this study has shown real, significant and 
sustained improvements in sleepiness, behaviour and daytime function, and has 
demonstrated that adults with DS can both tolerate and benefit from CPAP therapy 
for OSAHS. This provides the first evidence to support a larger randomised, 
controlled trial of CPAP in this population. Given the logistical difficulties in 
recruiting to the study due to the large geographical area covered, it would be 
sensible for the next study to be of multicentre design. We have demonstrated that 
individuals from all parts of the UK are interested in research participation, and that 
ambulatory sleep studies conducted by individuals and their relatives/carers at home 
are feasible. 
This first randomised trial of CPAP in adults with DS and OSAHS has shown that 
this patient population can tolerate CPAP, although compliance was low. Further 
investigation of the barriers to CPAP use are required. It is likely that these are 
multifactorial, and related to the relative/carer of the individual with DS as well as 
the patient themselves. A number of studies in the general population have shown 
that CPAP compliance is related to a number of psychological factors including 
health beliefs, behaviour models and self-efficacy; in adults with DS, these factors 
might apply to both the patient themselves and the people who support them. 
Elucidation of these barriers would allow CPAP initiation and support to be tailored 
to the individual needs of the person with DS and their family, potentially improving 
compliance and treatment outcomes. The development of an evidence-based pathway 
for CPAP education, initiation and follow-up in adults with DS which could be rolled 
out in sleep centres would improve the availability of suitable services for adults with 
DS and OSAHS, and would be a step towards reducing some of the health 
inequalities experienced by individuals with DS generally. Mask fit was an issue in 
this study, and “DS-friendly” masks, designed to fit the common craniofacial 
phenotype of DS, minimise skin irritation and be aesthetically acceptable to a 
“medical-phobic” group would certainly be ideal.  
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Dementia was an exclusion criterion for this treatment study. However, as discussed, 
early-onset dementia is common in adults with DS, and untreated OSAHS may 
accelerate the cognitive decline seen in this group (Fernandez & Edgin 2013). 
Therefore, a trial of CPAP therapy in adults with DS and dementia to assess the 
effect of treating OSAHS on the symptoms of dementia is warranted. Studies in 
individuals with Alzheimer disease and OSAHS in the general population have 
shown that these patients can tolerate CPAP, and that its use is associated with 
improvements in sleepiness, cognitive function, depressive symptoms and behaviour; 
the sleep quality of caregivers was also improved (Chong et al. 2006; Ayalon et al. 
2006; Ancoli-Israel et al. 2008; Cooke et al. 2009).  Given the increasing life 
expectancy of adults with DS, coupled with the high prevalence of dementia in this 
group, treating OSAHS may result in not only improved health and quality of live for 
individuals and their carers, but also health economic benefits. 
The subjective and objective data presented here, as well as other published studies 
(Capone et al. 2013), suggest that adenotonsillectomy in children with DS may not 
confer sustained treatment of OSAHS into adulthood. A prospective study following 
children with DS and OSAHS into adulthood, pre- and post-adenotonsillectomy, 
would be of great value, documenting the natural history of OSAHS in individuals 
with DS across the lifespan and examining the potential factors influencing the 
efficacy of adenotonsillectomy in this group.  
We have shown that the pESS can be used effectively in adults with DS, though with 
some drawbacks relating to specific questions related to reading, driving and lying 
down in the afternoon. A modified version of the pESS, designed specifically for 
individuals with DS and ID in mind, would improve the utility of this measure in this 
specific patient population. The use of easy-read and pictorial questionnaires and 
information in sleep centres and other clinical settings would be another avenue 
whereby health inequality in people with DS and ID of other causes could be better 
addressed. 
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9.3 Final conclusions and clinical implications 
Prior to the commencement of this study, the prevalence of OSAHS in adults with 
DS was unclear, based on two very small studies (n=22 in total), with no published 
studies of the efficacy of CPAP treatment in this population available. 
This study has demonstrated that the prevalence of OSAHS in adults with DS in the 
UK is approximately 40%, using subjective and objective methods in a large 
population-based cohort (n=1067 subjective prevalence, n=134 objective 
prevalence). Comparison of subjective prevalence in Scotland and Japan found no 
significant differences between countries of differing ethnicity, albeit with a lower 
estimated prevalence of 15-20%. 
Furthermore, this study has shown that CPAP therapy is both tolerated and effective 
in adults with DS, even in a relatively small group (n=28). This work provides the 
first evidence to support the use of CPAP in adults with DS and OSAHS, whilst 
laying the foundations for further, large-scale trials. 
The study has a number of clinical implications. The extent of OSAHS in adults with 
DS been quantified for the first time in a large cohort, highlighting the need for 
individuals, carers and healthcare professionals to be vigilant for symptoms of 
OSAHS in this group. This work suggests that, in adults with DS, we must not only 
consider the symptoms typically associated with untreated OSAHS in adults (such as 
EDS, snoring and witnessed apnoeas), but additional features such as behavioural 
and emotional disturbances. Instruments which are commonly used to assess 
sleepiness and general health in the general population, such as the (p)ESS and EQ-
5D, have been shown to be of use in the adult DS population, although these may 
require adaptation to increase their utility in this group. This is particularly true for 
the pESS, where adaptation of the questions used to more adequately reflect daily 
living in adults with DS (or amendment of the diagnostic threshold) may improve the 
clinical value of the questionnaire. The feasibility of home-based diagnostic testing 
in this population has been demonstrated, offering a low-cost and easy-to-use option 
for OSAHS screening in adults with DS. Finally, although limited by the small 
number of participants, this study offers the first formal evidence that, with adequate 
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support, adults with DS can tolerate CPAP and gain long-term health benefits with 
even modest use. It is hoped that these findings, and those of further large scale, 
multi-centre trials, will inform future guidelines for screening, diagnosis and 
treatment on OSAHS in adults with DS in the UK and beyond.    
In this study, only 3% of responders surveyed had a prior diagnosis of OSAHS, 
despite a likely prevalence over ten times higher than this. It is hoped that the results 
of this study will increase awareness of OSAHS in adults with DS, highlighting that 
poor sleep is not “just part of the condition”, but is, in fact, a common comorbidity of 
DS which can be successfully treated in most cases, leading to benefits not just in 
terms of more settled sleep, but in daytime function and behaviour. Screening for 
OSAHS should form a standard component of ongoing health surveillance in adults 
with DS. 
With an increase in individuals and families seeking diagnosis and treatment of 
OSAHS, healthcare providers must make efforts to make their services more 
inclusive, providing care and support that is acceptable to and effective for 
individuals with DS. Literature must be provided in easy-read format, and the 
location and duration of appointments must be tailored to this group. Additional 
support from healthcare staff may be necessary to successfully initiate and maintain 
the use of CPAP therapy in adults with DS. Of course, this may have budgetary and 
staffing implications, and further studies on the health economic benefits of CPAP in 
adults with DS are required. 
In conclusion, OSAHS is a common disorder in adults with DS, affecting more than 
one in three individuals. However, with the appropriate care and support, OSAHS 
can be treated effectively, improving daytime function and behaviour. Testing and 
treatment should be routinely offered to all adults with DS; it is hoped that this study 
provides a first step towards this becoming common practice. 
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